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Cardiac fibrosis poses a central challenge in preventing heart failure for patients 
who have suffered a cardiac injury such as myocardial infarction or aortic valve stenosis. 
This chronic condition is characterized by a reduction in contractile function through 
combined hypertrophy and excessive scar formation, and although currently prescribed 
therapeutics targeting hypertrophy have shown improvements in patient outcomes, 
pathological fibrosis remains a leading cause of reduced cardiac function for patients 
long-term. Cardiac fibroblasts play a key role in regulating scar formation during heart 
failure progression, and interacting biochemical and biomechanical cues within the 
myocardium guide the activation of fibroblasts and expression of extracellular matrix 
proteins. While targeted experimental studies of fibroblast activation have elucidated the 
roles of individual pathways in fibroblast activation, intracellular crosstalk between 
mechanotransduction and chemotransduction pathways from multiple biochemical cues 
has largely confounded efforts to control overall cell behavior within the myocardial 
environment.  
Computational networks of intracellular signaling can account for complex 
interactions between signaling pathways and provide a promising approach for 
identifying influential mechanisms mediating cell behavior. The overarching goal of this 
dissertation is to improve our understanding of complex signaling in fibroblasts by 
investigating the role of mechano-chemo interactions in cardiac fibroblast-mediated 
fibrosis using a combination of experimental studies and systems-level computational 
models. Firstly, using an in vitro screen of cardiac fibroblast-secreted proteins in response 
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to combinations of biochemical stimuli and mechanical tension, we found that tension 
modulated cell sensitivity towards biochemical stimuli, thereby altering cell behavior 
based on the mechanical context. Secondly, using a curated model of fibroblast 
intracellular signaling, we expanded model topology to include robust 
mechanotransduction pathways, improved accuracy of model predictions compared to 
independent experimental studies, and identified mechanically dependent mechanisms-
of-action and mechano-adaptive drug candidates in a post-infarction scenario. Lastly, 
using an inferred network of fibroblast transcriptional regulation and model fitting to 
patient-specific data, we showed the utility of model-based approaches in identifying 
influential pathways underlying fibrotic protein expression during aortic valve stenosis 
and predicting patient-specific responses to pharmacological intervention. Our work 
suggests that computational-based approaches can generate insight into influential 
mechanisms among complex systems, and such tools may be promising for further 
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1.1. Study Significance 
Cardiac fibrosis remains a major barrier towards the treatment and prevention of 
heart failure. For the roughly 2.2% of Americans suffering from heart failure1, excessive 
accumulation of extracellular matrix (ECM) contributes to increased myocardial stiffness, 
loss of contractile function, and increased risk of mortality to as high as 75%2. Scar 
formation can result from multiple underlying causes including myocardial infarction 
(MI), aortic valve stenosis (AVS), and hypertension, and while current therapies for these 
conditions generally improve outcomes in patient populations through the reduction of 
myocyte hypertrophy3,4, no drug is currently approved by the FDA for the treatment of 
cardiac fibrosis. Moreover, although excessive fibrosis can reduce function, reparative 
scar formation is also at times necessary to retain structural integrity following a cardiac 
injury such as MI. Therefore, ideal pharmacologic therapies for treating fibrosis should 
reduce scar formation in a targeted manner both spatially and temporally. 
 Cardiac fibroblasts act as key mediators of fibrosis by controlling the balance of 
ECM formation and degradation, with cells assuming a contractile phenotype and 
synthesizing matrix proteins and proteases in response to both biochemical and 
mechanical cues5,6. Because local mechanics vary spatially within the myocardium (e.g 
infarcted versus remote tissue during MI), controlling fibroblast behavior based on local 
mechanical and biochemical cues has the potential to improve patient outcomes by 
producing matrix only where it is needed. However, decades of previous research has 
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identified numerous intracellular signaling mechanisms that transduce fibroblast 
responses to individual stimuli, and these pathways often overlap and interact with one 
another via a series of crosstalk and feedback mechanisms, thus complicating efforts to 
understand fibroblast behavior within the diverse biochemical and biomechanical 
environment of the myocardium.  
We hypothesized that integrating fibroblast biomechanical and biochemical 
signaling pathways into a suite of computational tools will enable predictions of novel 
mechanisms underlying cardiac fibrosis, and the studies presented in this dissertation 
integrate in vitro assessment of fibroblast mechano-chemo interactions with in silico 
modeling of cell signaling and transcriptional regulation to better understand the extent of 
crosstalk between environmental stimuli, the mechanisms-of-action that mediate fibrotic 
protein expression, and potential applications of computational networks towards the 
discovery of targeted anti-fibrotic therapeutics. 
1.2. Specific Aims 
Aim 1: Test the hypothesis that interactions between mechanical loading and 
canonical biochemical cues mediate fibrotic behavior in cardiac fibroblasts.  
Primary mouse cardiac fibroblasts were subjected to six biochemical 
cytokines with or without the presence of cyclic mechanical tension. Cell 
morphology and activation via smooth muscle actin were measured via 
immunofluorescence microscopy to assess fibroblast phenotypes, and cell 
secretion of collagens, matrix metalloproteinases, and matricellular proteins were 
assessed via high-throughput protein assays. Statistical tests for both the presence 
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of interactions between biochemical and mechanical stimuli and their 
contributions towards fibrosis-related protein secretion were conducted, finding 
that mechanical strain could alter cell sensitivities towards individual biochemical 
stimuli to influence protein expression. 
Aim 2: Refine and employ an existing, manually-curated computational model of 
fibroblast signaling to accurately predict fibrotic activity against available signaling 
datasets.  
Using a model of fibroblast intracellular signaling, we expanded this 
model to include new mechanotransduction studies and mechanisms of mechano-
chemo crosstalk. A manual search of new mechanotransduction literature was 
conducted to identify and incorporate new intracellular species into an expanded 
model. We compared model predictions to secreted ECM levels reported from 
previous in vitro and animal studies to test the hypothesis that this model will 
accurately predict fibrotic activity for both biochemical and mechanical stimuli, 
using both qualitative and semi-quantitative comparisons. We additionally 
conducted network perturbation analyses to identify influential mechanisms-of-
action under variable mechanical contexts, and we performed comprehensive drug 
screening to identify drug candidates leading to mechano-adaptive fibrotic 
behavior. 
Aim 3: Develop a new, data-driven model of fibroblast transcriptional regulation 
to identify influential regulators of fibrosis.  
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We employed an established gene regulatory network inference technique 
to model interactions between transcription factors and fibrotic gene expression. 
A series of topological analyses and simulations were used to test the hypothesis 
that select transcription factors act as “hubs” to mediate mechano-chemo 
interactions in cardiac remodeling. Combination of this network with the previous 
fibroblast signaling and subsequent parameter estimation using existing data of 
signaling inputs and fibrotic outputs additionally improved the accuracy of 
patient-specific predictions in the context of aortic valve stenosis, and network 
perturbation analyses and virtual drug screens were used for influential pathway 
identification and stratification of patient responses to simulated drugs. 
1.3. Study Impact 
 The combination high-throughput mechanical testing and computational modeling 
of cell signaling and transcription discussed investigated here improves our 
understanding of fundamental biological processes governing cardiac fibrosis. This 
strategy provides several key innovations over previous studies: (1) a robust dataset 
highlighting key mechano-chemo interactions that mediate fibroblast secretion including 
scenarios in which stretch sensitizes or desentizes fibroblasts towards biochemical 
stimulation, (2) the integration of a robust mechanotransduction topology into a 
mechanistic model for accurate prediction of fibrosis-related gene expression and 
identification of context-dependent regulators of cell behavior, and (3) inference of a new 
transcriptional model and fitting to patient-specific myofibroblast data for identifying 
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transcriptional points of control for fibrosis and stratifying patient responses to changes in 
plasma biomarkers. 
The results of these studies suggest that model-based strategies can accurately 
predict fibroblast behavior across many pathological scenarios, and that computational 
approached can generate insight into potential heart failure treatments for a variety of 
previous conditions. Because our models can be modified for patient-specific conditions, 
our work has the potential to advance precision medicine within cardiovascular medicine 
by predicting patient responses to current and potential treatments. Additionally, these 
tools have the potential to fast-track therapeutic discovery through the use of 
comprehensive drug screens and to improve rates of attrition during drug development by 
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2.1. Cardiac fibrosis in heart failure 
 Congestive heart failure represents a significant and persistent burden to global 
and national health as a subset of cardiovascular disease (CVD). Heart failure provides a 
significant contribution to the overall health and economic burden caused by CVD, with a 
prevalence of 2.2% of the U.S. population over 20 years old and almost 80,000 deaths 
attributed to this disease in 2016, resulting in over $30 billion in healthcare costs1,2. This 
disease, stemming from an inability of the heart to pump enough blood for oxygen and 
nutrient distribution to the body, can result from several initial cardiac pathologies such 
as myocardial infarction (MI), hypertension, valvular diseases, and muscular diseases 
such as dilated or inflammatory cardiomyopathy. The resulting patient prognoses have 
been bleak overall; of the patients who develop heart failure, community and national 
studies have found 5-year mortality rates to be as high as 75%3,4.  
Although underlying causes can vary, two major modes of pathogenesis are 
frequently responsible for the losses in cardiac function associated with heart failure: 
hypertrophy and fibrosis. Hypertrophy, or enlargement of cardiomyocytes, can act as a 
compensatory mechanism in response to the underlying conditions above resulting in 
thickening of the myocardium and loss of contractile function. Fibrosis, or accumulation 
of collagenous scar tissue, can additionally result in stiffening of the myocardium and 
loss in pump function due to decreased contractility and impaired electrical conduction5. 
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Taken together, these mechanisms form a detrimental combination that reduces heart 
function, and both must be addressed to improve patient survival and quality of life. 
2.1.1. Current standards of care for prevention and treatment 
 Pharmacologic therapies have been the gold standard of care for heart failure 
patients for several decades, as several major classes of drugs have been developed to 
antagonize neuro-hormonal pathways and ultimately reduce hypertrophic responses in the 
myocardium. Several of the most commonly prescribed drugs for heart failure include 
angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), 
beta blockers, and neprilysin inhibitors, although other classes such as diuretics are also 
frequently prescribed to reduce symptoms of congestion. ACE inhibitors, a class of renin-
angiotensin antagonists that block the conversion of angiotensin I to the bioactive 
vasoconstrictor angiotensin II (AngII), are recommended by both the American College 
of Cardiology and the European Society of Cardiology as a first-line treatment for heart 
failure6,7, and clinical trials have shown reductions in heart size, hospital admission for 
heart failure, and mortality rates overall compared to placebo8–10. For patients who may 
not tolerate ACE inhibitors, ARBs are recommended as an alternative vasodilator for the 
ability to competitively block angiotensin II type 1 receptors in smooth muscle cells, and 
individual ARBs have been shown in randomized clinical trials to provide a comparable 
benefit for patients11,12. Beta blockers are also recommended in combination with either 
ACE inhibitor or ARB treatment; these β-adrenergic receptor inhibitors act in parallel 
with AngII inhibitors by blocking binding of adrenaline and norepinephrine and have 
shown improvements in event-free survival in randomized clinical trials13,14. Recently, 
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the combination of the ARB valsartan and neprilysin inhibitor sacubitril has provided 
promising improvements for the outcomes of heart failure patients, as several clinical 
trials have demonstrated improvements in clinical endpoints and quality of life over the 
ACE inhibitor enalapril15–17.  
While the use of the above therapeutics has largely improved patient care over the 
past three decades, it is important to note that many patients do not respond to these lines 
of treatment as reported in the randomized clinical trials above. These therapeutics 
largely treat vasoconstricting processes that contribute to hypertension, thereby reducing 
cardiac load and antagonizing enlargement of the myocardium. But in many cases, 
residual hypertrophy or fibrosis still causes an overall reduction in heart function, leading 
to hospital admission, reduced quality of life, and a high risk of mortality for patients. As 
a late-stage intervention, implantable medical devices such as left ventricular assist 
devices or bi-ventricular assist devices can be used to relieve additional cardiac load7, but 
these interventions are generally intended as a bridge-to-transplant and drastically reduce 
patient mobility and quality of life. To improve patient outcomes without resorting to 
these interventions, it is essential to develop new therapeutics that target cardiac fibrosis 
in addition to hypertrophy. Furthermore, no FDA-approved drugs targeting cardiac 
fibrosis currently exist, further highlighting the critical gap in care for heart failure 
patients. Therefore, understanding the mechanisms-of-action behind cardiac fibrosis can 
directly impact patient outcomes by informing new therapeutic development. 
2.1.2. Role of scar formation in cardiac function 
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 Myocardial fibrosis is characterized by the excessive accumulation of 
extracellular matrix (ECM) components compared to degradation by matrix proteases. 
The processes of ECM deposition and degradation are typically balanced in healthy 
myocardium, where a resident population of quiescent cardiac fibroblasts maintain a 
network of ECM that fills the interstitial space between cardiomyocytes18,19. This matrix, 
primarily composed of collagens I and III, serves both as a scaffold for cardiomyocytes 
and other interstitial cells and acts as an integral component of normal function by 
resisting myocyte contraction and maintaining structural integrity. Low levels of both 
collagens and proteolytic enzymes, notably matrix metalloproteinases (MMPs), are 
synthesized in order to continually renew and reinforce interstitial ECM20,21. This 
continuous production forms a tightly controlled balance between degradation of old 
ECM and deposition of new ECM to maintain optimal structural integrity and resistance 
to cardiomyocyte contraction.  
 Upon injury such as MI or hypertension-induced pressure overload, the balance in 
ECM turnover is disrupted by multiple changes in the local biochemical and mechanical 
environment, and excessive accumulation in fibrillar collagens can cause severe 
reductions in heart function. While the underlying injury may alter the location, 
architecture, or magnitude of collagen accumulation, greater amounts of collagen are 
frequently deposited in interstitial and perivascular regions of the myocardium, which in 
turn increase tissue stiffness, impair diastolic performance, and reduce ejection fraction22–
24. Querejeta and colleagues observed this relationship between fibrosis and cardiac 
function in a study of heart failure patients with or without hypertension, wherein 
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histological analyses from endomyocardial biopsies revealed substantial increases in 
interstitial collagen for hypertensive patients, and serum levels of procollagen I carboxy-
terminal propeptides (PICP) strongly correlated with patient ejection fractions, suggesting 
a connection between collagen synthesis markers and clinical outcomes22. In support of 
these findings, Schelbert and colleagues found that nonischemic patients with higher 
extracellular volume fraction, used as a measure of interstitial scar formation and 
measured via cardiovascular magnetic resonance, experienced significantly higher end 
diastolic volumes, end systolic volumes, and lower ejection fractions compared to 
patients with lower extracellular volume fractions, as well as higher incidences of 
hospitalization for heart failure and death23.  
Excessive scar formation after MI has also been related to declines in cardiac 
function; while development of an organized scar at the infarct site is needed to maintain 
structural integrity after sudden ischemia and loss of cardiomyocytes, the accumulation of 
scar remote to the infarct zone (i.e. posterior and interior left ventricular walls) can also 
decrease contractile function25. It should be stressed, however, that cardiac fibrosis is not 
inherently detrimental to cardiac function. After an injury in which myocardial tissue is 
lost such as MI, scar tissue is essential to replace necrotic tissue to prevent continued scar 
expansion, compaction, and possible cardiac rupture26,27. However, limiting fibrosis 
where and when it is not needed is essential towards preventing the development of heart 
failure and improving prognoses for current patients28. 
2.1.3. Underlying causes and mechanisms of cardiac fibrosis 
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 As noted above, detrimental cardiac fibrosis can result from several different 
underlying pathologies, including chronic hypertension, MI, aortic valvular stenosis 
(AVS), aging-related processes, and various forms of cardiomyopathy. This review 
focuses on fibrosis related to MI and AVS due to their relevance in terms of 
biomechanics and experimental studies described in subsequent chapters, but 
mechanisms of fibrosis related to these additional underlying causes remain important 
facets of research and have been reviewed elsewhere29,30.  
2.1.3.1. Myocardial infarction. With approximately 800,000 Americans suffering 
a MI per year1, this disease represents a substantial proportion of patients experiencing 
maladaptive remodeling related to fibrosis. Infarcts are caused by an occlusion in a 
coronary artery (often the left coronary, left circumflex, or left anterior descending 
arteries), causing immediate ischemia and necrosis of the downstream myocardium. 
Within minutes, a dynamic wound healing process commences to replace necrotic tissue 
with collagenous scar. During an immediate inflammatory phase lasting within one week 
from the initial occlusion, neutrophils and macrophages infiltrate the infarct zone and 
release a variety of proteolytic enzymes such as MMPs and cathepsins to clear necrotic 
tissue and signal for the proliferation and migration of cardiac fibroblasts via secretion of 
a variety of biochemical cytokines31. In the following weeks post-MI, resident cardiac 
fibroblasts begin to undergo proliferation and transition to an activated phenotype 
commonly referred to as myofibroblast activation. These contractile cells begin to 
synthesize ECM proteins including procollagens, fibronectin, laminin, as well as 
matricellular proteins such as periostin, osteopontin, tenascins, and thrombospondins 
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which serve as new matrix to withstand hemodynamic forces in place of normal 
myocardium27,32.  
While scar formation is resolved in many cases via apoptosis and removal of 
fibroblasts19, excessive scar formation can result from sustained environmental cues such 
as increased local stiffness or chronic influxes of inflammatory and neurohormonal 
factors. This over-accumulation of collagenous scar at the infarct site, as well as the 
deposition of ECM in remote areas due to increased biochemical factors, can serve to 
increase stiffness levels beyond homeostatic levels resulting in contraction-related 
dysfunction as discussed above. Over time, infarct scar tissue can also undergo additional 
remodeling with changes in collagen orientation, thickness, and area, potentially resulting 
in infarct expansion and increased risk of complications such as cardiac rupture33. 
2.1.3.2. Aortic valvular stenosis. AVS is generally characterized by an inability of 
the aortic valve leaflets to adequately open and is also highly associated with heart failure 
diagnoses, due in part to fibrosis of the aortic valve itself and of the left ventricle34. Under 
homeostatic conditions, aortic valve leaflets maintain a unique 3-layered architecture 
consisting of the fibrosa layer composed of fibrillar collagen, the spongiosa layer 
composed of proteoglycans, and the ventricularis layer composed of elastin35,36. During 
stenosis of the valve, resident valvular interstitial cells (VICs), which typically secrete 
low levels of ECM components to maintain tissue homeostasis, assume a myofibroblast 
phenotype similar to that of cardiac fibroblasts, leading to overaccumulation of matrix in 
the valve. These cells can also assume an osteogenic phenotype associated with 
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calcification of the valve and increased alkaline phosphatase activity36, and both fibrotic 
and osteogenic processes severely reduce valve opening and blood flow.  
Due to a reduction in valve function, pressure overload is induced in the left 
ventricle, acting as a pathologic signal that stimulates a secondary phase of interstitial 
fibrosis via cardiac fibroblasts37 and further increases the risk of heart failure. This 
secondary fibrosis has been associated with declines in diastolic and systolic function in 
patients as evaluated by Milano and colleagues24, and stresses the importance of 
ventricular wall fibrosis even in valvular diseases. One of the most effective treatments 
for AVS has been valvular replacement with a biomechanical valve, and transcatheter 
aortic valve replacements (TAVR) have had a profound effect on improving outcomes for 
AVS patients while reducing surgery-related risks38. However, Azevedo and colleagues 
found that even for patients after valve replacement surgery, the degree of ventricular 
fibrosis was significantly correlated to reductions in ejection fraction at patient follow-up 
and predictive of overall survival39. Thus, preventing cardiac fibrosis caused by 
underlying diseases such as AVS remains a challenge for improving patient prognoses 
even following surgical intervention. 
2.1.5. Anti-fibrotic therapies: previous trials and challenges 
 Given the importance of fibrosis in determining heart failure development in 
patients, many previous efforts have focused on developing therapies that target specific 
fibrotic processes in previous animal and human trials. These therapies range in their 
mechanisms-of-action, from inhibition of known pro-fibrotic pathways such as renin-
angiotensin signaling and transforming growth factor-β (TGFβ) signaling40, inhibition of 
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inflammatory cytokines41, and inhibition of MMP or tissue inhibitor of MMP (TIMP) 
expression or activity42. However, many of these therapies have produced mixed results, 
with clinical trials showing little improvement in key endpoints and animal trials showing 
increased risk of adverse effects related to tissue remodeling.  
Two such clinical trials specifically surveyed cardiac remodeling post-MI, using 
either an inhibitor of interleukin 1 (VCU-ART trial) or a broad spectrum MMP inhibitor 
(PREMIER trial) to attenuate fibrosis-related declines in heart function43,44. Neither study 
found significant differences in clinical endpoints including the left ventricular end 
systolic and diastolic volume indices and left ventricular ejection fractions. In the VCU-
ART trial, Abbate and colleagues reported improvements in plasma levels of C reactive 
protein with interleukin 1 (IL-1) inhibition and an overall improvement in heart failure-
free survival when pooled with a previous pilot study, but limitations in study size and 
relatively small effect size raise questions as to whether this effect can be generalized to a 
wider population. Furthermore, these trials did not report evidence linking the respective 
therapies to scar formation, and so it is still unclear whether these candidate treatments 
provide benefit in preventing maladaptive fibrosis. 
Although preclinical animal studies of specific anti-fibrotic therapies have 
produced encouraging results for late cardiac remodeling after initial injury, increased 
risk of early dysfunction with treatment highlight the need for therapies that control scar 
formation in a spatially and temporally targeted manner, particularly in post-MI 
remodeling. Ikeuchi and colleagues investigated an anti-TGFβ gene therapy in mice 
following left coronary ligation and found that anti-TGFβ treated mice showed lower 
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collagen volume fraction levels and myocyte hypertrophy as well as improved clinical 
outcomes such as non-infarct wall thickness, left ventricular end systolic and diastolic 
diameters at 28 d compared to sham mice45. However, the same population also 
experienced a greater degree of wall thinning 9 h post-MI with anti-TGFβ treatment, 
which was accompanied by heightened neutrophil invasion, inflammatory cytokine 
expression, and rate of mortality at 24 h, which the authors suggest was caused by 
suppression of an early adaptive response resulting in reparative scar formation. This 
finding was later supported by Frantz and colleagues46 and demonstrates the temporal 
nature of fibrosis, in which early scar formation can prevent further dysfunction but late 
fibrosis can reduce contractility, as well as the spatial nature of fibrosis, in which the 
infarct zone requires a robust scar formation for continued function while excess scar 
deposition in remote zones can lead to dysfunction. Additional studies altering both 
signaling pathways and matrix-related proteins in a global manner have revealed similar 
challenges in temporal and spatial control. Ichihara and colleagues found that although 
inhibition of the angiotensin II type 2 receptor was able to prevent pressure overload-
induced fibrosis in mice47, the same treatment in mice subjected to MI caused marked 
reductions in survival at 1 week which were accompanied by decreases in infarct-
localized collagen, fibronectin, and ventricular wall thickness48. The Lindsey group has 
conducted several studies inhibiting specific MMPs in post-MI mouse models, finding 
that pharmacological inhibition of MMP9 and MMP12 further reduced end systolic and 
diastolic volumes as well as ejection fractions compared to saline-treated controls, with 
anti-MMP9 treatment increasing leukocyte infiltration and both treatment reducing 
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apoptosis at 1 week post-MI49,50. Interestingly, a knockout mouse model of TIMP3 also 
increased complications related to early ventricular wall thinning, with TIMP3-/- mice 
demonstrating lower hydroxyproline content, procollagen synthesis, and TGFβ 
expression 2 d post-MI as well as a 4-fold increase in cardiac rupture compared to wild-
type mice51. While this transgenic anti-TIMP model cannot be directly compared with the 
pharmacological anti-MMP treatments above, the increases in similar early complications 
after MI for seemingly opposite modes of treatment suggest that global inhibition of one 
single pathway or mechanism may produce counterintuitive effects towards overall tissue 
remodeling. Moreover, the studies discussed above share common challenges in spatial 
and temporal control of scar formation, suggesting that while treating excessive fibrosis 
via single pathway perturbations can improve long-term outcomes, scar formation is also 
needed to maintain structural integrity at sites of injury. In order to address this challenge, 
discovering mechanisms-of-action that adapt to environmental contexts in both spatial 
and temporal manners could tailor fibrosis for maximum benefit. 
2.2. Cardiac fibroblast signaling in post-injury fibrosis 
 Cardiac fibroblasts play a central role in mediating ECM synthesis and 
degradation in response to injury (see Sections 2.1.3.1 and 2.1.3.2 above for descriptions 
of fibroblast roles in MI and AVS). These cells make up 15-25% of non-myocyte cells in 
the myocardium52,53 and act as “sentinel cells” by responding to changes in the local 
environment via secretion of collagens, proteases, protease inhibitors, proteoglycans, and 
collagen cross-linking agents54. These changes in the cardiac environment are diverse 
upon injury, with influxes of biochemical cues such as growth factors, neurohormonal 
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factors, and inflammatory cytokines acting as signaling components as well as changes in 
the biomechanical environment including cyclic tension and tissue stiffening55–57. A 
growing body of research has explored cardiac fibroblast responses to these biochemical 
and mechanical categories of signaling, and the following subsections highlight several of 
the major factors involved in cardiac fibroblast activation and behavior within 
biochemical and biomechanical categories as well as studies showing their involvement 
in regulating cardiac fibrosis. 
2.2.1. Fibroblast chemotransduction 
  A wide variety of biochemical agonists have been shown to influence fibrotic 
remodeling in the injured heart at both tissue and cellular scales55,58. While it is unclear 
just how many signals regulate fibroblast activation and ECM-related secretion, several 
major categories of biochemical cues have been well-established as mediators of cardiac 
fibrosis. Inflammatory cytokines such as tumor necrosis factor-α (TNFα), IL-1, and 
interleukin 6 (IL-6) are upregulated immediately after injury as a stress response41,59 and 
act to suppress fibroblast activation and upregulate MMP secretion for the removal of 
necrotic tissue. Growth factors such as TGFβ and platelet-derived growth factor (PDGF) 
are later secreted by neutrophils and macrophages as part of both an anti-inflammatory 
response as well as a pro-fibrotic response via upregulation of proliferation and matrix 
synthesis60,61. Hormonal agonists such as AngII, norepinephrine (NE), natriuretic 
peptides (NPs), and endothelin-1 (ET-1), which act as modulators of vascular 
hypertrophy as described above, also modulate fibroblast behavior including ECM-
related gene expression62–64. These categories have diverse effects on fibroblast behavior 
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as demonstrated both in vitro and in animal studies, and studies highlighting the 
importance of each category are discussed in depth below. 
2.2.1.1. Inflammatory cytokine signaling. As one of the hallmarks of the 
immediate response to cardiac injury, inflammatory cytokines are upregulated in the 
myocardium as early as 3 h after coronary arterial ligation65 as well as in the -
subendothelium during AVS progression34. These cytokines are generally thought to be 
secreted by cardiomyocytes as an immediate response to ischemia and oxidative stress 
during MI59, as well as by T-lymphocytes and macrophages in response to endothelial 
disruption in early aortic lesions66,67. Although a wide variety of factors make up the 
entire inflammatory response, this section will focus specifically on IL-1, IL-6, and TNFα 
for their widely documented influence in cardiac remodeling. 
 These cytokines have a largely anti-fibrotic effect in cardiac fibroblasts and VICs 
by downregulating collagen secretion and upregulating the secretion and activation of 
MMPs to degrade existing matrix67. In vitro investigations of the effect of IL-1, IL-6, and 
TNFα on cardiac fibroblasts showed that all three cytokines decreased collagen synthesis 
as measured by [H3]proline incorporation, and IL-1/TNFα treatments increased total 
MMP activity68. Later experimental evidence focusing on TNFα corroborates these 
findings, as Porter and colleagues found that cardiac fibroblasts stimulated with TNFα 
showed both upregulated protein expression and activity of MMP9, and Awad and 
colleagues found that TNFα upregulates the expression of multiple MMPs as well as total 
collagenase activity69,70. Aguado and colleagues recently showed evidence of VIC 
deactivation with IL-1 and TNFα stimulation with cells transitioning from patient-
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specific sera to either IL-1 or TNFα decreasing αSMA-positive staining compared to 
control serum, suggesting that these cytokines exert similar effects within the context of 
AVS71. 
Studies utilizing transgenic mouse models have further demonstrated the anti-
fibrotic effects of these cytokines. Dziemidowicz and colleagues recently observed that in 
a mouse model of chronic β-adrenergic stimulation to induce pressure overload, IL-6-/- 
mice displayed significantly increased intramyocardial fibrosis compared to wild-type 
mice, suggesting an antagonistic effect of IL-6 on scar formation72. Sun and colleagues 
found that following left anterior descending ligation to mimic MI, TNFα-/- mice 
displayed lower MMP2 and MMP9 activity compared to wild-type mice, although lower 
collagen deposition in remote regions at 28 d indicates that MMP activity alone may not 
fully account for overall scar formation73. Taken together, these studies suggest a highly 
influential role of early inflammatory signaling in fibroblast phenotypes, and variable 
results in vivo suggest further complexities in translating these signals to scar tissue, such 
as context-dependent mechanisms-of-action or possible compensatory mechanisms by 
leukocytes. 
2.2.1.2. Growth factor signaling. A variety of growth factors also localize to 
myocardial and valvular tissue during post-injury remodeling, including TGFβ, PDGF, 
fibroblast growth factor (FGF), and insulin-like growth factor (IGF) among others. These 
agents are typically secreted by macrophages after early inflammation, and several 
groups have suggested that these factors serve to resolve inflammation and stimulate 
matrix remodeling through collagen production and cell proliferation61. In the post-MI 
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environment, TGFβ and PDGF have been shown to reach peak mRNA expression later 
than inflammatory cues, with TGFβ1 reaching peak levels at 4 d and remain upregulated 
for 8 weeks, and PDGFβ reaching peak levels at 7-14 d following MI25,60,74,75. Similarly, 
TGFβ1 has been detected in human calcified aortic valves both in sites of calcification 
and noncalcified ECM, demonstrating a later influx of growth factor-related signals76. 
TGFβ and PDGF have become well-known mediators of fibroblast activation and 
fibrosis both locally post-MI and systemically60,61,77. TGFβ has been particularly well-
studied for its ability to stimulate fibroblast and VIC contraction, αSMA stress fiber 
formation, and collagen synthesis in vitro, and has been extensively reviewed 
elsewhere78–82. Preclinical studies of PDGF suggest a similar role as a pro-fibrotic 
stimulant, as transgenic mice overexpressing PDGF-α and -β isoforms developed 
interstitial scar formation and cardiac hypertrophy77, and post-MI mice treated with anti-
PDGF receptor antibodies displayed attenuated interstitial fibrosis compared to sham 
mice60. Butt and colleagues further observed a proliferative effect of PDGF stimulation 
on cardiac fibroblasts even compared to TGFβ, which mirrors the proliferation of 
fibroblasts preceding scar formation in vivo and implicates PDGF as an influencer of the 
synthetic phenotype78. It should be noted that fibroblast responses to these factors are not 
completely pro-fibrotic; Tan and colleagues found that PDGF upregulated collagenase 
mRNA expression in human fibroblasts, both independently in the case of PDGF-BB as 
well as in synergy with serum as in the case of PDGF-AA83. Therefore, caution must be 
taken when accounting for these factors in overall fibroblast behavior in vivo, particularly 
when making quantitative predictions of ECM turnover. 
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2.2.1.3. Hormonal factor signaling. In addition to mediating blood pressure via 
vasoconstriction, several hormonal factors have also been implicated as mediators of 
cardiac fibroblast behavior and scar formation. These hormones are upregulated 
relatively late during post-MI remodeling, in which factors such as AngII, NP, and ET-1 
are upregulated at the infarct site roughly 5-7 d after injury and remain upregulated for as 
long as 2 months84–86. Additional detection of ACE, bioactive AngII, and angiotensin 
receptors in human aortic valve lesions suggests that upregulated hormonal agonists also 
play a role in AVS progression87. 
Decades of mechanistic studies investigating AngII in fibroblasts have identified 
several mechanisms by which AngII induces fibroblast activation and ECM deposition. 
These mechanisms include the activation of mitogen activated protein kinase (MAPK) 
pathways and upregulation of proliferation88–90, the activation of NADPH oxidase and 
nuclear factor-κB for downstream expression of collagen I, fibronectin, CTGF, and 
upregulation of interstitial fibrosis91, the activation of TNF receptor signaling pathways92, 
and expression of latent TGFβ as part of an autocrine feedback loop89,93,94. Further studies 
utilizing current pharmacological therapies such as ARBs show that cardiac fibrosis can 
be attenuated by inhibiting AngII-dependent signaling specifically in fibroblasts62,95. 
Similarly, ET-1 has been shown to promote cardiac fibroblast activation as evidenced by 
increased αSMA protein expression and [H3]proline incorporation64. Although ET-1 
signaling has not been widely studied in in vivo models of post-injury fibrosis, the ET 
antagonist bosentan was shown to reduce right ventricular procollagen I expression and 
 23
total collagen content in rats subjected to hypoxic conditions, supporting the role of ET-1 
as an additional hormonal agonist of cardiac fibrosis96.  
NPs represent another family of hormonal factors and are upregulated in parallel 
with AngII and associated with heart failure risk, AVS severity, and post-TAVR 
outcomes97–99; however, NPs appear to act as suppressors of fibroblast activation. For 
example, Watson and colleagues found that treating human cardiac fibroblasts with 
exogenous B-type NP in combination with TGFβ reduces αSMA protein expression 
compared to cells treated with TGFβ alone80. Burke and colleagues’ investigation of both 
A-type NP and the neprilysin inhibitor sacubitril in cardiac fibroblasts and a pressure 
overload mouse model provides additional evidence of NPs as negative regulators62. In 
the group’s in vitro studies, cardiac fibroblasts subjected to TGFβ and increasing doses of 
exogenous A-type NP showed reduced gene expression of αSMA, periostin, and collagen 
I compared to TGFβ treatments alone, and additional treatments with sacubitril further 
suppressed gene expression associated with fibroblast activation and proliferation via 
upregulation of cyclic GMP. Similarly, treatment of pressure overload-induced mice with 
valsartan and sacubitril, which increases the bioavailability of NPs due to neprilysin 
inhibition, attenuated both the recruitment of myofibroblasts, as evidenced by PDGFR- 
and vimentin-positive cells, as well as epicardial, interstitial, and perivascular scar 
formation compared to valsartan alone. This synergy of valsartan and neprilysin 
inhibitors was also demonstrated in both cardiac fibroblast-specific collagen synthesis 
and post-MI fibrosis by von Leuder and colleagues95, and provides convincing evidence 
that NPs act as a unique negative mediator of fibroblast activation and collagen synthesis. 
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Taken together, these studies suggest that while fibroblasts may not respond uniformly to 
all hormonal agonists, the late upregulation of hormonal factors play an essential role in 
cardiac remodeling among the additional categories of biochemical cues discussed above. 
2.2.2. Fibroblast mechanotransduction 
 Over the past several decades, a large number of studies have investigated how 
fibroblasts synthesize and build extracellular matrix proteins in response to mechanical 
stimuli. By subjecting cells to a variety of mechanical cues and examining the expression 
of matrix components at the genetic and protein levels, the mechanobiology field has 
gained valuable insight into how cells respond to normal and pathological environments. 
Fibroblasts have been examined under a variety of mechanical stimuli involved in the 
injured myocardium including tension, compression, and shear, although the variety of 
experimental conditions used across the literature has yielded a variety of results100. Two 
well-studied biomechanical factors in the injured myocardium across multiple initial 
pathologies are tensile loading and tissue stiffening. The below sections focus on 
fibroblasts that have been subjected to these mechanical stimuli and trends in ECM-
related protein synthesis. 
2.2.2.1. Fibroblast responses to cyclic tension. Tensile loading has been 
considered one of the principal forms of mechanical stimulation in the infarcted heart, 
with local myocardium experiencing cyclic tension within hours after MI. Compared to 
healthy myocardium, which undergoes compressive loading with normal cardiomyocyte 
contraction, the post-MI left ventricle has been shown to extend in the circumferential 
and longitudinal directions in porcine and rat models101–103. This stretching is likely due 
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to the sudden necrosis of cardiomyocytes and inability to contract, after which 
subsequent blood flow causes tensile loading dependent on the orientation of collagen 
fibers within the myocardium101. This overall process results in tensile strain levels of 
approximately 5-10% after 1-4 weeks27, resulting in activation of a variety of 
mechanotransduction signaling pathways in fibroblasts for altered proliferation, 
migration, and matrix turnover104. 
While cyclic tension has widely been shown to induce collagen expression and 
secretion using in vitro culture systems, the exact relationships between tension and 
changes in matrix-related expression remain unclear. Compiling data from a variety of 
studies measuring the gene expression and secretion of collagens I and III in response to 
tensile load indicates that no one single factor is completely responsible for mediating 
cellular behavior105–126. Rather, a multitude of variables contribute to the extracellular 
matrix expression in each experiment, including cell source, tensile directionality, 
frequency, duration, and several additional environmental factors. As multiple variables 
are altered from study to study, the data results in a scattering of values, even within 
similar strain amplitudes (Figure 1.1 A-B). No one factor alone can entirely account for 
the variation in matrix expression, although parameters including strain amplitude, 
frequency, and directionality all contribute to fibroblast behavior individually100. 
2.2.2.2. Fibroblast responses to substrate stiffness. Changes in the mechanical 
environment surrounding fibroblasts can also result from changes in material properties 
arising from ECM turnover and fiber remodeling. Healthy myocardium has been shown 
to have an elastic modulus of 10-25 kPa as measured by atomic force microscopy127, 
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representing an intermediate levels of stiffness compared to softer tissues such as brain 
and harder tissues such as bone56. Under pathological conditions, however, changes in 
tissue composition can increase stiffness levels perceived by fibroblastic cells. Following 
MI, the infarcted zone becomes stiffer with the accumulation of scar tissue, resulting in 
an average elastic modulus of 55 kPa127. Similarly, increased calcification and scar 
formation following AVS decreases elasticity and increases stiffness of valvular tissue 
during AVS, resulting in upregulated myofibroblast activation128.  
Perceived changes in substrate stiffness can influence fibroblast responses 
including proliferation, migration, cell spreading, and protein synthesis. Previous studies 
have used acrylamide hydrogels, PDMS substrates, collagen scaffolds, and other culture 
environments of tunable stiffness to assess the expression of signaling intermediates and 
matrix proteins116,129–132. These studies have found that increased substrate stiffness can 
induce various cell types to upregulate synthesis of matrix proteins by inducing 
cytoskeletal tension and activating tension-dependent signaling pathways. For example, 
Herum and colleagues recently found that cardiac fibroblasts alter a host of ECM-related 
genes with culture on increasingly stiff substrates, including genes for collagens I and III, 
tenascin-c, periostin, osteopontin, thrombospondin 1, and secreted protein acidic and rich 
in cysteine (SPARC)131. Conversely, the Anseth group demonstrated that reductions in 
stiffness can rescue VICs from an activated phenotype133,134. By using a photodegradable 
hydrogel system to reduce the elastic modulus for cultures from 32 kPa to 7 kPa, Wang 
and colleagues found that cells displayed reduced αSMA stress fibers, proliferation, and 
connective tissue growth factor associated with a quiescent phenotype134. Taken together, 
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these findings across studies suggest that pathologically stiff environments induce 
fibroblast activation consistent with that observed in post-injury myocardium.  
2.2.2.3. Mechano-chemo interactions. The myocardial extracellular environment 
contains a multitude of biochemical signals after an injury, and fibroblasts are constantly 
Figure 1.1. Collagen I and III expression at both the mRNA and protein levels vary greatly in response 
to mechanical strain in vitro across a variety of fibroblast types (A/B) and strain environments (C/D). In 
general, most studies have reported increased production in stretched fibroblasts, though the response is 
clearly not consistent across studies and seems to depend on many factors, including strain magnitude, 
strain frequency, matrix adhesion type, chemical environment, and others. Reproduced from Rogers et 
al.100 
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stimulated by a dynamic mixture of signaling molecules, growth factors, hormones and 
other stimuli. Even in vitro, cell culture media are filled with a rich biochemical milieu. 
When combined with mechanical stimuli, these factors can alter cellular responses to 
mechanical loading, and a number of studies have examined these combinatory effects, 
typically focusing on growth serum or transforming growth factor β (TGFβ) (both of 
which are known to increase collagen expression independently of mechanical stimulus). 
As a simple example of this interaction, the presence of serum, which contains a 
number of growth factors, has been shown to amplify the production of collagen by 
neonatal cardiac fibroblasts after 48 hours of cyclic tension135. Other studies demonstrate 
conflicting evidence, however, as Husse and colleagues found a decrease in collagen 
mRNA expression for adult cardiac fibroblasts with increasing serum concentration and 
mechanical tension126. The combination of the specific factor TGFβ and mechanical 
tension can also act synergistically, increasing collagen expression beyond that of either 
factor alone. Other studies have also observed interaction effects on expression in 
neonatal cardiac fibroblasts, anterior cruciate ligament fibroblasts, and dermal 
fibroblasts115,124,135,136. While the rationale for this trend is not definitively known, a 
diversity of interaction possibilities should not be surprising given the multiple signaling 
pathways downstream of both mechano- and chemo-stimulation and the many 
intersections of these pathways.  
 Studies investigating individual biochemical and mechanical signals have 
identified evidence of crosstalk between modes of signaling, both through common 
intermediate pathways as well as through secondary activation of one or more additional 
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pathways. Examples of common intermediates include angiotensin II type 1 receptors, 
which have been shown to mediate cardiac fibroblast gene expression in response to both 
increased stiffness and interstitial fluid flow137,138, and phosphoinositide 3-kinase/Akt 
signaling, which in addition to regulating TGFβ and TNFα signal transduction139–141 has 
been shown to function downstream of β1-integrin signaling to regulate fibroblast 
apoptosis142. Several groups have observed the secondary activation of biochemical 
signaling mechanisms initiated by biomechanical signaling and vice versa. The Hinz 
group has investigated the activation of TGFβ by fibroblasts in response to mechanical 
stimuli for example finding that fibroblast-generated forces can release latent TGFβ from 
the surrounding ECM via β-integrins, thereby inducing a positive feedback loop for 
further activation143,144. Conversely, canonical transient receptor potential (TRPC) 
channels have been appreciated for their role as stretch-activated ion channels in 
promoting cardiac fibroblast activation104, but Davis and colleagues observed that the 
TRPC6 channel was required for TGFβ-induced activation of fibroblasts145. TRPC6-/- 
cells displayed attenuated αSMA fiber incorporation and gel contraction in dermal 
fibroblasts with TGFβ treatment as well as significantly smaller scar size and higher rates 
of ventricular rupture in a post-MI mouse model, demonstrating an additional 
mechanism-of-action beyond canonical signaling via Smad signaling. While these studies 
demonstrate the complexity of fibroblast signaling, in which pathway crosstalk and 
feedback play a significant role, the full extent of these interacting pathways remains 
unclear, and further studies investigating the extent and dynamics between pathways are 
needed. 
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2.2.3. Challenges in regulating cardiac fibroblast behavior 
While an increasing amount of experimental research has discovered many of the 
mechanisms governing fibroblast behavior, the complexity of this underlying signaling 
network can complicate efforts to control fibroblast behavior in a targeted manner. For 
therapeutic applications such as preventing the overaccumulation of cardiac scar tissue, 
perturbing a single pathway may not produce the intended overarching effect due in part 
to additional competing cues, potentially confounding results in large animal models or 
clinical trials. This challenge is further complicated by spatial and temporal differences in 
the cellular microenvironment. Spatial differences in mechanical cues such as cyclic 
tension and tissue stiffness observed in the post-MI environment act as local mediators of 
fibroblast activation compared to remote myocardium, and so it is expected that global 
pharmacological treatments such as ACE inhibitors would exert differential responses on 
infarct- and remote-localized fibroblasts. Indeed, Ramirez and colleagues observed that in 
a post-MI mouse model, pharmacological treatments with valsartan (an ARB) and 
aliskiren (a renin inhibitor) primarily affected cardiac gene expression of ECM-related 
proteins in remote regions, with minimal changes in infarcted myocardium146. 
A nuanced understanding how fibroblasts respond to biochemical and mechanical 
cues is essential for developing targeted anti-fibrotic therapies, and several groups have 
suggested that computational approaches can address the above challenges by predicting 
influential mechanisms-of-action and cellular behavior while accounting for complex 
conditions and non-linear network dynamics57,147. Systems-wide computational models 
have shown promise in prediction and therapeutic discovery for both cardiac systems as 
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well as other biological systems, and these approaches are further discussed in the 
following section. 
2.3. Systems modeling of cardiac pathologies 
 The field of systems biology has gained significant traction over the past decade 
for its alternative paradigm for generating insight into biological systems. Computational 
models of molecular and cellular systems using mechanistic models, statistical models, 
and artificial intelligence approaches have been valuable in drug discovery and regulatory 
approval, both from academic and industry perspectives148. While models using all of 
these approaches can be useful for discovering new relationships governing disease 
progression149, ordinary differential equation-based cell signaling network models have 
been particularly exciting for their ability to provide a mechanistic basis for disease 
progression while accounting for complex system dynamics. These networks have been 
used to discover influential pathways and druggable targets across a variety of diseases, 
including a variety of cancers150–152, lymphocyte development153, and drug-induced 
cardiotoxicity154. Using a system of ordinary differential equations to approximate 
changes in activation of signaling proteins, cellular responses to both individual stimuli 
and combinations of stimuli can be predicted across in vivo time scales, providing a basis 
for targeted experimental validation of new mechanisms-of-action or treatments with 
therapeutic potential. This computational approach has also been applied to 
cardiovascular biological systems and has provided insight into mechanisms underlying 
cardiac hypertrophy, arrhythmias, inflammation, and fibrosis. Several cardiac-specific 
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network models are highlighted in Section 2.3.1 below, and remaining challenges in 
modeling cardiac fibrosis computationally are discussed in Section 2.3.2. 
2.3.1. Cardiovascular cell signaling networks 
 Cell signaling networks have been used to describe the roles of multiple cell types 
within cardiovascular pathologies. In particular, many groups have found success in 
approximating cell behavior using fully mechanistic networks, i.e. a system of differential 
equations derived from mass-action kinetics to represent biochemical reactions involved 
in the network155. This strategy has been used to study cardiomyocyte signaling for a 
relatively long period of time; Saucerman and colleagues published one of the first 
models of cardiomyocyte β-adrenergic signaling in 2003, and the authors used this model 
to identify phospholamban and L-type calcium channels as influential regulators of 
isoproterenol-induced calcium signaling156. The group also predicted an alternative 
therapeutic strategy to treat heart failure by improving isoproterenol-mediated cyclic 
AMP induction without increasing basal levels for adverse hypertrophic effects, 
demonstrating the applicability of cell signaling networks towards drug discovery for 
hypertrophy-related heart failure. Zhao and colleagues expanded on this model to account 
for phosphodiesterase (PDE) mediated degradation of cyclic AMP, adding a subsystem of 
equations denoting biophysical interactions between four phosphodiesterase isoenzymes 
and cyclic AMP/GMP157. The authors predicted that partial compensation between 
PDE2/4 occurs upon inhibition of either isozyme, forming a novel, influential synergy 
that inhibits cyclic AMP accumulation during heart failure development. The authors also 
show that cyclic GMP potentiates cyclic AMP accumulation via suppression of PDE3, 
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overturning previous hypotheses about PDE regulation and suggesting that suppression of 
β-adrenergic signaling by cyclic GMP may be mediated by an alternative mechanism. 
These studies highlight the value of mechanistic systems in explaining mechanisms 
governing heart failure progression by accounting for complex behavior that are difficult 
to elucidate experimentally, and similar networks have been used to study calcium 
signaling for excitation-contraction coupling158,159. It should be noted that while relatively 
few fibroblast-specific mechanistic models exist in the literature currently, these existing 
models and generalized signaling pathway models have also provided insight into 
fibroblast mechanotransduction and chemotransduction. For example, Schroer and 
colleagues developed a model of fibroblast signal transduction by integrating TGFβ, 
fibroblast growth factor (FGF), and β-integrin pathways to predict the expression of 
αSMA160, demonstrating that focal adhesion kinase dampens fibroblast sensitivity to 
TGFβ stimulation and that extracellular regulated kinase (ERK) largely inhibits αSMA 
expression.  
 While fully mechanistic networks can be advantageous for accurate prediction of 
signaling dynamics, this approach becomes challenging to scale up due to an incomplete 
knowledge of individual reaction parameters. When it is desirable to include a larger 
number of environmental stimuli, as with the post-injury cardiac environment, individual 
rate law parameters must be either known or estimated from robust, time-resolved 
datasets for a larger number of reactions and may not be feasible experimentally149,155. 
Furthermore, most previous experimental literature employed to identify network 
topology identifies qualitative relationships between signaling species (i.e. ‘reactant A 
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activates product B’ or ‘reactant A inhibits product B’), and so direct extrapolation of 
previous literature to a continuous, quantitative biochemical model is often limited. In 
order to overcome these challenges in capturing larger scopes with signaling networks, 
several groups have developed methods for creating logic-based ordinary differential 
equation models by transforming Boolean logic relationships between signaling species 
into a system of normalized Hill differential equations161,162. While these models may not 
always capture quantitative characteristics of mechanistic models, these approaches 
bridge the gap between discrete reaction logic and dynamical models without requiring 
full knowledge of kinetic parameters.  
These models have additionally been shown to accurately predict cellular 
responses to pathological stimuli and therapeutic interventions in cardiovascular systems, 
including fibroblasts, cardiomyocytes, and macrophage-specific changes in behavior. The 
Saucerman group in particular has applied logic-based ordinary differential equations to 
cardiac cell signaling by developing large-scale signaling networks for cardiomyocyte 
chemotransduction and mechanotransduction as well as fibroblast chemo-/mechano-
transduction163–165. Additional groups have also used this approach to describe other 
cardiovascular systems, such a model published by Irons and Humphrey describing 
chemo-/mechano-transduction in vascular smooth muscle cells and adventitial fibroblasts 
during hypertension166 and a recent model developed by Wang and colleagues describing 
pulmonary arterial adventitial fibroblast signaling167. Excitingly, these networks are 
capable of simulating crosstalk between various signaling pathways that may not be 
possible with fully mechanistic models of limited scope. Ryall and colleagues found that 
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based on their model of cardiomyocyte chemotransduction, the proto-oncongene Ras 
acted as a central hub for signaling related to cell area by integrating upstream signaling 
from multiple agonists and maintaining activation of downstream signaling, even with 
knockdown of any individual biochemical input163. Zeigler and colleagues demonstrated 
sizable cross-talk between TGFβ and biomechanical signaling in a model of cardiac 
fibroblast signaling, as both model predictions and experimental validation found that the 
TGFβ1 receptor is necessary for mechanically-induced αSMA expression and contraction 
of collagen gels165. By incorporating multiple signaling inputs at once, logic-based 
signaling networks can predict cell responses to complex environmental conditions with 
direct translational applications. Using their model of cardiac fibroblast signaling for 
example, Zeigler and colleagues recently simulated cellular responses to time courses of 
post-MI biochemical stimuli mimicking the inflammatory, reparative, and maturation 
phases of wound healing168. The authors found that different intracellular signaling 
species mediate collagen I and III expression during early, intermediate, and late phases 
of wound healing, thus informing potential time courses for treating MI patients with 
anti-fibrotic therapeutics.  
An exciting translational application of logic-based signaling networks is the 
ability to conduct comprehensive drug screens in silico by predicting cell responses to 
knockdowns of individual or combinations of signaling species, which act as analogs for 
pharmacological perturbations. Tan and colleagues conducted one such drug screen using 
a model of cardiomyocyte mechanotransduction, finding that several perturbations in 
combination with angiotensin receptor blockers could provide therapeutic benefit above 
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the use of angiotensin receptor blockers alone, such as those inhibiting ET-1 receptors or 
integrins164. Applications of this computational approach to specific pathological 
scenarios can provide a basis for further experimental studies and ultimately improve the 
efficiency of drug discovery by accounting for many connected signaling pathways 
simultaneously. 
2.3.2. Remaining challenges in model-informed therapeutic development 
 Network models of cell signaling have created a wealth of opportunities to 
accelerate drug discovery across multiple disease areas by pointing investigators towards 
influential mechanisms-of-action within a large-scale system. While several groups have 
made progress in tailoring these models for cardiac fibrosis as discussed above, several 
challenges remain in using this approach to predict pathological fibrosis in a spatially 
resolved manner.  
As discussed in Section 2.2, fibroblast-mediated ECM synthesis is informed by a 
diverse range of biochemical and biomechanical cues, and in order to predict fibroblast 
behavior in response to these stimuli simultaneously, a robust understanding of the 
signaling pathways underlying both types of stimuli is essential. While previous 
computational studies of fibroblast signaling have incorporated both chemotransduction 
and mechanotransduction pathways to predict ECM turnover by fibroblasts, the model 
topologies have often relied on a subset of mechanotransduction pathways such as 
integrin-focal adhesion kinase signaling, thereby predicting cell behavior without full 
knowledge of the system. Moreover, recent in vitro studies have discovered additional 
surface sensors of biomechanical forces with implications for cardiac fibroblast signaling, 
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such as the mechanosensitive ion channels Piezo 1/2 or the transcriptional co-activator 
Yes Associated Protein 1104. Because preceding fibroblast signaling networks do not 
account for these newly discovered signaling species, implementing these species and 
related signaling crosstalk may provide further insight into fibroblast responses to 
changes in local biomechanical cues. 
 An additional challenge remaining for predicting fibrosis is predicting changes 
across multiple layers of regulation. In addition to the intracellular signaling interactions 
studied in previous network models, regulation of cell behavior can occur in at the 
transcriptional level via expression of additional transcription factors which initiate or 
block transcription of target genes. Previous studies have shown that these transcriptional 
mediators play an essential role in controlling responses to environmental signals, such as 
the SOX9 transcription factor during cardiac fibroblast-mediated fibrosis after ischemic 
injury169,170. Additionally, a variety of computational methods have been developed to 
derive transcriptional networks from large-scale transcriptomic data, making the 
prediction of transcriptional regulation in biological systems viable171. Integrating 
networks of transcriptional regulation with cell signaling models has been shown to 
generate more nuanced insight into disease states than gene expression or signaling 
information alone, with one such model identifying influential transcription factors 
associated and sensitive targets of anti-cancer drugs in multiple subtypes of breast 
cancer172. By combining signal transduction and transcriptional regulation, these 
composite networks can improve predictive capabilities for complex disease states, and 
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such integrated strategies could prove advantageous for predicting cardiac cell behavior 
underlying cardiac fibrosis.  
 One additional challenge to be addressed in model-informed drug discovery stems 
from a need to treat disease progression in a patient-specific manner. As discussed in 
Section 2.1.1, current pharmacological treatments for post-injury heart failure progression 
do not improve outcomes for a substantial proportion of patients, and similar rates of 
ineffectiveness persist for drugs across many pathological conditions173. While traditional 
clinical trials have shown overall improvements in patient populations with these 
treatments compared to placebo or previous standards of care, a shift towards precision 
medicine, in which patient-specific features are used to inform decisions about treatment, 
can improve outcomes for a greater proportion of patients. Systems-level models are 
uniquely positioned to address this need by integrating patient-specific data with 
mechanistic knowledge of a biological system, ultimately predicting cell- and tissue-level 
responses on a patient-by-patient basis. Such methods have been used successfully in 
various computational models of cancer and lysosomal disorders among other 
diseases174,175. This approach has not yet been extensively applied towards treating 
cardiac fibrosis, however, and integrating patient populations into models of cardiac cell 
signaling and transcription could enable a more comprehensive understanding of 
maladaptive fibrosis and create predictive tools for optimizing outcomes for individual 
patients. While solving each of the challenges above will ultimately require long-term 
efforts in model development and use, building on current models of cardiac fibroblast 
signaling with these goals in mind will enable further insight into the mechanisms 
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underlying cardiac fibrosis and generate new hypotheses towards treating fibrosis in a 
targeted manner. 
2.4. Introduction to dissertation aims 
 The following chapters of this dissertation will focus on investigating mechano-
chemo interactions in cardiac fibroblast-mediated fibrosis through experimental and 
computational studies. As discussed in Section 2.2.3, interactions between biomechanical 
and biochemical stimuli after cardiac injury frequently guide overall fibroblast behavior 
and complicate efforts to prevent maladaptive fibrosis. While previous experimental 
studies have elucidated relationships between individual cues, systems-level experimental 
and computational approaches can be used to account for a larger scope of interactions 
consistent with the in vivo microenvironment. By combining a high-throughput 
mechanical and biochemical testing of cardiac fibroblasts with computational models of 
fibroblast signaling and transcriptional regulation, this work aims to further understand 
the extent of interactions between mechanical and biochemical signal transduction, the 
mechanisms integrating these signals, and potential pharmacological avenues for treating 
pathological fibrosis in patients.  
In Chapter 3, a high-throughput bioreactor was used to subject cardiac fibroblasts 
to mechanical tension in combination with several fibrosis-related biochemical agonists, 
testing the hypothesis that interactions between mechanical loading and canonical 
agonists mediate fibrotic behavior. In Chapter 4, a manually curated computational model 
of cardiac fibroblast signaling was expanded to include new mechanotransduction 
signaling mechanisms, and global sensitivity analyses, targeted validation against current 
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literature, and comprehensive drug screens were used to demonstrate the model’s ability 
to predict context-dependent changes in ECM expression. In Chapter 5, a new network of 
fibroblast transcriptional regulation was inferred from patient-specific transcriptomic 
data, and this network was integrated into the above model of cardiac fibroblast signaling 
to predict changes in gene expression on a patient-by-patient basis. Taken together, this 
work suggests that cardiac fibroblast responses to the local biochemical environment are 
highly context-specific, and the integration of multiple pathways using large-scale 
modeling approaches can be a powerful approach for identifying influencers of network-
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AIM 1: TEST THE HYPOTHESIS THAT INTERACTIONS BETWEEN 
MECHANICAL LOADING AND CANONICAL BIOCHEMICAL CUES MEDIATE 




Myocardial infarction (MI) affects a significant proportion of the US population, 
with approximately 8 million adults diagnosed from 2011-2014 1. Although short-term 
outcomes have improved with the widespread adoption of percutaneous coronary 
intervention and reduced response times 2, maladaptive scar tissue formation in the 
myocardium can lead to serious post-MI complications such as cardiac rupture, infarct 
expansion, or heart failure. These complications are dependent on a balance between 
tissue formation by the synthesis of extracellular matrix (ECM) and tissue degradation by 
a variety of proteases including matrix metalloproteinases (MMPs). While ECM 
synthesis is desirable at the infarct site for maintaining the structural integrity necessary 
to prevent cardiac rupture, excessive matrix accumulation can reduce systolic and 
diastolic function by increasing wall stiffness and decreasing wall conductivity, resulting 
in progression to heart failure 3. Thus, controlling local ECM turnover is an essential 
component in promoting healthy scar formation post-MI.  
Cardiac fibroblasts mediate the fibrotic response to injury by assuming an 
activated phenotype and synthesizing both matrix proteins and proteases, thereby 
controlling the balance in matrix turnover to form collagenous scar tissue 4. Fibroblasts 
are highly responsive to post-infarct biochemical cues consisting of pro-inflammatory 
cytokines, growth factors, and hormonal agents that stimulate fibroblasts to degrade or 
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deposit ECM. A growing body of research has also shown that fibroblast functionality is 
dependent on local mechanical cues; MI-induced loss of cardiomyocytes results in 
increased circumferential stretch at the infarct 5,6, which stimulates fibroblast activation 
through several mechano-sensing mechanisms 7. While biochemical and mechanical 
signaling pathways have been studied individually in cardiac fibroblasts, few studies have 
examined the interplay between biochemical and mechanical signaling. Previous studies 
have shown that cytokine-stretch combinations can alter fibroblast activation beyond 
either cytokine or stretch treatment alone 8,9, but several questions remain regarding the 
role of stretch within the context of biochemical signaling, such as the relative 
contribution of stretch towards fibrosis compared to biochemical agonists and the ability 
of stretch to regulate biochemical signaling.  
In this study, we address these questions by assessing the effects of six different 
biochemical agonists on cardiac fibroblast behavior in different mechanical contexts. 
Using a multi-well cell stretching device, we subjected adult mouse cardiac fibroblast 
(mCF)-seeded fibrin gels to multiple doses of each agonist under static conditions or 
cyclic stretch. By measuring the secretion of 13 fibrosis-regulating proteins across all 
mechano-chemo combinations, we examined how stretch contributes to overall fibrotic 
activity when combined with each agonist as well as how stretch alters agonist-mediated 
protein secretion. We found that stretch contributed to overall fibrotic activity when 
added to individual agonists by either amplifying agonist-mediated downregulation or 
suppressing agonist-mediated upregulation of several matrix metalloproteinases. We 
further analyzed these data to identify cases in which stretch alters fibroblast sensitivity 
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towards biochemical agonists and found that stretch sensitized fibroblasts towards 
agonists that downregulate protease expression and dampened the effects of agonist 
stimulation on protease upregulation. This systems-level study provides a resource of 
fibroblast protein expression in response to interacting environmental stimuli and 
highlights the complexity of intracellular signaling pathways in determining fibroblast 
phenotypes within the post-MI environment. 
3.2. Results 
mCF-seeded fibrin gels secrete matrix-regulating proteins across several orders of 
magnitude 
In order to subject fibroblasts to biochemical stimuli and mechanical stretch, we 
used a multi-well stretching device in which deformable culture wells transmit uniaxial 
tension to 3-dimensional cell-seeded fibrin constructs suspended by opposite sets of 
vertical polydimethylsiloxane (PDMS) posts (Figure 3.1A-B, see Materials and Methods 
for full description). When subjected to uniaxial stretch within the culture wells, 
constructs experienced tensile strain primarily in the axial direction with non-zero strains 
in the transverse direction, mimicking increases in tissue strain in the circumferential-
longitudinal plane measured in rat and porcine models following coronary ligation 5,10. 
mCFs maintained viability over a 96-h treatment period (Figure A-2) and  aligned 
preferably towards the direction of stretch across all experimental groups (Figure A-3), 
which parallels previous studies that show preferential cell orientation towards both static 
boundary conditions and applied strain 11,12.   
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 We used this culture platform to treat mCFs with either one of six biochemical 
agonists alone, cyclic stretch alone, or combinations of agonist treatments and stretch 
over a 96-h period to facilitate measurable protein secretion (Figure 3.1C). Using a 
multiplexed immunoassay for simultaneous, quantitative detection of soluble proteins, we 
measured secreted levels of 13 secreted proteins associated with cardiac fibrosis in 
agonist-/stretch-treated samples (see Materials and Methods for full description). Across 
all experimental groups, protein secretion varied across several orders of magnitude, from 
μM levels of collagen I-associated peptides to pM levels of several proteases and 
inhibitors (Figure 3.2A). Interestingly, mCFs consistently expressed several species that 
have not been widely associated with fibroblast-specific protein expression, namely 
Figure 3.1. Generation and treatment of cardiac fibroblast-seeded constructs. (A) Schematic of 
multi-well membrane modified with PDMS posts. Red surfaces represent silicone culture surfaces, with 
the addition and culture of cell-seeded fibrin resulting in anisotropic constructs that can be uniaxially 
stretched (cutout). (B) Brightfield (BF) and immunofluorescent staining for DAPI and αSMA for 
fibroblast-seeded gels after treatment. (C) Combinations of low dose (LD) and high dose (HD) 
biochemical agonists used in combination with cyclic stretch on fibroblast-seeded constructs. 
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MMP12, TIMP4, and THBS4 13. Additionally, select proteins exhibit greater variance 
across experimental groups than others as evidenced by coefficients of variation (Figure 
3.2B), even within similar functional categories (e.g. MMP2/MMP9), which may be 
indicative of proteins with higher general sensitivity vs. robustness against stimulation.  
Biochemical stimuli differentially modulate secretion profiles of proteases and 
matricellular proteins 
 We examined the relationships between biochemical cues and fibrosis-related 
protein secretion by comparing the effects of biochemical agonists with un-stretched 
controls on proteins secretion. Consistent with analyte coefficients of variation across all 
experimental groups, matricellular proteins POSTN and OPN and MMPs 1, 8, 9 and 12 
were highly sensitive to biochemical simulation with variable expression across all 
Figure 3.2. Cardiac fibroblasts express fibrosis-regulating proteins across orders of magnitude in 
response to biochemical and mechanical perturbations. (A) Cell count-normalized protein 
concentrations for un-stretched controls and all perturbations (i.e. stretched, agonist-treated, or stretched 
and agonist-treated). (B) Coefficients of variation (CV) for protein concentrations across all conditions. 
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treatment groups (Figure 3.3A). Other species were robust to changes with biochemical 
cues resulting in minor trends with stimulation by TNFα and PDGF, including protease 
inhibitors, collagen I-associated peptides and MMPs 2 and 3. Across both sets of 
treatment doses, inflammatory cytokines IL-1β and TNFα uniquely regulated protein 
secretion compared to other agonist types, with high doses of both agonists particularly 
upregulating MMP9 secretion compared to unstretched controls (p=5.1E-4 and 3.9E-10 
for IL-1β and TNFα respectively). Trending and significant increases in MMP1, MMP12, 
and collagen I-associated peptide levels additionally suggest that mCFs shift in balance 
towards the secretion of anti-fibrotic proteins in response to these inflammatory stimuli 
(p-values shown in Figure A-5A).  
Cyclic stretch combines with biochemical stimuli to dictate overall protein secretion  
 Although the importance of mechanotransduction in cardiac fibrosis has gained 
attention recently, it is still unclear how this signaling axis integrates with complex 
Figure 3.3. Biochemical agonists and mechano-chemo combinations alter profiles of fibroblast 
secretion of matrix-related proteins. All values represent log2(fold-change) comparing each agonist 
treatment to designated controls. (A-C) Dot plots representing changes in secretion with individual 
agonists (A), changes in secretion with cyclic stretch (B), either alone (left column) or in combination 
with agonists, and changes in secretion with agonist-stretch in comparison to stretch-only samples (C). 
All statistical comparisons against respective controls were made using two-way ANOVA with 
Dunnett’s post-hoc tests. 
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biochemical signaling during cardiac remodeling. We first examined cyclic stretch as an 
individual stimulus compared to un-stretched controls and found that stretched mCF 
cultures upregulated collagen I-associated peptide levels and showed trending increases 
in POSTN and MMPs 1, 8, and 12 compared to un-stretched controls (Figure 3.3B, left 
column, p-values shown in Figure A-5B), indicating that stretch alone did not produce 
definitively pro-fibrotic behavior. We then examined the role of stretch in conjunction 
with biochemical signaling by comparing secreted protein levels for cultures subjected to 
agonist-stretch combinations to un-stretched controls. Like static cultures, matricellular 
proteins and MMPs 1, 8, 9 and 12 were the most variably secreted across agonists (Figure 
3.3B, right heatmap), although inflammatory cytokines showed notably weaker 
upregulation of MMPs 1, 9, and collagen I-associated peptides under stretch compared to 
static conditions.  
In order to understand how mechanical stretch contributes to overall fibroblast-
mediated remodeling, we quantified differences between the effects of agonist treatments 
alone (i.e. agonist-only treatments vs. un-stretched controls) and agonist-stretch 
combinations (i.e. combinations vs. un-stretched controls, see Materials and Methods for 
full description). We categorized these differences in overall protein secretion into three 
groups: (1) stretch can have an additive effect by enhancing secretion levels beyond those 
of agonist stimulation alone (Figure 3.4A with example in 3.4D), (2) stretch can have a 
subtractive effect by suppressing changes in secretion with agonist treatment (Figure 3.4B 
with example in 3.4E), and (3) stretch can have an inverting effect by overriding the 
effect of agonist stimulation alone, thus changing the overall effect from upregulation to 
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Figure 3.4. Cyclic tension differentially alters the effects of biochemical stimulation on fibroblast 
protein secretion. (A-C) Effects of agonist-stretch combinations on overall protein secretion. X-
coordinates represent the effect of agonist treatments alone relative to un-stretched controls, and y-
coordinates represent the effect of agonist-stretch combinations relative to un-stretched controls. 
Shaded areas indicate secreted proteins that show an additive effect compared to agonist treatment 
alone (A), a subtractive effect (B), or an inverting effect from downregulation to upregulation and vice 
versa (C). (D-F) Representative plots demonstrating effects of agonist-stretch combinations compared 
to agonist treatment alone. Values for all groups are normalized to mean levels of un-stretched controls, 
solid lines represent median levels, dashed lines represent mean levels, and whiskers represent 1.5(IQR) 
levels. (G-I) Stretch effect magnitudes for cases of additive effect (G), subtractive effects (H), or 
inverting effects (I). Magnitudes are expressed in log2(fold-change), and Student’s t-tests with 
Bonferroni correction for multiple comparisons are used for all comparisons against un-stretched 
controls. Asterisks represent level of confidence in interactions: * p< 0.2; ** p< 0.1; *** p< 0.05.  
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downregulation or vice versa (Figure 3.4C with example in 3.4F). From this analysis, we 
found that stretch showed trending or significant additive effects on agonist stimulation 
for 11 agonist-secreted protein pairs and showed trending or significant antagonistic 
effects for 8 pairs.  
Within the additive effect group, stretch showed the most evidence of further 
upregulating MMP12 (Figure 3.4G), with increases in expression in conjunction with IL-
1β (p=0.013 for agonist/stretch combination versus un-stretched controls), TNFα 
(p=0.023), NE (p=0.055), and AngII stimulation (p=0.12). Secreted levels of OPN were 
also further increased by stretch when combined with low-dose TGF-β1 and AngII 
treatments, resulting in approximately 3-fold increases relative to un-stretched controls 
(p=0.050 and 0.11, respectively). Stretch also showed synergistic trends in a suppressive 
manner; when combined with TNFα, TGF-β1, and NE treatments, stretch further 
decreased the expression of MMP2, leading to over 2-fold reductions in protease levels 
compared to un-stretched controls (p=0.10, 0.16, and 0.18, respectively). By quantifying 
differences between agonist-only effects and combination effects across all agonist-
secreted protein pairs, we found that the addition of stretch exerts the largest changes in 
expression for MMP12, with multiple agonist/stretch combinations increasing secreted 
levels approximately 2-fold above agonist-only counterparts (Figure 3.4G).  
Stretch demonstrated subtractive effects on protein secretion by suppressing the 
secretion of matrix metalloproteinases that were upregulated by agonist treatments alone 
(Figure 3.4B). MMP9 upregulation by several agonists was especially suppressed by 
stretch, as both IL-1β and TNFα significantly reduced expression in combination with 
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Figure 3.5. Cyclic tension alters cardiac fibroblast sensitivity to biochemical agonists. (A-C) 
Changes in agonist effect on protein secretion for fibroblasts in static or strained cultures. X-coordinates 
represent effects of agonist treatments relative to un-stretched controls, and y-coordinates represent 
effects of agonist-stretch combinations relative to samples subjected to stretch only. Shaded areas 
indicate secreted proteins that show sensitization towards agonists (A), desensitization (B), or 
sensitivity reversal from upregulation to downregulation (C). (D-F) Representative plots demonstrating 
stretch-mediated changes in sensitivity of fibroblasts to agonist treatment. Values for un-stretched 
groups (gray) are normalized to mean levels of un-stretched controls, and values for stretched groups 
(colors) are normalized to mean levels of stretch-only groups. (G-I) Sensitivity magnitudes for cases of 
sensitization (G), desensitization (H), or sensitivity reversal (I). Magnitudes are expressed in log2(fold-
change), and Student’s t-tests with Bonferroni correction for multiple comparisons are used for all 
comparisons against respective controls. Asterisks represent level of confidence in interactions: * p< 
0.2; ** p< 0.1; *** p< 0.05.  
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stretch compared to treatment with either cytokine alone (Figure 3.4H). However, stretch 
also demonstrated antagonism towards the secretion of collagen I-associated peptides and 
protease inhibitor PAI1, as upregulated secretion of these species by IL-1β or TNFα were 
suppressed to near-control levels. Several agonist-secreted protein pairs also trended 
towards an inverting effect in which agonist/stretch combinations upregulated the 
expression of proteins that were downregulated by agonists alone (Figure 3.4C), such as 
TGF-β1-mediated secretion of MMP12 (Figure 4F). Although not meeting our criteria for 
statistical significance, these cases could also prove important in determining the full 
effect of stretch on cardiac remodeling, and further studies are necessary to explore these 
trends. 
Cyclic stretch modulates fibroblast sensitivity to biochemical stimulation 
 In order to quantify the ability of stretch to regulate biochemical signaling, we 
adapted the analysis discussed above to compare the effects of agonist treatments in a 
static context (i.e. agonist-only treatments vs. un-stretched controls) and in a stretched 
context (i.e. agonist/stretch combinations vs. stretch-only treatments). We categorized 
changes between contexts into three groups: (1) stretch can sensitize fibroblasts towards 
biochemical stimuli by enhancing the effect of agonist treatment under stretch (Figure 
3.5A, with example in 3.5D), (2) stretch can desensitize fibroblasts by suppressing the 
effect of agonist stimulation (Figure 3.5B, with example in 3.5E), and (3) stretch can 
reverse fibroblast behavior completely by causing agonists to downregulate secretion 
compared to upregulation in a static environment, or vice versa (Figure 3.5C, with 
example in 3.5F). We found that stretch showed trending or significant evidence of 
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agonist sensitization for 12 agonist-secreted protein pairs and showed similar evidence of 
agonist de-sensitization for 12 pairs compared to the same treatments under static 
conditions. None of the reversals were statistically significant. 
 Within the sensitizing group, stretch primarily acted to amplify agonist-mediated 
suppression, mediating further suppression of MMP8 levels by TNFα (p=0.044 for 
agonist/stretch combination versus stretched-only samples) and PDGF (p=0.059). 
Multiple agonists also exhibited amplified suppression of POSTN secretion with stretch, 
Figure 3.6. Cyclic stretch modulates 
overall secretion of matrix-related 
proteins. (A) Sensitivity of individual 
secreted proteins to all biochemical agonists 
in both stretch contexts. Levels for each 
output were calculated as the sum of 
log2(fold-change) values with each agonist 
relative to control as a representation of 
overall response of each output towards all 
agonists. (B) Influence of individual agonists 
across all secreted proteins in both stretch 
contexts. Values for respective analyses are 
ranked by un-stretched levels for each 
species. Levels for each agonist were 
calculated as the sum of log2(fold-change) 
values of each output relative to control as a 
representation of overall effect of each 
agonist towards all outputs. 
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with TNFα, PDGF, and IL-1β all showing trending or significant suppression in a 
stretched context (p=0.020, 0.034, and 0.16 respectively). Interestingly, AngII appeared 
to further suppress MMP1, MMP12, and OPN under stretch, with MMP1 levels 
decreasing to almost 25% of those for stretch-only samples (Figure 3.5D). Of these 
trends, secreted outputs MMP8 and POSTN appeared to have the highest degrees of 
sensitization, as TNFα and IL-1β reduced expression of these proteins by approximately 
2.5-fold more under stretch than under static conditions (Figure 3.5G).  
Fibroblasts also showed decreases in sensitivity towards select agonist treatments 
under stretch (Figure 3.5B); in particular, expression of MMP9 and OPN, both of which 
were upregulated in response to multiple agonists in static conditions, were not 
significantly altered by the same agonists under stretch (Figure 3.5E). Interestingly, 
secretion of PINP and PAI1 also showed significant desensitization towards low-dose 
TNFα stimulation under stretch, although magnitudes of these changes were less than 
those for TNFα-mediated MMP9 secretion (Figure 3.5H).  
We additionally found that several agonist-secreted protein pairs demonstrated a 
reversal in sensitivity in which agonists that upregulated protein expression in static 
conditions downregulated expression under stretch (Figure 3.5C). Similarly to our 
findings of overriding effects described above, these cases did not meet our criteria for 
statistical significance. However, this type of behavior appears to be consistent for 
MMP1, MMP8, and POSTN expression (Figure 3.5I), with TNFα stimulation reducing 
MMP1 expression to roughly 40% of stretch-only levels (Figure 3.5F). Further studies 
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validating these trends are necessary to fully understand the ability of stretch to reverse 
the effects of biochemical stimulation. 
Cyclic stretch differentially regulates global fibroblast sensitivity to cytokine stimulation 
 We lastly assessed the sensitivity of each secreted protein to all biochemical 
agonists in either static or stretched conditions to identify global trends in mechano-
chemo interactions. Using a summed fold-change metric for total sensitivity, we found 
that matricellular proteins OPN and POSTN as well as MMPs 1, 8, 9, and 12 ranked as 
the most sensitive to biochemical treatment in both mechanical conditions  (Figure 3.6A). 
Within these outputs, OPN, MMP9, and MMP1 all showed de-sensitization towards all 
agonists under stretched conditions, although total sensitivity levels still ranked highly 
overall. Alternatively, both POSTN and MMP8 showed increased sensitivity to agonist 
stimulation in a high-stretch environment, indicating that these species may be more 
readily regulated within infarcted areas. Using a similar analysis to compare agonist 
regulation across all secreted outputs, we found that stretch altered the overall influence 
of TNFα, NE, and AngII on the secretion of all proteins (Figure 3.6B).  While stretch 
decreased the total magnitude of effects from TNFα stimulation, however, both NE and 
AngII exerted greater changes in protein levels within a stretched environment, more than 
doubling the influence of AngII on protein secretion. 
3.3. Discussion 
Study design 
The contribution of fibrosis to heart failure after MI has gained attention due to its 
role in chronic mechanical and electrical dysfunction. Prior studies of fibroblast behavior 
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have highlighted the central role of dynamic mechanical stretch in the development of 
scar tissue, and future drug therapies that account for cell responses to this mechanical 
environment as well as responses to biochemical signals could improve patient outcomes. 
By screening the effect of individual biochemical stimuli for their effects on fibroblast-
specific matrix remodeling in the presence and absence of cyclic stretch, we sought to 
generate new insight into stretch-mediated fibrosis within the complex post-infarct 
environment. 
In order to subject fibroblasts to biochemical stimuli and stretch while simulating 
myocardial architecture and material properties, we employed a previously developed 
strategy in which cells are incorporated into a fibrin matrix and seeded into culture wells 
containing vertical, opposing sets of silicone posts. Fibroblasts cultured in this manner 
have been shown to remodel the surrounding matrix and form aligned constructs with 
comparable stiffness to myocardial levels 14–17, thus mimicking in vivo mechanical 
conditions more closely than 2-dimensional mechanical testing systems which typically 
utilize culture surfaces with supraphysiologic stiffnesses. It should be noted that even 
upon returning to a soft substrate after culture on stiff substrates such as tissue culture 
plastic, fibroblasts permanently exhibit altered adhesion and maintain an activated state 
as reported by the Hinz group 18,19. We acknowledge that this fundamental issue in 
mimicking in vivo conditions can confound mechanotransduction-related cell behavior, 
and although mCFs assumed an activated state throughout treatment the use of soft gels 
prevented further stiffness-related stimulation during treatment, and myofibroblast-
mediated remodeling could be examined without confounding mechanical factors.  
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Relative secretion levels of matrix proteins and proteases 
We first aimed to contextualize the effects of environmental cues on fibroblast-
mediated scar formation by comparing absolute concentrations of mCFs-secreted proteins 
across and within functional categories. Collagen I-associated peptides were 
predominately secreted along with MMP1, MMP2, MMP8, and TIMP1, which although 
secreted at distinct stages after myocardial injury 20, point to dominant mechanisms of 
ECM turnover via fibrillar collagen synthesis collagenase-mediated degradation. We also 
detected relatively small, but consistent levels of MMP12, TIMP4, and THBS4, all of 
which have been observed in fibroblast-specific gene expression studies but have not yet 
been directly measured at the protein expression level 13,21–23. These biomarkers have 
been implicated in post-infarct remodeling either through paracrine signaling toward 
resolving inflammation as in the case of MMP12 24, or by modulating responses to 
pressure overload as in the case of THBS4 25. Their direct link to cardiac fibroblast 
secretion suggests that fibroblasts may act in a communicatory role in addition to directly 
mediating matrix turnover. 
Differential sensitivity of secreted proteins and influence of biochemical stmuli 
We compared fibroblast-specific matrix remodeling across biochemical stimuli by 
measuring matrix-related protein expression for six canonical agonists that have been 
shown to individually mediate fibroblast function 26. MMPs 1, 8, 9, and 12 and 
matricellular proteins OPN and POSTN were highly sensitive to agonist treatments 
compared to all other measured proteins. This finding of differential sensitivity towards 
stimuli is supported by targeted studies of MMP expression and activity such as that of 
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Siwik and colleagues in which IL-1β treatment  induced large increases in MMP9 activity 
relative to MMPs 2 and 13 27. Although absolute concentration levels were small for 
several proteins relative to other secreted outputs, large changes in expression suggest 
that select proteases may play an essential role in mediating biochemically driven matrix 
turnover.  
Both inflammatory agonists used in our study exhibited a unique influence on 
protease expression relative to other agonists. We observed that both IL-1β and TNFα 
mediate significant increases in MMP9 levels, with TNFα additionally upregulating 
MMP12 expression, which suggest that inflammatory factors primarily acted to 
upregulate protease expression. These trends agree with parallel increases of 
inflammatory and protease levels within the acute post-infarct phase, which form the 
basis for removing necrotic tissue from the infarcted area 28–30, as well as in vivo studies 
in which TNFα-/- mice displayed reduced MMP9 expression, earlier collagen deposition, 
and reduced incidence of rupture post-MI compared to wild-type mice 31. Both MMP9 
and MMP12 have been implicated as key mediators of cardiac fibrosis and ventricular 
function post-MI, as MMP9-/- mice subjected to left coronary arterial ligation displayed 
enhanced MMP levels and attenuated collagen accumulation compared to wild-type mice 
32, and Ramirez and colleagues found MMP9-/- mice exhibited improved responses to 
renin inhibitor aliskiren and angiotensin receptor inhibitor valsartan by attenuating 
increases in fibrotic gene expression, collagen content, and improving overall survival 33. 
Pharmacological inhibition of MMP9 and MMP12 both exacerbated left ventricular 
function post-infarction 24,34, confirming the highly influential roles of both proteases and 
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suggesting that MMP9-regulated tissue remodeling may be specific to the spatial and 
temporal context. 
Contribution of tension to overall protein secretion 
Mechanical stretch has been widely shown to induce pro-fibrotic phenotypes in 
cardiac fibroblasts as one component of overall mechanical stimulation 35. While 
previous work has shown that tensile forces can modulate fibroblast responses when 
combined with biochemical stimulation 8,9, it is still unclear how stretch contributes 
towards overall remodeling compared to biochemical signaling, and whether mechanical 
and biochemical signaling axes operate dependently or independently of each other. We 
aimed to answer these questions by treating mCF cultures with combinations of 
biochemical agonists and mechanical stretch and comparing the effects of these 
combinatory treatments to those of agonist-only treatments on protein expression. 
We found that cyclic stretch altered protein secretion in two primary modalities: 
stretch either added to the effect of biochemical stimulation by further upregulating or 
suppressing protein secretion, or stretch subtracted from biochemically-mediated effects 
by suppressing expression levels to near-control levels. Stretch further increased 
expression of MMP12 and OPN compared to biochemical stimulation alone whereas 
secreted levels of MMP2 and MMP9 were downregulated, suggesting that stretch 
reinforces pro-fibrotic activity in fibroblasts by suppressing matrix proteases and 
increasing matricellular protein production. Although overall MMP levels are increased 
in the post-MI inflammatory phase with macrophages and neutrophils acting as the 
primary sources for secretion 13, our observed reductions in expression match a transition 
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to the fibrotic phase involving the downregulation of MMPs and replacement of necrotic 
myocardium with collagenous scar 20. MMP12 levels were uniquely amplified with 
stretch compared to cytokine treatment alone, which could be indicative of further 
negative feedback by MMP12 as knockdown studies in post-MI mice have shown both 
an increase in inflammatory signals in the myocardium and a decrease in beneficial 
remodeling 24,36.  
Stretch-dependent sensitivity to biochemical stimulation  
We additionally tested the hypothesis that stretch can not only act alongside 
biochemical stimuli but also alter cellular responses to these stimuli, as previous studies 
have demonstrated similar signaling mechanisms in both chemo- and mechano-
transduction, such as mitogen-activated protein kinase and Akt signaling pathways 14,37–
39. We found that stretch altered fibroblast sensitivity towards agonists by either 
sensitizing cells towards agonists that suppress protease expression (e.g. MMP1, MMP8) 
or by de-sensitizing cells towards agonists that upregulate expression (e.g. MMP9). These 
changes in protease-related sensitivity indicate that stretch interacts with chemo-
transduction pathways to selectively dampen matrix protease expression. While we also 
observed de-sensitization of both OPN and PINP upregulation towards biochemical 
stimuli under stretch, stretch alone upregulated the expression of both proteins, 
suggesting that these ECM components remained upregulated regardless of biochemical 
cues in a stretched environment. These results suggest that the underlying network of 
fibroblast signaling plays a large role in dictating fibroblast responses to competing cues, 
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and further studies examining the intracellular signaling network are necessary to fully 
understand the mechanisms of action guiding fibroblast-mediated remodeling. 
Our findings suggest that cardiac fibroblasts act in a mechano-adaptive manner to 
regulate matrix turnover, with mechanical stretch acting to alter matrix protease and 
matricellular protein secretion both directly, acting independently of biochemical 
signaling, and indirectly, acting to modify biochemical signaling. We found that TNFα-
mediated protein secretion showed the highest degree of mechano-adaptive behavior 
compared to the other agonists tested, with stretch-mediated expression of MMP8, 
MMP9, MMP12, OPN, POSTN, PINP, and PAI1. Similar findings were recently found 
by Aguado and colleagues in which TNFα-mediated deactivation of cardiac fibroblasts 
was amplified depending on substrate stiffness, with a higher proportion of cells reverting 
towards quiescence on stiff hydrogels 40. Our evidence of stretch-mediated sensitization 
and de-sensitization towards TNFα suggests that TNFα signaling mediates fibroblast 
activation under dynamic mechanical conditions. Further studies are necessary to validate 
these relationships between inflammation and stretch in guiding fibroblast phenotypes. 
Study limitations and future directions 
One limitation of this study arises from the variability that arises from the 
measurement of protein expression across biological replicates. The use of separate pools 
of mCFs in our comparisons allowed for genomic variability between replicates, and 
although our use of a mixed-effect statistical model was able to discern agonist- and 
stretch-mediated behavior, we cannot rule out additional mechano-chemo interactions 
that we were unable to detect. However, the interactions that we identified in our analysis 
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persisted despite this variability, thereby improving our confidence in these findings. Our 
screen of mechano-chemo interactions was additionally limited to two doses of 
biochemical stimulation and two mechanical states, and further dose-response studies 
would further explore the extent of relationships between these stimuli. Additionally, a 
number of other secreted factors were not measured in our study that have been shown to 
play significant roles in matrix remodeling, including those related to matrix processing 
and turnover (e.g. cathepsins, lysyl oxidase, etc.) and paracrine signaling (e.g. tenascin-c, 
interleukins, thrombospondins, etc.). Further measurements would provide insight into 
the contribution of fibroblast secretion towards maladaptive remodeling.  
Lastly, our data suggest that fibroblast secretion relies on a complex network of 
intracellular signaling, which contains interactions between transduction pathways that 
dictate overall responses. Several groups have successfully identified influential 
mechanisms of mechano-transduction and mechano-chemo crosstalk using computational 
models of cell signaling 41–43, providing new directions towards controlling cell behavior 
in a dynamic mechanical environment. For translation of these model predictions to 
tissue-scale remodeling and clinical use however, proteomic datasets containing fully-
quantified information for protein states (i.e. absolute active/total protein concentrations) 
are critical for transforming semi-quantitative systems models into those capable of 
predicting absolute changes in cell and tissue properties. The quantitative nature of this 
current proteomic dataset presents opportunities for fitting systems-level models to 
quantitative data and allows for quantitative predictions of fibroblast secretion, and future 
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work integrating these models with proteomic datasets are necessary to predict fibroblast-
mediated matrix remodeling on a systems level. 
 We developed a screen of cardiac fibroblast protein secretion in response to 
combinations of biochemical agonists and mechanical stretch to investigate how cyclic 
stretch influences fibrotic activity within the context of biochemical signaling. We found 
that biochemical stimuli primarily altered the expression of MMPs 1, 8, 9, 12, OPN, and 
POSTN, and inflammatory agonists IL-1β and TNFα particularly promoted protease 
secretion, thereby shifting the balance in matrix turnover towards degradation. The 
addition of stretch to biochemical stimuli shifted fibroblast behavior towards matrix 
accumulation by either further upregulating matricellular protein expression, further 
downregulating protease expression, or antagonizing the upregulation of MMP9 by 
inflammatory agonists. We also found that stretch mediated fibroblast sensitivity towards 
biochemical stimuli by increasing sensitivity towards agonists that suppress MMP1, 
MMP8, and POSTN while decreasing sensitivity towards those that upregulate MMP9, 
thereby priming cells towards matrix accumulation. The screening approach employed 
here allows for the identification of emergent interactions between cell stimuli and can be 
used to inform targeted studies for interactions that govern matrix turnover. 
3.4. Materials and Methods 
Cardiac fibroblast isolation 
All animal procedures were conducted in accordance with the Institutional 
Animal Care and Use Committee at Clemson University. mCFs were isolated and 
cultured as previously reported 44. Wild-type C57BL/6 mice (male, 10-12 weeks old, ~25 
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g body weight) were sacrificed, and hearts were harvested and collected in Krebs-
Henseleit buffer (Sigma, St. Louis, MO). The ventricles were isolated, minced, and 
digested enzymatically at 37 °C with Liberase TM (Roche, Indianapolis, IN). 
Supernatants from six successive digestion periods were collected, centrifuged at 300 x g 
at 4 °C, and resuspended into Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma) 
containing 10% fetal bovine serum (FBS, Atlanta Biologicals, Flowery Branch, GA), 100 
U/mL penicillin G, 100 μg/mL streptomycin, and 1 ng/mL amphotericin B (all Sigma). 
Cells were plated in culture flasks and incubated at 37 °C and 5% CO2 for 4 h. Fresh 
culture medium was added to remove non-adherent cells, and culture medium was 
replaced every 48 h thereafter. mCFs were cultured on tissue culture plastic until passage 
2 before seeding in fibrin gels as described below.  
Fibroblast-seeded fibrin gels 
mCFs were seeded into fibrin gels using a previously reported procedure 16 and 
loaded gels into silicone 16-well plates (CellScale, Waterloo, ON). Fibrin was chosen as 
a scaffold material for its ability to promote de novo collagen synthesis and fibroblast-
mediated remodeling. Previous studies embedding human dermal fibroblasts and smooth 
muscle cells in fibrin gels have demonstrated improved synthesis of collagen compared to 
collagen gels, which tend to inhibit synthesis 45–47. Fibrin additionally allows for cell-
initiated remodeling and compaction of the matrix for a functional assessment of cell 
contractility, and cell-remodeled fibrin gels of a similar density as those used here have 
been shown to have a linear modulus of 19-28 kPa 48, which is more comparable to the 
stiffness of healthy myocardium (10-25 kPa) 35 than collagen gels of a similar density 48. 
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Fibrin has been the focus of tissue regeneration strategies post-MI as a scaffold for cell 
transplantation 49 with cell-seeded fibrin injected into the myocardium improving post-MI 
function in mice 50, and thus the study of fibroblast-mediated remodeling and secretion 
within this matrix could also prove useful for tissue engineering applications.  
Prior to plating gels, well plates were modified to contain six PDMS posts each, 
which have been shown to facilitate gel remodeling by fibroblasts 15,16,51,52. To construct 
the posts, a Delrin mold was fabricated via milling with a negative pattern for sets of 
three posts corresponding with axial ends of each construct. Individual post geometries 
were 1 mm x 1 mm x 2 mm (l x w x h), and posts were spaced 0.75 mm apart within each 
pattern. Upon fabrication of the negative mold, Sylgard 184 PDMS (Dow Corning, 
Midland, MI) was mixed at a 10:1 ratio (base : curing agent), poured into the mold, 
degassed via a vacuum desiccator for 10 min, and cured in a 95 °C oven for 1 h to allow 
for polymerization for an elastic modulus of approximately 700 kPa as determined by 
previous studies 53. Upon curing, sets of posts were removed from the mold and bonded 
to 16-well plates using freshly mixed Sylgard 184 PDMS as a glue. Two sets of posts 
were placed in each well and spaced 5 mm apart on opposing sides in the direction of 
stretch. Well plates were then placed in a 95 °C oven for 1 h to allow for polymerization 
of the PDMS glue. Prior to use, wells were additionally coated with 3.5% Pluronic F-127 
(Sigma) in phosphate buffered saline (PBS, Sigma) for 8 min to prevent adhesion to the 
well surfaces. 
Upon well plate modification, mCFs were removed from flasks with 0.25% 
Trypsin-EDTA (Gibco, Grand Island, NY) and incubated with DiI (Invitrogen, Grand 
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Island, NY) to visualize cell membranes after treatment. Cells were resuspended in a 
thrombin solution (0.44 U/mL bovine thrombin in DMEM with 0.5% FBS) and combined 
with a fibrinogen solution (6.6 mg/mL in 20 mM HEPES-buffered saline) at a 1:1 ratio to 
create a fibrin gel. Upon combining, 200 uL of fibrin gel was added to each well, and gels 
were incubated at 37 °C for 30 min to allow for polymerization. DMEM containing 0.5% 
FBS, 50 ug/mL L-ascorbic acid (Sigma), and 33.3 ug/mL aprotinin (Roche) was then 
added to each well to prevent premature degradation of fibrin gels.  Although a well-
known inhibitor of MMP activation, the expression of collagens, proMMPs, and gel 
contraction compared to negative controls have been shown to remain unchanged with 
added aprotinin in fibroblast- and mesenchymal stromal cell-seeded gels 54,55, suggesting 
that this inhibitor allows for the measurement of protease and matrix secretion while 
maintaining structural integrity of fibrin constructs. After addition of this culture 
medium, gels were cultured for 48 h to allow for gel remodeling. For each replicate, 14 
gels were seeded with 1x105 mCFs for compaction, viability, and immunocytochemistry 
analyses, and 14 gels were seeded with 2x105 mCFs to collect sufficient protein for 
secretomic analysis.  
Cyclic stretch and cytokine treatment 
Prepared well plates were loaded into MechanoCulture FX2 uniaxial stretching 
devices (CellScale, Waterloo, ON). For stretched gels, a strain amplitude of 6.5% and 
frequency of 1.0 Hz was used, which were chosen to match regional circumferential 
strains measured in rats following acute cryoinfarction 5 and in pigs following permanent 
coronary artery ligation 56. Axial and transverse strains for gels were validated by 
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measuring gel deformation during 0.33-mm increments of stretch by the device actuator 
and calculating the 11 (axial) and 22 (transverse) components of the Green strain tensor 
from each set of values (Figure A-1). Gels within each stretch condition were treated with 
either no agonist (control group) or one of six cytokines or growth factors: transforming 
growth factor-β1 (TGF-β1, Cell Signaling Technology, Danvers, MA), angiotensin II 
(AngII, Sigma), interleukin-1β (IL-1β, Cell Signaling Technology), platelet-derived 
growth factor-BB (PDGF, Cell Signaling Technology), L-norepinephrine bitartrate (NE, 
Sigma), and tumor necrosis factor-α (TNFα, Cell Signaling Technology). These agonists 
have all been shown to influence fibrotic remodeling post-MI at both tissue and cellular 
scales 57; AngII and NE, both canonical mediators of cardiac hypertrophy, have been 
shown to alter fibroblast-specific remodeling, with in vivo and in vitro studies of 
angiotensin receptor blockers and neprilysin inhibitors attenuating fibrosis caused by 
AngII infusion 58,59. TGF-β1 and PDGF as growth factors have also become well-known 
mediators of fibroblast activation and fibrosis both post-MI and systemically 60–62, and 
inhibition of either factor has been shown to attenuate fibrosis in the infarcted 
myocardium 61,63. Inflammatory agonists IL-1β and TNFα additionally alter cardiac 
fibrosis as shown in clinical trials of IL-1β inhibitor anakinra and animal studies 
overexpressing TNFα 64,65. While not an exhaustive study of possible fibroblast agonists, 
these six agonists represent several major modes of fibroblast activation post-MI. All 
concentrations were chosen from previous literature measuring fibroblast responses to 
individual agonists including collagen expression 43,66–68, MMP, TIMP, and growth factor 
expression 67,69, and αSMA expression or gel contraction 43 (concentrations displayed in 
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Figure 1C). All gels were treated for a total of 96 h, during which doses and medium 
were replenished after 48 h. 
Gel compaction analysis 
Brightfield images were taken at the beginning and end of treatment using an 
EVOS FL Auto microscope with a 4x Plan Fluor 0.13 NA objective (Life Technologies, 
Grand Island, NY). A 4x3 grid of images were captured and combined to create a 
composite image of each gel. Gel outlines were then segmented using the threshold 
feature in ImageJ 70. Gel compaction was calculated as the fold change of the final gel 
area from the initial gel area. 
Immunocytochemistry and image analysis 
Cell viability was determined via a fluorescence-based assay as described 
previously 71. Gels were stained using a live/dead cell double staining kit (Sigma) 
according to the manufacturer instructions, and fluorescent images were captured at the 
center of each gel for calcein and propidium iodide to identify viable and dead cells, 
respectively. CellProfiler software was used for quantitative image analysis 72. Viable 
cells were identified from calcein images using a minimum cross entropy thresholding 
method, and dead cells were identified from propidium iodide images using a manual 
threshold to remove false positives due to low numbers of dead cells per image. Cell 
viability for each gel was determined as the ratio of viable cells to total cells, and cell 
orientation was measured for viable cells as the angle from the axis of stretch to the major 
axis of each cell.  
 84
For analysis of fibroblast activation, immunostaining and quantitative analysis 
were performed as reported previously 43. Gels were fixed in 10% neutral buffered 
formalin (VWR, Radnor, PA) and washed 3x in PBS. Gels were permeabilized in 0.2% 
Triton-X-100 (Sigma) in PBS and washed 3x in PBS, and gels were blocked with 2% 
bovine serum albumin (Sigma) at 4 °C overnight. Gels were stained with alpha smooth 
muscle actin-Alexa Fluor 488 (αSMA, Invitrogen) and 4’,6-diamidino-2-phenylindole, 
dihydrochloride (DAPI, Invitrogen), washing gels 3x with PBS after applying each stain. 
Fluorescent images were captured at the center of each gel for DAPI, αSMA, and DiI 
stains. Using CellProfiler software, individual cells were identified by DAPI and DiI 
stains, and integrated αSMA intensity was measured within each identified cell. Mean 
αSMA expression levels were calculated as the average integrated intensities across all 
cells per image. Total cell counts for each gel were extrapolated using final gel areas 
calculated in compaction analysis (Figure A-4A). From the number of identified cells in 
each image, total cell counts for each gel were calculated as the product of the cell 
density in each image and the final gel area. 
Secreted protein measurement 
During cell treatments, culture supernatants were collected at both 48 h and 96 h 
after initial treatment and stored at -20 °C. Pro-collagen I amino-terminal propeptide 
(PINP) and matrix metalloproteinase-1 (MMP1) content were both measured via enzyme-
linked immunosorbent assay as per the manufacturer’s instructions (MyBiosource, San 
Diego, CA). Luminex magnetic bead assays (R&D Systems, Minneapolis, MN) were 
used to measure a panel of 11 additional analytes: MMP2, 3, 8, 9, and 12, tissue 
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inhibitors of matrix metalloproteinases-1 and 4 (TIMP1 and 4), osteopontin (OPN), 
periostin (POSTN), thrombospondin-4 (THBS4), and plasminogen activator inhibitor-1 
(PAI1). These analytes were chosen as representatives known to influence cardiac 
fibrosis via matrix production, degradation, or further signaling mechanisms involving 
fibroblasts or other cell types, and have been implicated as clinically-relevant soluble 
markers of scar formation 73. In addition to direct synthesis of matrix proteins as 
measured by PINP levels and secretion of matrix-degrading proteins as measured by 
MMP levels, matricellular proteins POSTN, OPN, and THBS4 have been shown to 
mediate fibrosis in pressure overload models by as in the case of OPN and THBS4 23,74, 
or in fibroblast-specific ablation post-MI as in the case of POSTN 75,76, suggesting 
possible sensitivity towards mechanical stress as well as prominent roles in matrix 
turnover. Therefore, we included these outputs to provide a representative dataset of 
mechano-chemo interactions that encompasses multiple fibrosis-related processes in 
addition to the secretion of matrix proteins and proteases. Luminex assays were measured 
using a MAGPIX magnetic bead reader (Luminex, Austin, TX). Absolute protein 
concentrations were determined from standard curves for each analyte, and all 
concentrations were normalized by total cell counts as determined above to account for 
proliferation-related bias. 
Agonist-stretch effect analysis 
For each measured protein, contrasts between two sets of experimental groups 
were assessed: (i) agonist treatments alone and controls (ΔT0), and (ii) combined agonist-
stretch treatments and controls (ΔTS). Contrasts for both sets were expressed as log2(fold 
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change), and effect magnitudes were calculated as change between contrasts: 𝐸 =
|∆𝑇𝑆 − ∆𝑇 |. Effect directions were calculated as the difference between contrast 
magnitudes: 𝐸 = |∆𝑇𝑆| − |∆𝑇 |. Signs of effect direction terms were used to determine 
categories of combinatorial effects: a positive term denoted an additive effect of 
combined treatment (i.e. stretch further increased or decreased protein secretion beyond 
agonist treatment alone), and a negative term denoted a subtractive effect (i.e. stretch 
suppressed the effect of agonist treatment alone). Individual contrasts that had opposite 
signs (e.g. ΔT0<0 and ΔTS>0) were denoted as inverting effects.  
Agonist-stretch sensitivity analysis 
In a similar manner to effect analysis above, contrasts between two sets of 
experimental groups were assessed: (i) agonist treatments alone and controls (ΔT0), and 
(ii) combined agonist-stretch treatments and samples subjected to stretch only (ΔTs). 
Contrasts for both sets were expressed as log2(fold change), and sensitivity magnitudes 
were calculated as the change between contrasts: 𝑆 = |∆𝑇 − ∆𝑇 |. Sensitivity 
directions were calculated as the difference between contrast magnitudes: 𝑆 = |∆𝑇 | −
|∆𝑇 |. Signs of sensitivity direction terms were similarly used to determine categories of 
sensitivity changes: a positive term denoted a sensitizing effect of stretch on agonist 
treatment (i.e. stretch caused a greater response to agonist stimulation), and a negative 
term denoted a de-sensitizing effect (i.e. stretch caused a dampened response to agonist 
stimulation). Individual contrasts that had opposite signs (e.g. ΔT0<0 and ΔTs >0) were 
denoted as reversal effects.  
Statistical analysis 
 87
Statistical analyses were performed using the lme4 package in the R statistical 
suite 77. mCFs were isolated from 8 groups of mice representing one biological replicate 
each, and cells were equally divided between all experimental groups within each 
replicate for N=8 replicates per experimental group. For each measured protein, 
normalized concentrations were fit to a linear mixed-effect model in which biochemical 
agonists and stretch states were modeled as fixed variables, and biological replicate was 
modeled as a random variable. Analysis of deviance was used to assess the model 
validity in comparison to a null model containing only random variables, using a type I 
error rate of 0.05 for valid models. Two-factor ANOVA was used to test fixed variables, 
Dunnett’s post-hoc tests were used for multiple comparisons between agonists and 
respective controls, and Student’s t-tests with Bonferroni correction were used for 
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AIM 2: REFINE AND EMPLOY AN EXISTING, MANUALLY-CURATED 
COMPUTATIONAL MODEL OF FIBROBLAST SIGNALING TO ACCURATELY 




Controlling cardiac fibrosis remains a major challenge in developing long-term 
treatments for patients suffering from myocardial infarction (MI). For a proportion of the 
over  800,000 patients diagnosed per year 1, excessive hypertrophy and scar formation in 
the non-infarcted myocardium can result in the development of heart failure, with 
decreases in contractility, myocardial conductivity, and pump function leading to poor 
rates of survival 2. Currently prescribed therapeutics for MI patients are designed to 
reduce hypertrophy via several neurohormonal mechanisms including inhibition of 
angiotensin II (AngII) and norepinephrine (NE) or increasing the bioavailability of 
natriuretic peptides (NPs) 3, but no drugs have been approved for treating cardiac fibrosis 
directly. Notably, scar formation serves a reparative function in post-MI wound healing 
by replacing necrotic myocardium and preventing infarct expansion and cardiac rupture 4. 
Therefore, developing therapeutics that limit excessive fibrosis to prevent the 
development of heart failure while preserving beneficial scar tissue at the infarct site 
would be a critical step towards improving long-term patient outcomes. 
Tissue remodeling in the myocardium is a dynamic process in which the 
accumulation of extracellular matrix proteins (e.g. collagens I and III, fibronectin) and 
matricellular proteins are balanced by degradation via proteases such as matrix 
metalloproteinases (MMPs). This balance is mediated largely by cardiac fibroblasts, 
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which infiltrate the infarct site and assume an activated, synthetic phenotype to promote 
matrix accumulation 5. A wide variety of biochemical factors regulate fibroblast behavior 
such as AngII, transforming growth factor-β (TGFβ1), endothelin-1 (ET1), and various 
inflammatory cytokines 6,7, but a growing body of research has demonstrated that 
biomechanical factors such as circumferential tension and tissue stiffness are also critical 
determinants of fibroblast behavior 8. Parallel transduction of biochemical and 
biomechanical stimuli is integrated by fibroblasts through a complex signaling network in 
which pathways interact via systems-level crosstalk and feedback mechanisms 9,10, 
making prediction and control of fibroblast behavior in the post-MI environment highly 
challenging. 
 Computational approaches for investigating cell signaling have shown promise 
for discovering mechanisms-of-action underlying pathological states and drug treatments. 
Previous models representing cardiac cell signaling as a network of interactions have 
proven successful in generating detailed insight into cardiomyocyte contraction and 
hypertrophy as well as fibroblast chemotransduction and various other biological systems 
11–14. Previous models have simulated cardiac and adventitial fibroblast activation and 
pro-fibrotic activity in response to biochemical and biomechanical cues, although limited 
exploration of mechanotransduction pathways in these models still leave unanswered 
questions about the role of tension in regional matrix turnover 15,16. In this current study, 
we expanded a model of fibroblast mechano-chemo signal transduction capable of 
accurately predicting fibrosis-related protein expression in response to canonical 
biochemical factors and mechanical tension. We examined the extent and dynamics of 
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mechano-chemo interactions by simulating biochemical dose-response behavior under 
varying levels of mechanical stimulation, finding that tension amplified, dampened, or 
reversed fibroblast responses to individual biochemical cues. Comprehensive simulations 
of fibroblast responses to over 23,000 combinatory drugs in low- or high-tension contexts 
identified several drug combinations that adapted fibrotic activity to the local mechanical 
state, demonstrating the potential of this model to act as a screening tool for targeted 
therapeutics.  
4.2. Results 
Development of Fibroblast Mechanotransduction Network 
 To develop a fibroblast signaling model capable of sensing and transducing 
dynamic tension, we performed a manual literature search of intracellular signaling 
reactions related to fibroblast mechanotransduction and integrated our search with an 
existing model of fibroblast signaling 15. Our extended model includes 9 cytokine inputs 
known to mediate fibroblast activation post-MI as well as mechanical tension, which is 
transduced via multiple mechanosensors including integrins, stretch-activated ion 
channels, and the G-coupled protein receptor angiotensin type I receptor (AT1R) (Figure 
4.1, see Figure B-1 for nodes added to the previous network). We also added several 
outputs that have been recently shown to mediate myocardial remodeling, including 
proMMPs 3, 8, and 12, tenascin-c (TNC), osteopontin, and thrombospondin-4 17–20, as 
well as autocrine feedback mechanisms found to regulate fibroblast activation 21–23. The 
total network, consisting of 109 nodes and 174 reactions, was implemented as a logic-
based ordinary differential equation (ODE) model using the open-source Netflux package 
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as previously described 24 in which node activity levels and reaction weights are 
normalized values between 0 and 1 (e.g. an activity of 0.5 represents 50% of maximum 
activity). All model species, reaction logic, default reaction parameters, and supporting 
references can be found in Supplementary File S1.  
 Model predictions were validated against an independent set of experimental 
studies by comparing qualitative changes (i.e., increase, decrease, or no change) in node 
activation to changes in protein activity measured in vitro. Parameter sweeps for half-
maximal effective concentrations (EC50) and Hill coefficients (n) identified default 
reaction parameters for optimizing predictive accuracy (Figure B-2, see Materials and 
Methods, Model Validation section for full description). For fibroblast-secreted outputs, 
simulated responses to biochemical and mechanical stimuli correctly predicted qualitative 
Figure 4.1. Schematic of expanded logic-based ordinary differential equation model of cardiac 
fibroblast chemo-/mechano-transduction. Extracellular stimuli, intracellular signaling species, 
transcription factors, and fibroblast-secreted outputs are represented as nodes (boxes, 109 total). 
Directed edges represent activating and inhibiting reactions (arrows and T junctions respectively, 162 
total) with AND logic indicated by circular nodes. 
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changes in protein secretion in 81.8% (63/77) of simulations (Figure 4.2A). Additionally, 
the model correctly predicted qualitative changes in activation levels of canonical 
signaling intermediates for 80.5% (33/41) of simulations compared to experimental 
studies (Figure 4.2B). Consistent with previous studies, the model predicted increased 
expression of collagens, matricellular proteins, and protease inhibitors with exposure to 
canonical agonists TGFβ1, AngII, platelet-derived growth factor (PDGF), tumor necrosis 
factor-α (TNFα), and mechanical tension, and secretion of these pro-fibrotic species was 
accompanied by increased MMP production. Disagreement between model predictions 
and experimental studies were typically found for studies that reported either decreases or 
no change in output expression with interleukin-1β (IL1), interleukin-6 (IL6), or NE 
simulation. However, as described in the next section, these incorrect model predictions 
could be rectified with the experimentally observed decreases under other input contexts.  
Mechanical Tension Amplifies, Dampens, or Reverses Network Responses to Biochemical 
Stimuli 
 Several previous experimental studies have established that combined 
biochemical and biomechanical signals can interact to produce context-dependent 
responses from fibroblasts  25–29. But the full scope and mechanisms behind these 
interactions are mostly unclear. We investigated interactions between tension and 
individual biochemical stimuli computationally by simulating dose-response relationships 
between biochemical inputs and all model nodes under increasing levels of tension, using 
area under the curve measurements (AUC) as a metric for total change in activity. We 
characterized interactions based on changes in each AUC from basal tension to increased 
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levels of tension, categorizing nodes with increased AUC levels with tension as being 
amplified, nodes with decreased AUC levels as being dampened, and nodes that changed 
the direction of activation with tension (i.e. from net activation to net inhibition or vice 
versa) as being reversed.  
We found that these interactions were dependent on both the individual inputs as 
well as the level of tension. Of the 9 biochemical model inputs, AngII, TGFβ1, IL1, 
TNFα, PDGF, and ET1 all demonstrated sizable changes in dose-response behavior with 
various levels of tension, based on a 5% change in AUC levels. Using this threshold, a 
tension level of 0.5 (i.e. 50% of maximum stimulation) amplified, dampened, or reversed 
Figure 4.2. Model accurately predicts qualitative changes in output expression and intermediate 
activity as measured by independent in vitro studies. (A) Expression of cell-secreted outputs and 
phenotypic markers (i.e. αSMA) were predicted in response to single biochemical stimuli and 
mechanical tension and compared to an independent set of experimental studies found in literature (46 
papers total). (B) Activation of intracellular intermediates representing major signaling pathways were 
predicted in response to single stimuli and compared to independent experimental studies measuring 
changes in activity (e.g. by phosphorylation, 27 papers total). All model predictions were categorized 
based on a ±5% change in activity levels compared to baseline conditions.  
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an average 56.7% of node AUCs towards these six inputs compared to basal levels of 
tension (Figure 4.3A), and a tension level of 0.9 (i.e. 90% of maximum stimulation) 
sizably altered an average 60.4% of node AUCs (Figure 4.3B). We additionally 
compared network-wide changes in AUCs between levels of tension as probability 
distributions, finding that tension significantly altered distributions of dose-response 
behavior of these six inputs at tension levels of both 0.5 and 0.9 (Figures B-3 and B-4). 
Conversely, tension altered the dose-response behavior of very few nodes with IL6, NE, 
and NP stimuli, with only 7.03% of node AUCs on average changing sizably towards 
these inputs for a tension level of 0.9 (Figure B-3A). We found that although tension 
levels of 0.5 and 0.9 significantly altered probability distributions of changes in AUC for 
these inputs (Figure B-4), the relatively small population of nodes with sizable changes 
suggests that these inputs were largely unchanged with tension., In support of their 
insensitivity to tension, we found that IL6, NE, and NP all displayed lower degrees of 
network connectivity compared to the remaining inputs as evidenced by lower measures 
of closeness centrality and higher measures of average shortest path length and 
eccentricity (Figure B-3B). While our previous work has shown that these measures do 
not correlate with functional measures such as sensitivity studies 15, these topological 
trends point to a less-influential role of tension for inputs that are relatively less 
connected to mechanotransduction pathways in the network. 
Within inputs that demonstrated tension-modulated dose-response behavior, the 
level of tension applied mediated different types of interactions. Moderate tension levels 
(reaction weights 0.2-0.5) largely amplified the effects of inputs; of the six inputs 
 102
Figure 4.3. Network-wide responses to biochemical stimuli are dependent on the tensional 
context. (A-B) Dose-response curves were simulated under elevated levels of tension with incremental 
doses of each biochemical input, and changes in area under normalized dose-response curves (ΔAUC) 
were calculated for all nodes in the model in comparison to basal dose-response simulations (i.e. 
tension = 0.1). Reversal cases were identified based on opposing AUC signs between basal and elevated 
tension simulations, i.e. nodes that exhibited a positive AUC with basal tension and a negative AUC 
with elevated tension, and vice versa. (C-E) Examples of mechano-chemo interaction categories 
identified from network-wide analysis in (A) and (B). Normalized dose-response curves for procollagen 
I (proCI) expression are shown following simulations with incremental doses of NE (A), TGFβ1 (B), 
and IL1 (C) under static levels of tension. (F-H) Sub-networks regulating the mechano-chemo 
interactions shown in (C-E) were determined by manual examination of node activity levels following 
dose-response simulations using NE (F), TGFβ1 (G), and IL1 (H) stimuli under basal and elevated 
levels of tension. 
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demonstrating tension-mediated changes in dose-response behavior, 51.8% of node 
AUCs were amplified at a tension level of 0.5 on average while 4.43% and 0.46% of 
node AUCs were dampened or reversed on average, respectively (Figure 4.3A). High 
levels of tension (reaction weights 0.6-0.9) largely dampened network responses to these 
inputs, with 56.4% of nodes on average decreasing AUCs with the same six inputs 
compared to 2.75% and 1.22% of node AUCs showing sizable amplification or reversal, 
respectively (Figure 4.3B). Repeated analyses with incremental levels of tension 
suggested that this change in tension-mediated behavior occurred at a tension reaction 
weight of 0.6, with an average 40.3±12.1 nodes changing from amplification to 
dampening at this level for these inputs compared to a reaction weight of 0.5 (Figure B-
3A). These changes in sensitivity were indicative of network interactions between tension 
and biochemical stimuli; we observed that NE-mediated inhibition of procollagen I 
expression was amplified by tension (Figure 4.3C), which can be explained by the logical 
requirement for tension-induced smad3 activation for effective inhibition by cAMP 
response element-binding protein (CREB) (Figure 4.3D). We also found that tension-
mediated desensitization of procollagen I expression towards TGFβ1 can be explained 
mechanistically by a common autocrine feedback loop integrating both tension and 
TGFβ1 signals via a reactive oxygen species (ROS)-activator protein 1 (AP1) signaling 
axis (Figure 4.3E-F).  
Notably, 4.40% of nodes reversed the direction of dose-response curves with IL1 
stimulation with a tension reaction weight of 0.6 or greater compared to baseline tension 
levels, including intermediate nodes involved in TGFβ1 signaling (TGFβ1R, NOX, 
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ROS), mitogen-activated protein kinase (MAPK) signaling (TRAF, ASK1, MKK3, 
MKK4, ERK) as well as the expression of procollagen I (Figure 4.3G). By comparing 
these reversed nodes to the network topology, we found that IL1 exerted both stimulatory 
effects via activation of AP1 and suppressive effects via activation of BMP and activin 
bound inhibitor (BAMBI), with suppressive behavior dominating procollagen I 
expression at high IL1 levels (Figure 4.3H). While low tension levels allowed for IL1-
mediated activation of AP1 and downstream procollagen expression, high levels of 
tension alone were sufficient to saturate AP1 levels, eliminating the stimulatory effects of 
IL1 and causing high cytokine doses to inhibit expression. Our model predicts a high 
degree of interaction between tension and biochemical stimuli, suggesting that the effects 
of current and potential therapeutics for cardiac fibrosis may be substantially altered by 
local tension. 
Network Perturbation Analysis Reveals Differential Roles of Tension  
   While targeted experimental studies of fibroblast signaling have identified 
numerous pathways mediating extracellular matrix turnover, it is still unclear whether 
certain mechanisms influence cell behavior more than others and whether these 
influences are altered with changes in the mechanical context. Using our systems-level 
model, we calculated changes in network activity following comprehensive knockdowns 
of individual nodes to functionally assess network-wide effects of perturbations. We 
calculated each node’s “knockdown influence” as the summed magnitudes of all changes 
in other nodes’ activities upon knockdown of that particular node, and we calculated each 
node’s “knockdown sensitivity” as the summed magnitudes of all changes in that 
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particular node’s activity with knockdown of all other nodes (see Materials and Methods, 
Network Perturbation Analysis section for full description). We repeated simulations for 
low, medium, and high levels of tension (reaction weights 0.25, 0.5, and 0.75 
respectively) and selected for the top 10 scoring nodes in both influence and sensitivity, 
Figure 4.4. Network perturbation analysis reveals influential pathways of fibroblast 
mechanotransduction. (A-C) Changes in activity levels for top 10 sensitive nodes with simulated 
knockdown of top 10 influential nodes at low (A), medium (B), and high (C) levels of tension. Nodes 
were ranked based on knockdown influence (rows) and knockdown sensitivity metrics (columns), and 
changes in activity levels with perturbations are compared un-perturbed (i.e. no knockdown) conditions 
at each tension level. (D-E) Comparison of top-ranked sensitive and influential nodes between levels of 
tension. Nodes shown reflect all unique nodes that ranked in the top 10 based on knockdown sensitivity 
(D) or knockdown influence (E) between all levels of tension simulated, and colors reflect nodes that 
were top-ranked starting at low tension (green), medium tension (orange), and high tension (purple). 
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which indicated differentially responsive sets of nodes (Figure 4. 4A-C, see Figure B-5 
for network-wide sensitivity results).  
At low levels of tension, knockdowns produced only small changes in node 
activities and correspondingly low influence and sensitivity values (Figure 4.4A, D, E). 
This is not surprising given all node activities are relatively low at this close-to-baseline 
context. In contrast, medium and high levels of tension demonstrated marked activity 
changes with knockdown perturbations and exhibited common influencers and unique 
sets of sensitive nodes. Under medium tension levels, knockdown of AT1R exhibited 
relatively broad inhibition compared to other top influencers, decreasing activity levels of 
several proMMPs, fibronectin, TNC, and members of the IL6 pathway by an average of 
35.9±5.4% (Figure 4.4B). While other top influencers mediated smaller reductions in 
activity across the top 10 sensitive nodes, NADPH oxidase (NOX), ROS, AP1, and c-Jun 
N-terminal kinases (JNK) demonstrated an increased capacity to mediate proMMP2, 
proMMP14, and smad7 levels under medium tension. Under high tension conditions, 
however, these four nodes ranked as the highest influencers network-wide, mediating 
decreases in activity for members of the MAPK pathways (80.6±4.3% reduction in 
activity on average), actin cytoskeleton-related signaling (68.7±22.2% average 
reduction), and outputs procollagen I, procollagen III, and proMMP1 (30.9±8.9% average 
reduction) (Figure 4.4C). Several members of the TGFβ1 pathway demonstrated similar 
trends in regulation including latent TGFβ1, suggesting that autocrine feedback may play 
a role in regulation at high tension. 
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Rankings of knockdown influence and knockdown sensitivity across all tension 
conditions suggest that influential mechanisms and their effects were dependent on the 
tensional context (Figure 4.4D-E). While ROS, AP1, JNK, and TGFβ1-related node 
knockdowns displayed an overall lower degree of influence on the network compared to 
knockdown of AT1R for low- and medium-tension conditions, knockdown of these nodes 
under high levels of tension mediated large changes in network-wide activity with 
knockdown influence levels increasing by up to 4.9-fold compared to medium tension 
(Figure 4.4D). Similarly, different sets of nodes were more sensitive towards 
perturbations between tension levels, with lower knockdown sensitivity levels of 
proMMPs 2, 9, and 14 and higher levels of proCI, proCIII, and proMMP1 at high tension 
relative to medium tension (Figure 4.4E). These behaviors suggest that tension acts via 
different pathways at different levels of stimulation, and cell behavior in a dynamic 
mechanical environment may not be dictated by a single mechanism alone. 
Fibroblast Signaling Network Predicts Behavior of Current Post-MI Therapeutics 
 Current post-MI therapeutics aim to reduce cardiac hypertrophy via inhibition or 
activation of neurohormonal signaling 3, both of which also alter cardiac fibroblast 
behavior and extracellular matrix turnover as a side effect. To test the hypothesis that our 
model can reproduce experimentally observed effects of current post-MI drugs on 
fibroblast behavior, we simulated the effects of three drug classes by modulating the 
maximum activation parameters of individual nodes: (1) angiotensin receptor blockers 
(ARB) were simulated via knockdown of the AT1R node, (2) neprilysin inhibitors 
(NEPi), which increase the bioavailability of natriuretic peptides, were simulated via 
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overexpression of the NP node, and (3) ARB-NEPi combination drugs were simulated 
via combination of (1) and (2) above (see Materials and Methods, Drug Effect 
Comparisons section for full description and Table 1 for simulation parameters). 
 We tested whether our model could discern both individual and synergistic effects 
of post-MI drugs by simulating dose-response relationships between the three drugs 
above and procollagen I expression. Von Lueder and colleagues previously found that 
Figure 4.5. Model-predicted effects of current post-MI drug treatments reflect experimental 
evidence from independent case studies. (A) Comparison of model-predicted effect of ARB doses 
with or without NEPi treatment on procollagen I expression with measurements of collagen synthesis in 
cardiac fibroblasts in vitro. Doses for model predictions reflect negative modifiers of the ymax parameter 
of AT1R, doses for the in vitro study reflect doses of valsartan in μM, and values reflect fold changes 
compared to control conditions. (B) Comparison of model-predicted effects of ARB and ARB-NEPi 
treatments on three output nodes with corresponding gene expression measurements of cardiac 
fibroblasts in vitro. Values reflect fold changes compared to TGFβ1/AngII/atrial NP (T/A/A) 
conditions. (C) Comparison of model-predicted effects of ARB treatment on five output nodes in 
representative remote (LVC) and infarct (LVI) zones with corresponding gene expression 
measurements in post-MI mouse hearts. Values reflect fold changes compared to control (non-
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valsartan primarily attenuated collagen expression in cardiac fibroblasts following 
exposure to AngII, with neprilysin inhibitor LBQ657 acting in a synergistic manner with 
valsartan but not altering collagen expression alone 30. Our model independently 
confirmed this conclusion, as increasing levels of AT1R knockdown combined with NP 
overexpression further attenuated procollagen I expression compared to AT1R 
knockdown alone (Figure 4.5A). We additionally observed that NP overexpression alone 
did not appreciably alter procollagen I expression while AT1R knockdown suppressed 
expression to near-control levels, further supporting the authors’ conclusions of the 
dominant mechanism for combinatory ARB-NEPi drugs (Figure B-6). This inability of 
NEPi class treatments to independently regulate AngII signaling can be attributed to a 
lack of overlap between AngII and NP pathways; AngII stimulation causes the activation 
of canonical and non-canonical TGFβ1 signaling via production of latent TGFβ1, and 
although NP overexpression inhibited canonical activation of smad3 by TGFβ1R, non-
canonical activation and downstream procollagen expression via Akt remained 
unchanged. Knockdown of AT1R inhibited both pathways of TGFβ1 signaling, thereby 
reducing procollagen I levels in a dose-dependent manner. 
 We next assessed our model’s capability to predict the expression of multiple 
gene products and potential mechanisms-of-action following perturbation by the drug 
classes above. We compared model predictions of three model outputs following ARB or 
ARB-NEPi treatments to a recent study by Burke and colleagues, who observed 
synergistic inhibition of genes encoding alpha-smooth muscle actin (αSMA), collagen I, 
and periostin by combinations of valsartan and the NEPi sacubitril 31. We found that 
 110
model simulations predicted a similar synergistic inhibition of all three gene products in 
high TGFβ1/AngII/atrial NP (T/A/A) conditions , and although simulations of ARB 
treatment alone reduced output expression as concluded in the von Lueder study, 
combinatory treatment in this context further reduced all three model outputs to an 
average 16.6% of positive controls (Figure 4.5B). The authors additionally suggested that 
sacubitril mediated on fibroblast behavior via activation of PKG and inhibition of the 
small GTPase Rho, with patient-derived fibroblasts responding to sacubitril or valsartan-
sacubitril treatment with decreased fractions of active Rho 31. Upon incorporating this 
interaction into the model reaction logic, model-predicted activation levels of PKG and 
Rho following NEPi and ARB-NEPi treatments confirm this mechanism-of-action by 
NP-related treatments, with ARB-only treatments failing to change activity levels of both 
PKG and Rho compared to TGFβ1/AngII/NP controls (Figure B-6). These comparisons 
demonstrate the ability of the model topology to predict both output-level changes with 
drug treatments as well as identify mechanisms-of-action compared to experimental data. 
 By incorporating known mechanotransduction pathways into network topology, 
we expanded our model’s capability to predict responses to drug treatments in local 
cardiac tissue based on differences in tension. This capability is particularly important in 
the context of an infarcted left ventricle wherein fibroblasts in the infarct scar are 
subjected to heightened tensile stretches compared to the fibroblasts in the remote, non-
infarcted myocardium that are subjected to normal myocardial tensions 32. We 
investigated this capability by simulating the expression of model outputs in response to 
valsartan treatment in both low- and high-tension contexts, while setting the model 
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cytokine inputs to experimentally matched post-infarct levels as previously described 13. 
We compared model output expressions to a study by Ramirez and colleagues, who 
observed significant differences in fibrosis-related gene expression between infarct and 
remote zones and negligible effects of valsartan treatment alone using a mouse model 33. 
Model predictions generally agreed with their findings, as the degree of tension sizably 
altered the expression of procollagens, matricellular proteins, and connective tissue 
growth factor (CTGF) relative to changes in expression with valsartan treatment (Figure 
4.5C). While we observed variable degrees of error between simulated levels of 
individual outputs and measured gene expression, our model accurately predicted 
qualitative differences in drug response based on regional tension. 
Computational Drug Screen Predicts Candidates for Mechano-Adaptive Therapy 
 The infarcted ventricle presents a spatially dependent need to maintain 
extracellular matrix content at the infarct region while limiting scar formation in remote 
regions. While targeted experimental studies involving individual or combinatory post-
MI drugs demonstrate efficacy either for individual cell types or bulk tissues, there is 
currently no evidence of current or potential drugs showing variable effects based on 
regional mechanics. Our analysis of mechano-chemo interactions above suggests that 
regional mechanics can alter the effects of positive and negative perturbations, so we 
investigated whether simulated drug treatments for low- and high-tension conditions 
could identify drug targets that provide regional therapeutic effects post-MI.  
Specifically, we sought potential drug targets that adapt matrix-related expression to the 
regional tension by increasing pro-matrix expression in high tension and decreasing 
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expression in low tension. To that end, we performed a comprehensive screen of 
individual and combinatory drug targets involving single node knockdown and 
overexpression and dual node knockdown, overexpression, and knockdown-
overexpression combinations for a total of 23,762 drug treatments.  
 We used a rank-based scoring strategy to score drug treatments based on changes 
in output expression compared to non-perturbed conditions, calculating a matrix content 
metric from individual output nodes and ranking treatments by the capacity to decrease or 
increase this metric with low or high tension stimuli respectively (see Materials and 
Figure 4.6. Comprehensive drug screen identifies mechano-adaptive candidates for post-MI 
fibrosis. (A) Target combinations meeting preliminary threshold for mechano-adaptive behavior (i.e. 
promoted negative change in matrix content in low tension and positive change in matrix content in 
high tension) were scored based on rankings of matrix content changes in low- and high-tension 
simulations. Boxed values represent scores of 13 candidates examined in panels (B) and (C). (B-C) 
Changes in output expression predicted with mechano-adaptive candidates under tensional contexts, 
expressed as changes in node activity compared to non-perturbed conditions for each level of tension. 
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Methods, Mechano-Adaptive Drug Screen section for full description). While no 
individual drug target perturbation achieved these opposing responses (Figure B-7), we 
found that 450 of 23,544 combinatory perturbations qualitatively altered matrix content 
based on regional tension, and we identified a cluster of 13 perturbations that scored 
highly in adapting expression of fibrosis-related outputs to regional tension (Figure 4.6A, 
boxed combinations). This cluster primarily involved dual knockdown of nodes related to 
the IL6 and Akt/mTOR signaling pathways, with 8 of 13 treatments targeting members of 
these pathways (Figure 4.6B-C). While most of these combinations exerted relatively 
minor changes in individual output levels compared to un-perturbed conditions, these 
combinations primarily acted to increase expression levels of procollagens, periostin, and 
PAI1 while decreasing proMMPs 1, 3, and 8 with high tension, thus aiding scar 
formation in high-tension conditions only (Figure 4.6C). Additionally, seven treatments 
showed evidence of increasing proMMP levels and decreasing procollagen and periostin 
levels with low tension (Figure 4.6B), suggesting that inhibition of the IL6 and 
Akt/mTOR pathways may simultaneously reduce pro-fibrotic matrix expression in 
remote tissues with low levels of tension. 
4.3. Discussion 
 Spatial control of myocardial fibrosis after MI has remained a challenge due in 
part to simultaneous signaling from biochemical cues and regional mechanics, both of 
which mediate fibroblast activation and synthesis of extracellular matrix components 34. 
In the current study, we employed a computational model of fibroblast signaling to 
predict the regional expression of fibrosis-related proteins by incorporating known 
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signaling pathways related to canonical biochemical agonists and mechanical tension. We 
found that the model correctly predicted qualitative changes in fibrotic protein expression 
with a similar degree of accuracy compared to other logic-based ODE networks 16,35, and 
model simulations of current therapeutics such as ARB and ARB-NEPi class drugs 
accurately reproduced trends in output gene expression observed in cardiac fibroblasts 
and a post-MI mouse model. Functional analyses identified influential mechano-chemo 
interactions and preferential pathways of mechanotransduction such as the production of 
latent TGFβ1 via a NOX-ROS-AP1 signaling axis. We additionally used the model as a 
targeted screening tool by simulating fibroblast responses to drug combinations in 
regions of low and high tension, and we identified 13 combinations that adapted the 
expression of matrix-related proteins to the regional mechanical environment. Our results 
suggest that this computational approach can aid the development of effective therapies 
for pathological tissue remodeling which involves simultaneous changes to paracrine 
signaling and tissue mechanics, and model predictions can generate targeted hypotheses 
for controlling fibroblast behavior for further experimental investigation. 
Crosstalk Between Biochemical and Biomechanical Factors in Fibroblast Signaling 
 Increased circumferential stretch in the post-MI infarct zone has been established 
as both a direct regulator of fibroblast activation and an indirect regulator of biochemical 
signaling pathways via crosstalk mechanisms 36,37.  Experimentally assessing the system-
wide extent and dynamics of these interactions would be exceedingly challenging due to 
time and resource constraints; however, biological network models can overcome this 
challenge by comprehensively simulating biochemical dose-response relationships under 
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a variety of mechanical contexts. Our findings indicate that tension exerts a wide 
influence on biochemical signaling in fibroblasts by either amplifying responses to 
biochemical stimuli in the case of NE, dampening responses in the case of TGFβ1, and 
even reversing responses in the case of IL1.  
The three example cases above share a common connection in tension-mediated 
expression and activation of latent TGFβ1, an autocrine feedback mechanism shown to 
influence cardiac fibroblast phenotypes 10,27. We found that NE acted to antagonize latent 
TGFβ1 expression via a cAMP-PKA-CREB signaling axis. Activation of CREB through 
the use of phosphodiesterase inhibitors has previously been shown to antagonize fibrotic 
expression of lung and cardiac fibroblasts 38,39 as well as cardiac fibrosis in a pressure 
overload mouse model 40 , suggesting a potential mechano-responsiveness of this 
mechanism. Simulated fibroblast responses to TGFβ1 indicated a synergistic response 
under tension with latent TGFβ1 activation and output expression occurring for lower 
input doses. This trend is consistent with experiments involving valvular myofibroblasts, 
which exhibited earlier and greater induction of bioactive TGFβ1 and aSMA protein 
levels when subjected to combined tension/TGFβ1 compared to either stimulus alone 26. 
 We additionally found that stimulation with IL1 produced opposite effects 
depending on the level of tension, with IL1 increasing procollagen I expression for low to 
medium tension levels and decreasing expression for high tension levels through 
activation of BAMBI and downregulation of downstream targets of TGFβ1R. As a 
positive regulator, IL1 upregulates MAPK and NFkB signaling pathways via myeloid 
differentiation factor-88 (MyD88) 41, and both IL1R-/- and MyD88-/- mice display reduced 
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fibrosis and progression towards heart failure in a model of acute myocarditis 42. As a 
negative regulator, IL1 upregulates the expression of BAMBI to act as a decoy receptor 
for TGFβ1, thereby reducing downstream signaling 43. In BAMBI-/- mice, pressure 
overload worsened fibrosis compared to wild-type mice in a TGFβ1-dependent manner, 
suggesting that this negative regulation is dependent on both mechanical stress and 
TGFβ1 stimulation 44. IL1 has additionally been shown to reverse the myofibroblast 
phenotype in valvular interstitial cells with culture on stiff substrates 45, further 
suggesting that context-dependent regulation by IL1 may be a determining factor of 
fibroblast phenotype. Our analysis of mechano-chemo interactions above suggests that 
computational approaches can reveal context-specific mechanisms of disease progression 
and reinforces the need to account for various environmental factors (such as local 
biomechanics) in developing therapeutic strategies. 
Influential Mechanisms Controlling Fibroblast Mechanotransduction 
 Fibroblasts transduce changes in their local mechanical environment using both 
well-known mechanosensors such as integrins and newly-discovered mechanisms such as 
piezo channels and actin-dependent translocation of YAP/TAZ 36. While these 
mechanisms have all been shown to alter cell phenotypes individually, it is still unclear as 
to whether individual pathways influence cell behavior over others. Network perturbation 
analysis predicted that tension is primarily mediated by an autocrine feedback mechanism 
in which a NOX/ROS/JNK/AP1 signaling axis stimulates latent TGFβ1 expression to 
drive further NOX activation as well as procollagen expression via smad3. The secondary 
activation of TGFβ1 has been demonstrated for various stimuli in fibroblasts such as 
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TNFα and AngII 46,47 as well as for other cell types by influencing changes in phenotype 
related to extracellular matrix deposition and angiogenesis 48–50. Inhibition of NOX2 and 
NOX4 in AngII-infusion mouse models has additionally been shown to attenuate 
interstitial collagen deposition, further implicating NOX/ROS signaling as a central 
influencer of cardiac fibrosis 51,52. Our model prediction that this pathway primarily 
influences fibrosis-related protein expression suggests that perturbation of this pathway 
may induce larger reductions in cardiac fibrosis compared to others, and experimental 
studies investigating this behavior could provide a basis for developing targeted anti-
fibrotic therapies. 
Fibroblast Network Model as a Screening Tool for Targeted Therapeutics 
 The heterogenous nature of myocardial infarctions creates a clear need for 
regionally targeted therapies for tissue remodeling, with the infarct zone requiring scar 
formation to provide local structural integrity and remote zones requiring scar 
downregulation to prevent adverse tissue stiffening. Loss of cardiomyocytes additionally 
presents different mechanical conditions between the infarct and remote zones 32, and our 
model predictions above and experimental evidence suggest that myofibroblast-mediated 
tissue remodeling is dependent on this mechanical context 53,54. Previous trials of anti-
fibrotic therapies have demonstrated the need to account for local increases in 
circumferential stretch in infarcted tissue. Studies inhibiting known mediators of 
excessive fibrosis such as TGFβ1, osteopontin, and TIMP3 have shown increased risk of 
left ventricular thinning and cardiac rupture, early complications associated with 
impaired scar formation at the infarct zone 55–57 - an indication that therapies designed to 
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inhibit global fibrosis are not sufficient to promote healthy scar formation where it is 
needed. A further complication of post-infarct fibrotic control is the lack of evidence of 
regional differences in tissue remodeling for current and potential drugs. While our 
comparisons of model-predicted and experimentally tested ARB and NEPi treatments 
above demonstrated the inhibitory effects of these drugs in a single context, not enough 
evidence exists to determine whether these drugs produce therapeutic effects in both 
remote and infarcted zones.  
We investigated the ability of our model to predict regional effects of drug 
treatments based on regional mechanical tension, and our computational screen of 23,762 
drug treatments yielded 13 candidates that adapted expression of extracellular matrix-
related proteins to the regional tension. These candidates implicated the IL6 and 
Akt/mTOR signaling pathways as well as the IL1/cAMP and MRTF/SRF pathways as 
mediators of mechano-adaptive behavior. Perturbations involving the IL6 and IL1 
inflammatory pathways individually have yielded mixed results clinically; while several 
animal studies and clinical trials perturbing IL6 and IL1 signaling have concluded that 
knockdown of these pathways suppresses cardiac fibrosis and mediates gain of function 
due to MI or factors associated with MI 58–60, others have concluded that IL6 and IL1 
knockdown exacerbate fibrosis post-MI or in response to MI-associated biochemical 
factors 7,61,62. The results from these studies indicate that the influence of these pathways 
on tissue remodeling is highly context dependent with varying responses between 
treatment time courses and methods of antagonism, and our drug screen indicates that 
mechanical signaling additionally modifies cellular and tissue responses to these drugs. 
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While we found no clinical evidence of tissue remodeling in response to the model-
predicted drug combinations above, these results suggest that pairing of anti-
inflammatory treatments with those for additional signaling pathways may provide an 
additional advantage in controlling regional cardiac fibrosis, and our predictions provide 
testable hypotheses for further investigation. Moreover, this model-based approach 
towards target discovery provides substantial value for potential drug development by 
focusing efforts on drugs or drug combinations with strong mechanistic evidence of 
therapeutic efficacy. This model and approach can additionally be expanded to 
investigate fibrosis across multiple disease states and for individual patient conditions to 
stratify patients based on predicted responses to current drugs or to identify drug 
candidates for subpopulations of patients. 
Study Limitations and Future Directions 
 One major limitation of the current study stems from the need for quantitative 
predictions of fibroblast signaling processes and matrix production. While the current 
model was able to make semi-quantitative predictions of cell behavior based on network 
topology and normalized reaction parameters, data-driven reaction parameters are 
necessary both to fully investigate mechanisms-of-action of fibrotic activity and to relate 
signaling processes to experimental measures of fibrosis. Phospho-proteomic datasets 
generated using methods such as reverse-phase array provide direct analogs to 
intracellular protein activation or inhibition as well as the scope of measurements 
required for systems-level modeling, and previous studies have demonstrated the utility 
of these datasets in inferring cell signaling networks and fitting literature-curated network 
 120
parameters 63–65. Future implementation of in vitro or clinical phospho-proteomic data 
would improve the accuracy of model predictions and reveal additional mechanistic 
insight into fibroblast behavior in the post-MI environment. 
 An additional limitation of the current model is that of scope as it relates to both 
cell signaling processes as well as additional levels of regulation. While the current 
model was developed based on direct experimental evidence of signaling interactions 
stemming from selected biochemical and mechanical stimuli, we must acknowledge that 
additional stimuli and signaling pathways play a role in cardiac fibroblast signaling, such 
as interferon-γ and epidermal growth factor receptor signaling pathways 66,67. While not 
meeting our requirements for inclusion (see Materials and Methods, Fibroblast Signaling 
Model Development section for criteria), we expect these additional signaling 
mechanisms to aid in model predictions across the diverse range of stimuli represented in 
vivo. It is also important to note that a variety of biomechanical factors alter fibroblast 
behavior in the post-infarct environment in addition to circumferential stretch (classified 
as “mechanical tension” in the current study), such as tissue stiffening, compression, and 
radial and longitudinal stretch 68. While these applied loads are sensed and transduced via 
similar mechanisms as circumferential stretch, the type, magnitude, and directionality of 
applied loads differentially mediate fibroblast behavior and matrix turnover 69,70, and thus 
a more robust understanding of the interactions between biomechanical stimuli is needed. 
Lastly, much evidence exists to suggest that many additional dimensions of regulation 
mediate cardiac fibrosis including transcriptional regulation 71, remodeling of collagen 
fibers 72, paracrine signaling involving inflammatory cells, immune cells and myocytes 73, 
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and additional modes of cell signaling (e.g. microRNA, matrix degradation products) 
74,75. Several groups have made progress in modeling regulation within these levels in the 
heart 76–78, and while incorporating all factors into a model-based approach is a non-
trivial effort, a combined, multi-dimensional approach will ultimately be necessary to 
fully predict tissue remodeling given the range of variables involved in post-infarct 
wound healing.  
 Through our simulated studies of fibroblast signaling and fibrotic activity above, 
we demonstrated the utility of computational models of mechano-chemo signal 
transduction in identifying mechanisms-of-action governing cell behavior in complex 
environments. While in vitro and in vivo evidence validating these results are crucial for 
translating this mechanistic insight into clinical solutions for cardiac fibrosis, this model-
driven approach can be advantageous in focusing experimental efforts towards promising 
candidates that limit scar formation to regions where it is beneficial to do so. Excitingly, 
our simulations identified 13 novel drug target pairs whose modulation resulted in 
desirable mechano-adaptive effects - namely, an increase in matrix accumulation within 
the infarct zone (where scar material is beneficial to maintain structural integrity) and a 
simultaneous decrease in matrix within the remote zone (where scar material is 
detrimental to myocardial mechanical and electrical function). Given the broad 
significance of the involved pathways in many different cell types, our computational 
predictions also suggest that similar mechano-chemo-signaling interactions are likely 
present across many cell types and tissues, potentially confounding the translation of in 
vitro findings to in vivo applications where the mechanical context is strikingly different. 
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Therefore, predictive models integrating both modes of signal transduction represent a 
critical step towards discovering targeted therapeutics across many disease states 
involving complex environmental signals. Future phospho-proteomic studies of fibroblast 
signaling in combination with targeted studies of influential signaling pathways will both 
enable further development of targeted treatments for cardiac remodeling and enable 
therapeutic development for a range of fibrosis-related diseases. 
4.4. Materials and Methods 
Data and Code Availability 
The code generated during this study is available at GitHub 
(https://github.com/SysMechBioLab/Fibroblast_Signaling_Network_Model). The 
published article includes all model and validation databases generated or analyzed 
during this study. 
Fibroblast Signaling Model Development 
Our previously published model of cardiac fibroblast signaling was expanded 
using a manual literature search of over 100 peer-reviewed studies to include newly 
identified proteins and/or signaling pathways associated with fibroblast 
mechanotransduction, as well as several secreted proteins newly-associated with cardiac 
fibrosis. New individual proteins (model nodes) and signaling reactions (edges) were 
identified from studies that concluded direct interactions between proteins altering 
protein activity (e.g. by phosphorylation). New nodes and/or edges were included if at 
least two independent studies contained evidence of either activation of a node or 
activation of another species by a node in either cardiac or other fibroblast subtypes. As 
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previously described 12,15, the final network was implemented as logic-based ordinary 
differential equations in which activity levels of all nodes were modeled as a system of 
Hill equations, and all activity levels and input stimuli were represented as normalized 
values between 0 and 1. Logical NOT, AND, and OR gates were used for inhibitory and 
complex signaling interactions by applying logical operations 1 − 𝑓(𝑥), 𝑓(𝑥)𝑓(𝑦), and 
𝑓(𝑥) + 𝑓(𝑦) − 𝑓(𝑥)𝑓(𝑦) to Hill equations respectively. The system of differential 
equations was constructed using the open-source Netflux package for MATLAB 
(https://github.com/saucermanlab/Netflux), and all subsequent analyses were conducted 
using MATLAB (Mathworks, Natwick MA). Visualizations of the full network and sub-
networks were created using Cytoscape software 79. 
Model Validation 
 Qualitative changes in select model outputs and signaling intermediates were 
compared between model predictions and independent experimental studies. A set of 
studies independent from model development (47 papers total) were selected based on 
direct measurement of either output secretion or activity of a signaling intermediate in 
response to a single input stimulus in fibroblasts. Outputs included in this set were either 
collagens, matrix proteases, protease inhibitors, matricellular proteins, autocrine signaling 
species, or αSMA as a marker of fibroblast activation. Intermediates included were 
limited to members of canonical signaling pathways (i.e. Akt, CREB, ERK, JNK, p38, 
PKC, smad3, ROS), and only intermediates with direct measurements were included in 
the final set. Model predictions were performed by simulating basal conditions (all input 
weights = 0.1) for 80 s, followed by simulating single input stimuli (weight = 0.8) for an 
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additional 240 s in order to allow for the system to reach steady-state activity levels. 
Because studies used for validation conducted in vitro experiments on tissue culture 
plastic, a tension input weight of 0.4 (40% of maximum stimulation) was used for all 
validation simulations. Changes in intermediate and output node activity from basal to 
stimulated conditions were binned into either “increase”, “decrease”, or “no change” 
categories using ± 5% change in activity levels, which has been shown previously to 
distinguish qualitative changes in behavior for single-stimulus simulations 12,16. To fit 
default model parameters to best describe experimental data, parameter sweeps of Hill 
coefficient (n) and half-maximal effective concentration (EC50) were conducted to 
maximize the accuracy of model predictions, using the percentage of correct predictions 
as a metric. Maximum activation levels (Ymax) were set to a default value of 1, and time 
constants (τ) were set to default values of either 0.1, 1, or 10 corresponding with species 
involved in intracellular signaling reactions, ligand-receptor reactions, or transcription-
translation events respectively. Reaction weights (w) were set to default values of 1 with 
the exception of autocrine feedback-associated reactions, which were set to default values 
of 0.8 due to the lowered probability of these reactions resulting diffusion of output 
proteins or sequestering by the extracellular matrix 10. Values for n and EC50 found to 
maximize predictive accuracy were used with the other described parameters for all 
subsequent simulations. All model species, reactions, and assigned parameters are 
available at the GitHub URL above. 
Mechano-Chemo Interaction Analysis 
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 Dose-response behaviors of biochemical stimuli were simulated for incremental 
levels of the ‘tension’ input reaction to assess interactions between mechanical and 
biochemical stimulations. For 0.1 increments in tension reaction weight ranging from 0.1 
(10% of maximum stimulation) to 0.9 (90% of maximum stimulation), steady-state 
activity levels of all nodes in the network were simulated following stimulation of each 
biochemical input reaction (AngII, TGFβ1, IL6, IL1, TNFα, NE, PDGF, ET1, and NP) 
for 240 s, ranging in reaction weight from 0 to 1 in 0.01 increments. The resulting dose-
response curves were normalized to steady-state activity levels for a biochemical input of 
0, and the total response of each node to a biochemical stimulus was calculated as the 
area under the normalized curve (AUC). Changes in AUC due to tension (ΔAUC) were 
calculated for each tension level as the difference between AUCs with added tension and 
with baseline tension (tension = 0.1). Sizeable mechano-chemo interactions were 
identified using a threshold of ±5% in ΔAUC. ΔAUCs greater than or equal to 5% were 
categorized as amplifying interactions (tension increases node response to a biochemical 
stimulus), ΔAUCs less than or equal to -5% were categorized as dampening interactions 
(tension decreases node response), and AUCs with opposite signs between baseline and 
tension conditions and exceeded the threshold of ±5% were classified as reversal 
interactions (tension causes biochemical stimulation to exert the opposite effect on node 
activity). This threshold has been shown previously to distinguish qualitative changes in 
activity levels with individual node perturbations 12,16, and while these studies did not use 
an integrated AUC metric for comparison, our comparison of AUCs requires greater peak 
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activation levels to meet the threshold, thereby imposing a stricter comparison than these 
previous studies.  
To compare the extent of interactions between tension levels for each input, two-
sample Kolmogorov-Smirnov tests were conducted for distributions of ΔAUCs, 
comparing (1) distributions for tension = 0.2 vs. tension = 0.5; (2) distributions for 
tension = 0.2 vs. tension = 0.9; and (3) distributions for tension = 0.5 vs. tension = 0.9. 
Corrections for multiple comparisons were made using the Benjamini-Hochberg 
procedure 80, and adjusted p-values are displayed in Figure B-4. As an additional measure 
supporting the input-related differences in interactions found above, topological network 
parameters were computed using the NetworkAnalyzer plugin for Cytoscape 81.  
Network Perturbation Analysis 
 To identify influential signaling mechanisms across various mechanical contexts, 
a series of node knockdowns were simulated for several levels of tension. For tension 
reaction weights of 0.25, 0.5, and 0.75, basal conditions were simulated for 80 s (all other 
input weights = 0.1) followed by knock down of individual nodes (Ymax = 0.1) for 240 s. 
Steady-state activity levels of all nodes were measured across knockdowns of all nodes, 
and changes in activity (ΔActivity) were calculated as the difference between node 
activity after knockdown and basal activity. Knockdown sensitivity of each node was 
calculated as the total change in activity of the node across all knockdown simulations, 
and knockdown influence of each node was calculated as the total change in activity of 
all other nodes in the network upon knockdown. 
Drug Effect Comparisons 
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 Predicted responses of the network to currently prescribed pharmacologic 
therapies were compared three studies measuring cardiac fibroblast or myocardial tissue 
gene expression or protein expression in vitro or in vivo 30,31,33. All drugs were simulated 
by knockdown or overexpression of individual nodes: angiotensin receptor blocker 
valsartan (VAL), simulated by applying a negative modifier to Ymax for the AT1R node, 
neprilysin inhibitors LBQ657 (LBQ) and sacubitril (SAC), simulated by applying a 
positive modifier Ymax for the NP node, and angiotensin receptor neprilysin inhibitors 
LCZ696 (VAL+LBQ) and sacrbitril/valsartan (VAL+SAC). All negative control 
simulations were conducted using input reaction weights of 0.1, and all input reaction 
weights and drug perturbation levels for in vitro studies were chosen to maximize the 
dynamic range of network responses. Input reaction weights for in vivo studies were 
interpolated from experimental data of cytokine levels post-MI as previously described 13 
using a time point of 4 weeks post-infarction, and tension reaction weights for control 
and infarct zones were set to 0.1 and 0.6, respectively. All input reaction weights and 


















30 - 0.4 - 0.3 0.01 0.5 0.05 4 
31 0.4 0.4 0.6 0.3 0.5 0.5 4 4 
33 Int. Int. Int. 0.1/0.6 0.5 0.5 - - 
Mechano-Adaptive Drug Screen 
Table 4.1. Model parameters used for drug effect simulations. Minimum/maximum AT1R inhibitor 
(AT1Ri) values represent modifiers subtracted from the Ymax parameter of the AT1R node, and 
minimum/maximum neprilysin inhibitor (NEPi) values represent modifiers added to the Ymax parameter 
of the NP node. Non-specified input levels were set to a default value of 0.1.  Int.: interpolated from 
measurements of post-MI cytokine levels in vivo. 
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 A computational screen of single and double network perturbations was 
conducted to identify drug targets with potential to adapt fibrotic activity to the local 
mechanical environment. Biochemical input reaction weights used for all simulations 
were interpolated using the method described for in vivo study comparisons at a time 
point of 2 weeks post-infarction. To represent remote (low tension) and infarcted (high 
tension) zones post-MI, tension reaction weights of 0.1 and 0.6 were used, respectively. 
For each simulation, baseline conditions were simulated using the input reaction weights 
above for 80 s, and single or double perturbations were simulated by setting Ymax values 
of nodes to 0.1 (knockdown) or 5 (overexpression) for 240 s. Single perturbations were 
simulated for all individual nodes as both knockdown and overexpression for a total of 
218 perturbations, and double perturbations were simulated for all node combinations as 
double knockdown, double overexpression, or knockdown-overexpression combinations 
for a total of 23,544 perturbations.  
Perturbations that exhibited mechano-adaptive behavior were identified using a 
rank-based score metric based on changes in activity levels for model outputs 
(ΔActivity). For each perturbation and tension level, ΔActivity levels were calculated as 
the difference in each node’s activity between baseline and perturbed conditions, and 
changes in overall matrix content (MCC) for each perturbation and tension level were 
calculated based on ΔActivity levels for all procollagens and matricellular proteins 
(ΔActivityMatrix), ΔActivity levels for all MMPs (ΔActivityMMP), and ΔActivity levels for 
all protease inhibitors (ΔActivityInhib): 𝑀𝐶𝐶 = ∑ ∆𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 − ∆𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 +
∆𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 . Output nodes were categorized as follows: ΔActivityMatrix: proCI, 
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proCIII, fibronectin, periostin, osteopontin; ΔActivityMMP: proMMPs 1, 2, 3, 8, 9, 12, 14; 
ΔActivityInhib: TIMP1, TIMP2, PAI1. To identify perturbations that (1) qualitatively alter 
matrix content in a desirable manner based on the tensional context and (2) maximize 
differences in low- and high-tension expression, a two-step procedure was used to score 
mechano-adaptive behavior from MCC values: 
(i) Perturbations were first filtered based on the numeric signs of MCC values 
at each tension level to identify categorically desirable behavior. 
Perturbations that exhibited negative MCC values (i.e. greater anti-fibrotic 
activity than pro-fibrotic activity) at low tension and positive MCC values 
at high tension (i.e. greater pro-fibrotic activity than anti-fibrotic activity) 
were retained for subsequent steps, and all others were removed. 
(ii) Retained perturbations were then ranked based on MCC values at each 
tension level. MCC values at low tension were ranked in ascending order 
(i.e. low to high values), and MCC values at high tension were ranked in 
descending order (i.e. high to low). The mechano-adaptive score for each 
perturbation was then determined by summing each perturbation’s rank 
for low and high tension and subtracting two times the sum from the 
number of retained perturbations, thereby denoting highly adaptive 
perturbations with high scores and less adaptive perturbations with low 
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AIM 3: DEVELOP A NEW, DATA-DRIVEN MODEL OF FIBROBLAST 
TRANSCRIPTIONAL REGULATION TO IDENTIFY INFLUENTIAL 
REGULATORS OF FIBROSIS 
 
 
5.1.  Introduction 
 The development of valvular and myocardial fibrosis has proven to be a major 
obstacle for the treatment of patients suffering from aortic valve stenosis (AVS). This 
disease is characterized by obstruction of the aortic valve leaflets by progressive fibrosis 
and calcification, reducing blood flow through the valve and leading to compensatory 
cardiac hypertrophy, myocardial fibrosis, and eventually heart failure in a large 
proportion of patients1. Current surgical interventions that replace the diseased valve with 
a biomaterial-based valve have substantially improved outcomes for patients diagnosed 
with severe AVS, and the transcatheter aortic valve replacement (TAVR) procedure has 
proven to be particularly effective for patients with high surgical risk2. While these 
replacements prevent further valve and myocardial remodeling by reestablishing blood 
flow, interstitial fibrosis prior to surgery is not necessarily reversed after surgery, and 
investigations of patient outcomes after valve replacement have associated high 
perioperative degrees of fibrosis with reductions in long-term survival and cardiac 
function3–5. Therefore, preventing valve and myocardial fibrosis during initial AVS 
progression by slowing the accumulation of extracellular matrix (ECM) remains crucial 
for preserving heart function and preventing the late onset of heart failure. 
 As a mediator of ECM turnover, cardiac and valvular myofibroblasts play a key 
role during AVS progression by synthesizing matrix proteins, proteases including matrix 
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metalloproteinases (MMPs), and regulatory matricellular proteins to dictate overall 
changes in scar formation and tissue mechanical properties6. Valvular interstitial cells 
(VICs) and cardiac fibroblasts undergo activation into a myofibroblast phenotype in 
response to an influx of inflammatory cytokines, growth factors, and hormonal peptides 
as well as changes in local biomechanical cues including pathological stiffness and 
tensile loading7,8. These extracellular cues are transduced through a complex network of 
regulation in which multiple intracellular signaling pathways interact via crosstalk and 
feed-forward mechanisms to dictate overall cell responses9, thus further complicating 
efforts to understand how myofibroblasts respond within the AVS microenvironment. 
While previous studies have shown that myofibroblasts can undergo deactivation in 
response to changes in plasma biomarkers after TAVR, macrophage-secreted 
inflammatory cues, and local mechanical stiffness10–13, the complexities of myofibroblast 
signal transduction among a diverse microenvironment complicates efforts to determine 
mechanisms of action for therapeutic intervention. 
 To discover potential mechanisms of action that can be targeted to rescue 
myofibroblast activation during AVS progression, we employed a computational 
approach in which simulated environmental cues are transduced via a network of 
signaling and transcriptional interactions to predict changes in myofibroblast protein 
expression. Similar approaches have been used to model various cardiovascular and 
systemic diseases and have successfully generated insight into influential mechanisms 
within a broad biological scope14–17. We adapted this approach to simulate myofibroblast 
responses to patient-specific plasma biomarker levels before and after TAVR by 
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combining our published network of fibroblast signaling with a new, data-driven network 
of myofibroblast transcriptional regulation capable of predicting the regulation of 
transcription factors (TFs) associated with fibrosis-related genes. Model calibration using 
patient-matched plasma biomarker and myofibroblast RNA-sequencing data allowed for 
accurate predictions of ECM protein expression for pre- and post-TAVR patient 
biomarker profiles, and comparisons between simulated ECM expression levels and 
clinical measurements suggest strong correlations between select myofibroblast-secreted 
proteins and AVS severity. Global network perturbation analysis revealed several 
influential signaling axes that mediated ECM protein expression including the interleukin 
6 (IL6)-glycoprotein 130 (gp130)-signal transducer and activator of transcription (STAT) 
pathway as well as the transforming growth factor-β (TGFB)-reactive oxygen species 
(ROS)-c-Jun N-terminal kinase (JNK) pathway. Using these influential pathways as a 
basis for possible drug candidates, we screened myofibroblast responses to simulated 
pathway inhibitors for patient biomarker profiles and found stratified patient responses to 
inhibitors, demonstrating the ability of our approach to both prioritize therapeutic 
candidates for AVS progression and to predict patient-specific responses to anti-fibrotic 
therapies. 
5.2. Results 
Development of Myofibroblast Transcriptional Network 
 Using a published dataset of myofibroblast gene expression in response to pre- 
and post-TAVR patient sera, we developed a new model of myofibroblast transcriptional 
regulation using established gene regulatory network inference algorithms. Upon initial 
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topology inference and implementing several filtering steps to prioritize experimentally-
supported and fibrosis-related interactions (Figure 5.1A), our transcriptional network 
represents 10 TFs activated by intracellular signaling, 27 intermediate TFs, and 18 target 
genes related to ECM turnover or autocrine feedback (Figure C-1). This network 
inference strategy identified pathways mediating ECM-related genes that have been 
shown to alter collagen crosslinking, degradation, and tissue elasticity in vivo but have 
seen limited implementation into fibroblast signaling networks, namely cathepsin C 
(CTSC), cathepsin L (CTSL), lysyl oxidase homolog 1 (LOXL1), prolyl-4-hydroxylase 
(P4H), and elastin. Additionally, this data-driven approach identified several intermediate 
TFs known to regulate cardiac fibrosis, including SOX9, CCND1, ATF3, and NOTCH1, 
suggesting agreement between the inferred topology and previous experimental findings. 
Composite Myofibroblast Network Improves Accuracy of Protein Expression Predictions 
 Myofibroblast activation and expression of ECM proteins during AVS relies not 
only on regulatory mechanisms at the transcriptional level, but also on changes to 
intracellular signaling which often involves crosstalk between multiple pathways. To 
provide a predictive model that accounts for both levels of regulation simultaneously, we 
integrated the inferred transcriptional network above with our published network of 
fibroblast signaling, incorporating signaling reactions and TF-target interactions into a 
single composite network for semi-quantitative simulation (Figure 5.1B). This composite 
network, consisting of 151 nodes and 334 edges in total, predicts the expression of 27 
fibrosis-related proteins (output nodes) based on 10 canonical biochemical chemokines 
and mechanical tension (input nodes), thus giving a comprehensive view of 
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myofibroblast responses to environmental cues observed during AVS progression. This 
network was implemented as a system of logic-based ordinary differential equations 
(ODEs) as previously described18, in which normalized node activity levels are 
approximated via Hill equations using normalized node and reaction parameters (see 
Materials and Methods for full description).  
 In order to calibrate this network to the biochemical and biomechanical conditions 
experienced during severe AVS and after surgical intervention, we implemented a genetic 
algorithm to estimate the relative weight parameters of all network reactions based on a 
published multi-omic dataset consisting of (1) proteomic profiling of serum samples for 
AVS patients collected before and after TAVR procedures, and (2) RNA-sequencing of 
myofibroblasts treated with each patient’s serum10. An ensemble of parameter sets was 
estimated using proteomic and transcriptomic datasets as analogs for model inputs and 
outputs respectively, and the resulting fitted network emphasized downstream signaling 
pathways from TGFβ, endothelin-1 (ET1), tumor necrosis factor-α (TNFα), interleukin 1 
Figure 5.1. Composite myofibroblast regulatory network accurately predicts fibrosis-related 
protein expression based on patient-specific biochemical stimuli. (A) Schematic of gene regulatory 
network inference and model pruning scheme resulting in a targeted myofibroblast transcriptional 
network. (B) Topology of combined network consisting of a curated network of fibroblast signaling and 
an inferred transcriptional network derived from myofibroblast RNA-sequencing. Biochemical and 
biomechanical input nodes (orange boxes), signaling-activated TFs (yellow boxes), and fibroblast-
secreted output nodes (green boxes) are connected by directed edges representing activating and 
inhibiting reactions (red and blue lines respectively, 334 total) with AND logic indicated by circular 
nodes. Line widths represent average reaction weight parameters estimated via genetic algorithm. (C) 
Comparison of experimentally measured changes in output gene expression between pre- and post-
TAVR conditions (ΔExpressionTAVR) with model predicted changes in output protein activity between 
pre- and post-TAVR conditions (ΔActivityTAVR). Individual comparisons made for each patient (boxes) 
represent mean levels across an ensemble of estimated parameter sets, and statistical comparisons of 
activity levels between pre- and post-TAVR groups were conducted via two-tailed Student’s t-tests. * 
p<0.05, † p<0.05 for model predictions and experimental values. (D) Comparison of squared errors 
(SE) of predicted patient ΔActivityTAVR levels between fitted model (x-axis) and a default model (y-
axis). All SE values were calculated in reference to experimental ΔExpressionTAVR levels. 
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(IL1), and IL6 as well as STAT- and nuclear factor kappa B (NFKB)-mediated 
transcriptional regulation (Figure 5.1B). 
 We compared model predictions of myofibroblast-expressed proteins to measured 
gene expression levels by simulating myofibroblast responses to each patient’s pre- or 
post-TAVR serum profiles and measuring changes in output activity between pre- and 
post-TAVR conditions (ΔActivityTAVR). Changes in model predicted protein expression 
matched changes in gene expression in pre- and post-TAVR serum-treated 
myofibroblasts (ΔExpressionTAVR), as significant decreases in simulated plasminogen 
activator inhibitor-1 (PAI1) and elastin activity along with significant increases in 
simulated CTSC, CTSL, P4H, periostin, and IL6 activity mirrored significant changes in 
respective gene expression before and after TAVR (Figure 5.1C). Across the ensemble of 
estimated parameter sets, the average mean squared error (MSE) between ΔActivityTAVR 
and ΔExpressionTAVR levels all patients and model outputs was 0.0329 ± 0.0531, yielding 
a similar level of error as other fitted mechanistic and logic-based networks19,20.  
We additionally assessed the accuracy of our parameter estimation strategy 
against a default model without fitted reaction weight parameters (i.e. all reactions weight 
parameters set to 1) by comparing ΔActivityTAVR levels for each model against the 
previous ΔExpressionTAVR levels. We found that parameter estimation improved 
predictive accuracy for individual outputs with respect to each patient’s serum, as fitted 
model ΔActivityTAVR levels for individual patients and outputs had lower squared errors 
against respective ΔExpressionTAVR levels compared to the default model (Figure 5.1D). 
Moreover, comparisons of significantly altered output levels between pre- and post-
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TAVR conditions as predicted by the two models and as measured in myofibroblasts 
suggests a sizeable improvement in predictive accuracy. We found that while the default 
model had a classification accuracy of 43.5% in predicting truly significant and non-
significant changes in output activity compared to gene expression data, the fitted model 
improved the accuracy to 69.6%, thus predicting a higher proportion of truly significant 
and non-significant changes in output levels than the default, un-fitted model.  
Model-Predicted ECM Expression Correlates with Clinical Measures of AVS Severity 
 The relationship between cardiac fibrosis and reduced valve and heart function 
during AVS is well-known, but because scar formation involves a variety of matrix 
proteins, proteases, matricellular proteins, and crosslinking proteins for overall changes 
in tissue architecture, linking individual secreted proteins to changes in valve and heart 
function remains challenging. Our myofibroblast network can account for many of the 
species involved in scar formation, so we hypothesized that comparing model-predicted 
trends in myofibroblast protein expression to patient-matched clinical measurements can 
identify strongly correlated proteins among a diverse protein expression profile. We 
performed a systematic correlational analysis between activity levels of 23 outputs 
predicted for each pre-TAVR patient serum and 13 clinical features measured prior to 
surgery. We found correlation coefficient directions between model-predicted outputs 
and clinical features generally matched those for pre-TAVR myofibroblast gene 
expression (Figure 5.2A). Several ECM proteins and secreted cytokines demonstrated 
significant negative correlations and linear regression goodness-of-fit with aortic valve 
area including matricellular proteins periostin and osteopontin, collagen crosslinker P4H, 
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and autocrine feedback-associated proteins latent TGFB, IL6, and ET1. These 
associations suggest that high levels feedback signaling and matricellular protein 
expression persist for patients with a greater degree of stenosis, although the underlying 
mechanisms remain unclear. 
 We additionally aggregated individual ECM protein levels into a single matrix 
content score (MCS) via a rank-based procedure as an analog for net matrix accumulation 
for each patient (see Materials and Methods for full description). Significant negative 
Figure 5.2. Model-predicted expression of fibrosis-related proteins correlates with clinical 
measures of disease severity. (A) Correlational analysis of pre-TAVR output node activity levels with 
clinical features measured before and after TAVR surgery and comparison between model-predicted 
output expression and experimentally measured gene expression. All dots represent Pearson correlation 
coefficients and respective p-values. (B) Trending and significant correlations between aggregated 
matrix content score (MCS) and clinical features. Spearman correlation coefficients (r) and p-values 
were used to determine statistical significance.  
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correlations between pre-TAVR MCS values and pre-TAVR left ventricular end systolic 
internal diameter (LVIDS) and pre- to post-TAVR changes in Kansas City 
Cardiomyopathy Questionnaire score (ΔKCCQ score) as well as a trending positive 
correlation with Society of Thoracic Surgeons risk score (STS score) all suggest that 
predicted shifts in overall myofibroblast secretion towards ECM accumulation may be 
connected to declines in ventricular function as well as negative post-surgical outcomes 
(Figure 5.2B). 
Network Perturbation Analysis Reveals Influential Pathways Mediating Fibrosis during 
AVS 
 A key barrier to understanding myofibroblast activation during AVS is a lack of 
insight into whether select regulatory pathways influence cell behavior over others within 
the larger network. Systems-level models may be able to provide key insight into relative 
pathway influences on cell behavior through comprehensive perturbation simulations to 
measure network-wide signal propagation. Using our model, we performed 
comprehensive knockdown simulations of individual nodes for all individual patient 
serum levels, measuring changes in network activity with each knockdown (ΔActivityKD) 
to assess network-wide effects in a patient-specific manner. We calculated a knockdown 
influence level for each node as a metric for the total effects that one node has on all other 
nodes, and we calculated a knockdown sensitivity level for each node as a metric for the 
total change in activity for one node across the knockdown of all other nodes (see 
Materials and Methods for full description). Selection of the top 10 scoring nodes in both 
metrics for each pre- and post-TAVR serum condition showed similar trends in node 
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Figure 5.3. Network perturbation analysis reveals influential pathways and differences in 
myofibroblast responses across patient conditions. (A-B) Comparison of top-ranked influential and 
sensitive nodes between patients and pre-/post-TAVR conditions. Nodes shown reflect all unique nodes 
ranked in the top 10 based on knockdown influence (A) or knockdown sensitivity (B). Dark bars 
represent knockdown influence/sensitivity levels for each pre-TAVR patient condition, and light bars 
represent levels for each post-TAVR patient condition. (C) Topological representation of influential and 
sensitive pathways within the myofibroblast network. Node sizes represent average knockdown 
influence levels across all patient and pre-/post-TAVR conditions, node colors represent average 
ΔActivityTAVR levels across all patients, and node border sizes/colors represent average knockdown 
sensitivity levels across all patient and pre-/post-TAVR conditions. (D) Correlational analysis between 
pre-TAVR knockdown influence levels for top-ranked nodes and ΔActivityTAVR levels for model 
outputs. All dots represent Pearson correlation coefficients and respective p-values. (E) Correlational 
analysis between knockdown influence levels for top-ranked nodes and predicted ΔMCS levels between 
pre- and post-TAVR conditions. 
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sensitivity and influence across patients, with a total of 19 nodes ranking in the top 10 
knockdown influence and 17 nodes ranking in the top 10 knockdown sensitivity for at 
least one patient (Figure 5.3A-B, see Figure C-2A for network-wide sensitivity analysis).  
 Across all patient biomarker profiles, several intracellular signaling pathways 
were consistently influential with respect to network-wide activity. Among the top 
biochemical inputs represented were IL6, TGFB, and ET1, and these factors were 
typically propagated by gp130/STAT activation in the case of IL6 as well as by smad3, 
NOX/ROS, and mitogen activated protein kinase (MAPK) activation in the case of TGFB 
and ET1 signaling. (Figure 5.3C). Nodes downstream from these pathways consistently 
scored highly in knockdown sensitivity, including smad7, TCF4, TP53, and NOTCH1 as 
targets of IL6 signaling, and AP1, NFKB, cmyc, and MECOM as targets of TGFB/ET1 
signaling. These intermediates were also predicted to sizably change from pre- to post-
TAVR conditions for patients, as average ΔActivityTAVR levels across all patients indicate 
consistent upregulation of IL6 pathway activation after TAVR and large increases or 
decreases in downstream activity for connected TFs and target output nodes depending 
on individual connectivity to the IL6, TGFB, or ET1 signaling pathways (Figure 5.3C). 
We next compared knockdown influence and sensitivity levels for top-ranked 
nodes across patient-specific conditions to assess differences both between individual 
patients and between pre-/post-TAVR conditions. We found that influential nodes 
representing IL1 and TGFB signaling pathways fluctuated between the patient cohort, as 
select patient sera showed large network-wide changes in activity compared to others 
(Figure 5.3A) and calculated coefficients of variation across patient conditions were 
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largest for IL1 and TGFB-associated nodes out of all top-ranked nodes (Figure C-2B). 
While patient-specific differences in knockdown sensitivity were not as pronounced and 
coefficients of variation were lower overall (Figure C-2C), overall knockdown sensitivity 
levels did vary by patient, with select patients showing little sensitivity across all top-
ranked nodes compared to others (Figure 5.3B). We also observed differences in 
influence and sensitivity from pre-TAVR to post-TAVR conditions across top-ranked 
nodes. Knockdown influence levels for IL6 signaling nodes increased for post-TAVR 
conditions compared to pre-TAVR conditions for 7 of 8 patients, which was consistent 
with increases in IL6-related activity during post-TAVR simulations and demonstrated a 
greater degree of responsiveness to the IL6 pathway after surgical intervention. Select 
patients also showed increased influence of TGFB signaling in post-TAVR conditions, 
including levels of TGFB1R, JNK, and NFKB, suggesting that select patients may be 
more susceptible to therapeutic agents inhibiting the TGFB signaling pathway than 
others. 
As an additional exploratory analysis of influential pathway effects on 
myofibroblast secretion, we correlated pre-TAVR knockdown influence levels of top-
ranked nodes with ΔActivityTAVR levels for all fibrosis-related outputs to assess whether 
influence levels of top intermediates during severe AVS relate to changes in ECM protein 
expression after surgical intervention. A total of 82 out of 437 correlations between pre-
TAVR influence and output ΔActivityTAVR levels were significant including 27 positive 
correlations and 55 negative correlations (Figure 5.3D). Influence levels of IL6-
associated nodes and ET1-associated nodes significantly correlated with ECM proteins 
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that were highly sensitive to knockdown from our perturbation analysis. Positive 
correlations with elastin, PAI1, and LOXL1 as well as negative correlations with multiple 
matrix proteases, periostin, and P4H suggest that changes in the IL6 and ET1 signaling 
pathways may explain changes in protease, protease inhibitor, and collagen crosslinking 
protein expression observed with surgical intervention. We additionally correlated pre-
TAVR influence levels with changes in MCS values from pre-TAVR to post-TAVR 
(ΔMCS) as a metric for overall changes in myofibroblast-mediated matrix turnover, and 
we found that knockdown influence of the IL1- and ET1-associated nodes positively 
correlated with changes in matrix content for patients, suggesting that changes in these 
signaling pathways may explain reductions in overall myofibroblast-mediated fibrosis 
observed after TAVR (Figure 5.3E).  
Targeted Virtual Drug Screen Predicts Stratified Patient Responses to Therapies 
 Our perturbation analyses above suggested that while select signaling pathways 
may mediate myofibroblast protein expression over others, responses of individual 
patients to pathway alteration vary widely with some patients experiencing little to no 
benefit for a given therapy. This challenge is a common theme among currently 
prescribed therapies for cardiovascular diseases, and computational models of biological 
systems have gained recent attention for their capacity to predict patient-specific 
responses to therapeutic intervention. We investigated whether our myofibroblast 
network could discern patient-specific responses to simulated drugs by predicting 
changes in fibrosis-related outputs after inhibiting each of the 19 top-ranked influential 
nodes identified from the network perturbation analysis above. Inhibition of each node 
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Figure 5.4. Virtual drug screen reveals stratified patient responses to inhibitor treatments. (A) 
Comparison of ΔActivityinhib levels for fibrosis-related model outputs upon knockdown of top-ranked 
influential nodes. Values represent average ΔActivityinhib levels across all patients for pre- and post-
TAVR conditions after 80% inhibition of each node relative to respective un-perturbed conditions. (B-
C) Example dose-response relationships between influential node inhibition and predicted output 
activities for individual patients. Steady-state periostin  and proCI levels were measured with Inhibition 
of STAT (B) and JNK (C) respectively. Inhibitor levels represent negative modifiers applied to node 
Ymax parameters, and activity levels represent mean ± SD levels measured across all estimated 
parameter sets. (D-E) Network representations of influential signaling pathways and affected outputs 
with inhibition, corresponding with IL6 (D) and TGFB/ET1 (E) pathway inhibition. Extracellular 
inputs, signaling intermediates, signaling-mediated TFs, and model outputs are labeled as orange, 
white, yellow, and green boxes, respectively. 
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was performed for each patient’s pre- and post-TAVR serum profile in a dose-response 
manner by limiting of the maximum activation of each node, and average changes in 
activity of output nodes (ΔActivityinhib) were measured for each patient relative to un-
perturbed levels. Using a 5% change in mean activity as a threshold, we found that 13 of 
19 influential nodes sizably altered the expression of output proteins with inhibition on 
average, and 14 of 29 outputs responded to inhibition overall suggesting a selective 
response of myofibroblasts towards simulated drugs (Figure 5.4A).  
We found that responses to inhibitory drugs sizably varied across the patient 
cohort, particularly simulated pre-TAVR conditions. Progressive inhibition of IL6 
signaling species such as gp130 and STAT resulted in varying degrees of protein 
suppression. For example, periostin activity decreased by as little as 19.3% or as much as 
56.9% for individual patient conditions with 80% inhibition of STAT, suggesting large 
differences in response to treatment (Figure 5.4B). This variance in output response was 
not as apparent in post-TAVR simulations, as periostin activity was reduced in all 
patients by at least 41.1%. This trend persisted across several ECM proteins in response 
to IL6 pathway inhibition including P4H, CTSC and CTSL. Interestingly, patient-to-
patient variance in ECM protein expression persisted across pre- and post-TAVR 
conditions when nodes associated with TGFB and ET1 signaling were inhibited. For 
example, inhibition of JNK variably increased proCI activity across the cohort in pre-
TAVR simulations (8.1% to 22.7% increase in activity), and similar ranges in response 
were observed under post-TAVR conditions (12.2% to 24.1% increase), suggesting a 
persistent stratified response towards TGFB/ET1 pathway inhibition. 
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5.3. Discussion 
 Preventing cardiac fibrosis during AVS is crucial for long-term patient outcomes 
even after surgical intervention, and although previous studies have shown that 
alterations in plasma protein levels after valve replacement can deactivate 
myofibroblasts10,11, the underlying mechanisms of cell activation and deactivation remain 
unclear due in part to the complexities of intracellular regulatory mechanisms. In order to 
aid our understanding of such mechanisms and prioritize therapeutic strategies for 
slowing fibrosis-related AVS progression, we hypothesized that a computational model 
of myofibroblast intracellular regulation could elucidate mechanisms-of-action mediating 
myofibroblast activation by predicting fibrosis-related protein expression in response to 
biochemical and biomechanical stimuli. We found that by developing a model that 
encompasses signaling and epigenetic pathways and calibrating our model to multi-omic 
data derived from patients undergoing surgical valve replacement, we efficiently and 
accurately predicted fibrotic protein expression and used such predictions to inform 
preclinical studies of anti-fibrotic therapies during AVS.  
Our strategy above improved the accuracy of patient-specific predictions over 
simulations based on model topology alone and resulted in a similar degree of accuracy 
against experimental gene expression data compared to other fitted network models19,20. 
Correlational analyses demonstrated strong trends between both individual matrix 
proteins predictions and aggregated matrix content scores with clinical measures of 
disease severity and patient quality-of-life, and network-wide perturbation analyses 
identified influential signaling pathways and transcriptional regulators of network activity 
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and output expression such as the IL6-gp130-STAT and TGFB-ROS-JNK signaling axes, 
which suggest that both axes serve as central mechanisms-of-action during myofibroblast 
activation. We additionally demonstrated the capacity of the model to detect stratified 
patient responses to targeted inhibition in a virtual drug screen, suggesting that select 
patients may respond favorably to myofibroblast inhibitors based on plasma biomarker 
profiles while the same inhibitor may not be suitable for others. Our results suggest that 
our computational strategy can accelerate the development of anti-fibrotic therapies 
during AVS progression by both generating insight into plausible mechanisms governing 
cell behavior and by stratifying patients based on plasma biomarker levels. 
Identification of Transcriptional Regulators in Myofibroblast-Mediated Fibrosis 
While intracellular signaling processes remain a crucial step in transducing 
environmental cues into changes in cell protein expression and phenotype, regulation on 
a transcriptional level adds an additional layer of complexity and can further confound 
predictions of cell behavior. Our construction and simulation of a myofibroblast 
transcriptional network derived from RNA-sequencing data suggests that this layer of 
regulation plays a highly influential role in myofibroblast behavior during AVS 
progression. Transcriptional regulators identified here via gene regulatory network 
inference have also been shown to mediate VIC and cardiac fibroblast behavior in other 
cardiovascular pathologies. The transcription factor SOX9 has been identified as a 
positive regulator of cardiac fibrosis and heart failure development in models of 
ischemia-reperfusion injury and myocardial infarction (MI), with ischemia causing 
increased SOX9 gene expression and spatial correlation with collagen gene expression 
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and scar formation measured via histology21. Fibroblast-specific deletion of SOX9 in an 
MI mouse model was also shown to attenuate increases in fibroblast αSMA expression 
and proliferation as well as scar formation and functional measures such as ejection 
fraction and left ventricular end diastolic area, demonstrating a strong connection 
between this factor and fibrotic processes. NOTCH1 and ATF3 have also been implicated 
in cardiac fibrosis and myofibroblast activation, as overexpression of the NOTCH1 
intracellular domain in rat cardiac fibroblasts antagonized TGFB-induced smad3 
activation and in vivo overexpression after MI reduced fibrotic area in rats22, and cardiac 
fibroblast-specific overexpression of ATF3 attenuated scar formation and reductions in 
left ventricular internal diameter in end-systole and ejection fraction after MI23. It should 
be noted that several regulators identified by our approach play influential roles in 
osteogenic differentiation such as NOTCH124–26, and although the scope of our model 
does not directly reflect osteogenic phenotypes for valvular cells, this similarity in 
regulatory species suggests that pathways mediating myofibroblastic and osteoblastic 
phenotypes are not mutually exclusive. Our identification of these transcriptional 
intermediates and connecting interactions suggests that the regulation of myofibroblast 
behavior involves numerous pathways simultaneously, and that changes in expression of 
SOX9, NOTCH1, and ATF3 likely mediate a number of fibrosis-related functions of 
myofibroblasts during AVS progression. While the full contribution of these factors 
towards fibrosis-related gene expression is unclear, modulating the expression of these 
factors may be a plausible direction for new anti-fibrotic drug candidates. 
Influential Signaling Axes and Regulatory Hubs Mediate Overall Myofibroblast Behavior 
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 Myofibroblasts respond to a variety of environmental stimuli including 
inflammatory cytokines, growth factors, and hormonal peptides, all of which have been 
shown to alter cell behavior individually6,27. Within the context of AVS progression, 
however, the relative contribution of each stimulant and their downstream signaling 
pathways remains unclear. We performed a network-wide perturbation analysis to 
identify globally influential pathways within the patient cohort during pre-TAVR and 
post-TAVR scenarios, and our simulations predicted that the transduction of IL6, and 
TGFB primarily influence activation levels across the network. IL6 signaling and 
downstream activation of STAT has been previously linked to cardiac fibrosis across 
several cardiovascular pathologies with effects across multiple pathways28. 
Dziemidowicz and colleagues found that IL6-/- mice treated with isoproterenol developed 
interstitial ventricular fibrosis and increased phosphorylated levels of multiple signaling 
intermediates including ERK, Raf, and p38 compared to wild-type mice29. In a similar 
finding, Hilfiker-Kleiner and colleagues found decreases in ERK and Akt 
phosphorylation for mice carrying a point mutation in gp130 and subjected to MI 
compared to wild-type mice. Recent evidence of IL6 as a promoter of VIC osteogenic 
differentiation via the increased expression of RUNX2 and osteopontin suggest that this 
pathway may serve multiple phenotypic roles11, and future targeted investigations of this 
behavior may explain possible context-dependent roles of IL6 signaling during AVS 
progression. 
Noncanonical TGFB signaling via the activation of NADPH oxidases (NOX) and 
ROS has also proved to be an effective regulator of fibrosis both in the myocardium as 
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well as in valvular tissue. Inhibition of NOX4 in cardiac fibroblasts has been shown to 
reduce TGFB-stimulated intracellular superoxide production, which in turn mediates 
αSMA expression, CTGF and fibronectin secretion, and phosphorylation of smad2/3, 
suggesting a largely pro-fibrotic role of this pathway30. The NOX-ROS signaling axis has 
also been shown to mediate changes across multiple pathways to alter fibrosis in mouse 
models of hypertension31, and decreases in NOX4 expression and ROS generation 
following genetic knockout of SOD1 in mice mitral valves has been associated with 
changes in αSMA, connective tissue growth factor (CTGF), and MMP expression in 
mitral VICs32, suggesting a similar systemic effect of this noncanonical mechanism on 
valvular myofibroblast behavior.  
Our global analysis additionally suggests that select TFs may act as regulatory 
hubs for expression of ECM-related proteins during AVS progression. We predicted that 
STAT, NFKB, and Jun influence large changes in activity across the entire network, and 
all three TFs have been well-studied for their roles in pathological scar formation. Our 
simulations indicated that STAT primarily influenced myofibroblast behavior via the 
expression of matricellular proteins, matrix proteases, and crosslinking enzymes, and 
previous experimental studies have confirmed this central role of STAT in cardiac 
fibrosis and systemic sclerosis. Using IL-11 as a positive regulator of STAT3 after MI in 
mice, Obana and colleagues demonstrated that STAT3 activation reduced left ventricular 
scar formation and improved infarct wall thicknesses compared to un-treated MI, 
demonstrating a primarily anti-fibrotic effect during ischemic injury33. However, 
disruption of STAT3 phosphorylation via inhibition of EphrinB2 in a post-MI mouse 
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model reduced αSMA protein expression, collagen I expression, and cell proliferation34, 
and inhibition of STAT3 during bleomycin-induced skin fibrosis reduced gene expression 
of multiple ECM proteins35, suggesting that STAT may exert both pro- and anti-fibrotic 
effects. In agreement with experimental evidence of IL6 signaling during AVS, the 
activation of STAT3 was also associated with osteogenic de-differentiation in VICs via 
downregulation of RUNX2 and BMP-236, reinforcing the need to further investigate this 
intersection between fibrotic and osteogenic phenotypes. Given the experimental 
evidence implicating IL6, however, our simulations make clear that targeting the IL6-
gp130-STAT pathway has significant therapeutic potential for AVS by modulating the 
expression of ECM-crosslinking and degradation proteins. 
Systems Models Relate Cell Phenotypes to Disease Severity and Predict Patient 
Responses 
 Our model-centered approach provides unique advantages for relating cellular-
level behavior to clinical manifestations of AVS through the prediction of protein 
expression based on patient-specific conditions, and our findings above indicate that 
computational predictions of cell behavior correspond with multiple measures of AVS 
severity including aortic valve area, LVIDS, and STS scores. Previous plasma biomarker 
studies in AVS cohorts have shown individual biomarkers to be predictive of patient 
outcomes such as N-terminal pro B-type natriuretic peptide (NT-proBNP) and C-reactive 
protein37,38, and while useful for stratifying patient risk and informing surgical 
intervention, these biomarkers alone may not connect alterations in cellular function with 
overall disease progression. Our patient-specific predictions and correlation with pre-
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TAVR clinical measurements suggest that reductions in matricellular protein expression, 
autocrine feedback-related cytokine expression, and collagen crosslinking enzyme 
expression all corresponded with improved aortic valve areas, and aggregation of all 
output proteins into a single ECM-related metric further demonstrated a strong 
relationship between myofibroblast-mediated scar formation and reduced heart function. 
Virtual drug screens for individual patient conditions further demonstrated the ability of 
our model-based approach to discern responders versus non-responders towards 
hypothetical drug candidates. Using this approach for preclinical drug development and 
as a predictive tool in the clinic may improve patient responses to therapeutic 
intervention, as drug discovery efforts can be directed towards patients that meet 
selection criteria based on plasma biomarker levels, and treatment and/or dose decisions 
for individual patients can be made in the clinic from non-invasive testing results. While 
experimental validation of these trends is essential for further development and 
application of this approach, the framework developed here provides opportunities to 
further investigate fibrotic mechanisms-of-action for targeted patient cohorts or for other 
fibrosis-related diseases. 
Study Limitations and Future Directions 
 Our study was primarily limited by the size of patient datasets used for model 
training and simulated scenarios. While this multi-omic, patient-matched design formed 
an essential aspect of our model development strategy through the robust measurement of 
plasma proteins and cell-specific gene expression, a lack of cohort size and diversity 
limited our predictive capabilities in terms of both model training and predicted trends in 
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myofibroblast behavior. Additionally, the insufficient availability of select biochemical 
stimuli (e.g. estrogen), tissue biomechanical properties, and cell-secreted outputs limited 
our predictions related to these stimuli and associated regulatory pathways, and further 
measurement of these environmental factors will allow for the balanced predictions of 
influential mechanisms-of-action while limiting bias towards measured species. While 
our current parameter estimation approach using model input/output levels did improve 
overall predictive capabilities compared to the model topology alone, the additional 
measurement of intracellular intermediate activation via high-throughput 
phosphoproteomic arrays will also improve predictive accuracy of our model through the 
robust estimation of multiple reaction parameters. 
 Because both fibrosis and calcification processes play key roles in the 
development of AVS, we acknowledge that our model of myofibroblast protein 
expression alone accounts for only one component mediating overall disease progression. 
Future adaptation of this modeling strategy towards osteogenic differentiation may 
provide additional insight into dominating mechanisms responsible for calcification and 
complement our current model of fibrosis-related gene expression for an overall picture 
of cell behavior. Because several influential pathways identified here also correspond 
with the expression of calcification-related proteins, implementing these same pathways 
along with those known to mediate severe AVS may be valuable for investigating 
differences in fibrotic versus osteogenic differentiation. 
 Our development of a fibroblast regulatory network and analysis of patient-
specific changes in myofibroblast behavior demonstrated the translational possibilities of 
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network models by identifying key mechanisms governing cell behavior within a larger 
signaling context. Predicted intracellular species and pathways influencing fibrosis-
related gene expression provide targeted hypotheses for future validation, and future 
experimental studies are necessary to confirm the roles of these species are necessary and 
explore related signaling dynamics. Our findings of strong correlations between model-
predicted protein expression and clinical measures of disease severity additionally 
suggest that simulated biological networks can relate cellular phenotypes to clinical 
manifestations of AVS, and future exploration of the predictive capabilities of such 
models could prove useful for clinical translation. Our virtual drug screen of individual 
patient responses to pathway-inhibiting drugs further demonstrated the ability of our 
model-based approach to stratify patient cohorts based on plasma biomarker profiles. 
While future experimental validation is necessary to confirm these trends and improve 
predictive accuracy, this strategy provides a framework for predicting cell behavior 
within a complex signaling context and enables further investigation into pathways 
mediating valvular fibrosis before and after surgical intervention. 
5.4. Materials and Methods 
Data and Code Availability 
The code generated during this study is available at GitHub 
(https://github.com/jdroger/Fibroblast_Gene_Regulatory_Network). The published article 
includes all models generated or analyzed during this study. 
Fibroblast Transcriptional Network Construction 
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 Gene Regulatory Network Inference. We employed a previously published 
method of gene regulatory network inference to derive a network of transcription factor 
(TF)-target gene interactions based on a transcriptomic dataset of VIC populations after 
stimulation with patient sera. Bulk RNA-sequencing datasets recently published by our 
collaborators were used as a training set for network inference, and this dataset represents 
the gene expression of VIC populations stimulated with serum derived from a small 
cohort of patients undergoing a TAVR procedure10. Briefly, patient blood samples were 
collected at the time of surgery and at the 1-month follow up visit (n = 4 female patient 
pairs and n = 4 male patient pairs, 16 samples total). The resulting serum samples were 
used to treat porcine VIC cultures seeded on soft PEG hydrogels (elastic modulus of 5.8 
kPa) for 48 h prior to RNA-sequencing, and counts per million (CPM) for gene 
expression were used for subsequent network inference and model fitting methods. 
 We utilized the GRNBoost2 machine learning algorithm to infer a network of TF-
target interactions from the transcriptomic dataset above. This regression-based method is 
based on the GENIE3 tree-based algorithm for predicting regulatory links between input 
genes and target genes via the construction of decision tree ensembles39. Each ensemble 
of decision trees, which predicts the expression of a given target gene from the 
expression of all input genes, is used to determine the relative “importance” of each input 
gene in predicting the expression of the specified target gene. Decision tree ensembles are 
built for all genes across the transcriptome, and input-target gene links are aggregated to 
form a composite network of ranked interactions. The GENIE3 algorithm has been 
shown to out-perform other methods in inferring gene regulatory networks as part of the 
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DREAM4 In Silico Multifactorial challenge39, and it provides several advantages over 
other common inference algorithms: (1) inference can be performed with minimal 
assumptions of network topology, (2) directed interactions (i.e. gene A activates gene B) 
can be inferred compared to correlation- and probability-based methods, and (3) non-
linear or combinatorial regulation can be derived compared to other regression-based 
methods40. The GRNBoost2 implementation optimizes this approach using stochastic 
gradient boosting, which grows decision tree ensembles on a subset of observations and 
estimates the loss function on the remaining observations with each iteration. The 
algorithm implements an early stopping criterion if the loss function does not improve 
above a set threshold, thereby preventing unnecessary iterations of each decision tree and 
reducing overall computational time41. The Arboreto library for python was used to apply 
this algorithm to the RNA-sequencing data described above, and the average 
computational time for network inference using a 4-core computer was approximately 10 
min. 
 Network Pruning. Upon inference of the initial network, a 3-step workflow was 
applied to filter the network for TF-target interactions that satisfy 3 requirements: (1) 
interactions must be supported by experimental evidence, (2) interactions must relate to 
either literature-supported TFs (primary TFs) or fibrosis-related target genes in 
myofibroblasts, and (3) resulting pathways connecting primary TFs and target genes must 
have relatively strong links across all individual edges as determined by interaction ranks 
assigned by the GRNBoost2 algorithm (Figure 5.1A). The first step was performed by 
comparing inferred TF-target interactions with databases of known TF-target interactions 
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aggregated from chromatin immunoprecipitation (ChIP) studies. Curated lists of known 
TF-target interactions from the ChIP-X Enrichment Analysis (CHEA) and TRANSFAC 
databases were downloaded using the Harmonizome web interface42, both of which were 
chosen to maximize coverage of TFs related to myofibroblast activation. Upon filtering 
the initial gene regulatory network for interactions contained in either database, the 
resulting network was filtered further for interactions containing TFs or fibrosis-related 
target genes in myofibroblasts. Lists of TFs and target genes were derived using our 
curated network model of fibroblast signaling (see Chapter 4), which contains 11 primary 
TFs and 20 target genes coding for ECM-related proteins. For TFs that consist of several 
subunits (e.g. activator protein 1 [AP1] complex), both constituent genes were included 
for filtering. An additional 8 target genes that were differentially expressed by patients 
between pre- and post-TAVR sera were also considered: CTSC, CTSL, COL4A5, 
LOXL1, P4HA1, P4HA3, LAMA4, and ELN. Proteins coded by these genes have been 
shown to alter matrix degradation, collagen processing, and alter material properties of 
cardiac tissue, and significant differences in expression within the RNA-sequencing 
dataset provide a rationale for exploring possible regulatory pathways affecting gene 
expression. After list construction, the database-filtered network above was filtered again 
for interactions containing genes in either list. After filtering, interactions contained only 
TF-TF interactions or TF-target interactions in which intermediate TFs not included in 
the primary TF list above regulate target gene expression (i.e. primary TF A activates 
secondary TF B, which activates target gene C). 
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 After the second stage of filtering above, the final network topology was derived 
by ensuring that all resulting pathways between primary TFs and target genes contained 
interactions that ranked highly among possible regulatory links according to the 
GRNBoost2 algorithm. A modified depth-first-search algorithm was implemented to find 
all possible pathways between each primary TF and target gene and check whether each 
interaction within that pathway met this requirement using the “importance” score for the 
interaction output by GRNBoost2. Individual interactions were only allowed if the 
importance score of each edge was greater than either a threshold of 1 or the 75th 
percentile of all interactions stemming from the same TF. This hybrid threshold was 
chosen to both limit interactions driven by noise, in which overall importance scores are 
low, and to prevent premature exclusion of related interactions when all possible 
regulatory links may be ranked low relative to the entire network. By implementing this 
method, all interactions mediating expression of target genes were ensured to meet a 
threshold of confidence relative to neighboring interactions such that one TF within a 
pathway is not predictive of its downstream target. All network filtering steps were 
performed in a python environment using the numpy43 and pandas44 packages. 
Composite Signaling/Transcriptional Network Implementation 
 Topological Integration. We combined the final transcriptional network with our 
previous fibroblast signaling network describing intracellular mechanotransduction and 
chemotransduction (see Chapter 4) to form a composite network capable of predicting 
fibrosis-related protein expression in response to mechanical and biochemical stimuli. 
New TFs (model nodes) and/or transcriptional reactions (edges) were added to the 
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fibroblast signaling topology if they were not redundant to the original transcriptional 
reactions described by the signaling network.  
Logic-Based Ordinary Differential Equation Approach. The final network was 
implemented as a system of logic-based ordinary differential equations in which activity 
levels of all nodes were modeled by Hill equations. Logical NOT, AND, and OR gates 
were used for complex signaling interactions by applying the respective logical 
operations: 1 − 𝑓(𝑥) for NOT gates, 𝑓(𝑥)𝑓(𝑦) for AND gates, and 𝑓(𝑥) + 𝑓(𝑦) −
𝑓(𝑥)𝑓(𝑦) for OR gates. The open-source Netflux package for MATLAB was used to 
build this system of differential equations18, and all simulations were conducted using 
MATLAB (Mathworks, Natwick MA). All visualizations of network topology were 
constructed using Cytoscape45. 
Network Parameter Estimation 
 Dimensionality Reduction. To improve model predictions of myofibroblast 
behavior within the context of AVS before and after TAVR, we implemented a model 
fitting procedure to optimize the reaction weight parameters (w) of all reactions within 
the composite network. From the initial set of parameters (334 total), k-means clustering 
was conducted based on a global sensitivity analysis to group reaction weights based on 
changes in network-wide activity with knockdown. This method has been utilized in 
previous logic-based ordinary differential equation models to identify modules with 
similar functional behavior14 and provides an advantageous method for reducing model 
dimensionality based on biological function. Reactions were clustered via the kmeans 
MATLAB function using k = 11, which was determined to produce the highest degree of 
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separation between clusters. Reactions in which the product contained a fibrosis-related 
output gene were excluded from clustering to allow for additional degrees of freedom to 
predict the expression of individual output proteins, and k-means clustering was repeated 
1000 times for the remaining reactions using randomly chosen starting points. Clusters of 
reactions occurring most frequently were assigned to final clusters and shared a weight 
parameter during fitting, thus reducing the dimensionality of the final parameter set for 
optimization (129 parameters total). 
 Multi-Omic Data Normalization. A genetic algorithm was used to fit the reduced 
parameter set above to normalized model input and output concentrations extracted from 
patient-specific proteomic and transcriptomic datasets recently published by our 
collaborators10. In addition to the VIC RNA-sequencing data described above, relative 
concentrations of 1193 proteins from the same patient serum samples were measured via 
DNA aptamer array, allowing for the direct relation of changes in serum proteins before 
and after TAVR to changes in myofibroblast activation. Using serum protein levels for all 
patients as input concentrations and VIC gene expression levels as output concentrations, 
data for each input and output node were transformed to a normalized scale useable by 
the model. All input levels were normalized between activity levels of 0.1 and 0.6 
(representing 10% activation and 60% activation respectively), matching previous studies 
transforming biochemical cytokine and growth factor levels measured in myocardial 
tissue post-MI to normalized values while maximizing network dynamic range46. All 
output levels were normalized between activity levels of 0.1 and 0.7, keeping the same 
basal values as input levels while expanding the dynamic range of output expression 
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beyond the default half-maximal effective concentration (EC50) to account for multi-
input stimulation. All normalized input levels were implemented as initial reaction 
weights within the model as representative rates of generation of each species, and all 
normalized output levels were implemented as steady-state concentrations of each 
species. Because not all input/output nodes were represented in the experimental datasets, 
unrepresented input reaction weights were included as parameters within the fitting 
parameter set, and unrepresented output activity levels were included for prediction but 
not used in the final objective function. 
Global Parameter Estimation. Using normalized input/output sets for each patient, 
the ga MATLAB function was used for all parameter estimation. For each set of 
randomly generated parameter sets within the function, steady-state output levels for each 
patient were measured after 80 h given either pre-TAVR or post-TAVR levels for that 
patient. Changes in steady-state output levels were calculated for each patient from pre-
TAVR levels to post-TAVR levels (ΔActivityTAVR), and the mean squared error (MSE) 
between ΔActivityTAVR values and experimental changes in normalized gene expression 
between conditions (ΔExpressionTAVR) for all patients and outputs were used as the 
objective function. A population of 500 was chosen to maximize intra-generational 
variation while limiting computational resources, and a maximum of 100 generations 
were used as minimal improvements in the objective function were found in subsequent 
generations (data not shown). Program defaults were used for all other algorithm 
hyperparameters, and default values for the fibroblast signaling model were used for all 
other model parameters including Hill coefficient (n), EC50, maximum node activation 
 170
(Ymax), and time constant (τ) (see Chapter 4, Materials and Methods section for full 
description). Due to the stochastic nature of generating initial parameter sets for global 
optimization, the model fitting procedure was repeated 50 times using random initial 
parameter sets resulting in an ensemble of parameter sets. Predicted node activity levels 
for all subsequent simulations reflect the mean activity levels predicted across all 
estimated parameter sets.  
Network Perturbation Analysis 
 To identify influential signaling mechanisms across pre-TAVR and post-TAVR 
signaling contexts, a series of node knockdowns were simulated using normalized input 
levels from each patient serum sample. For each set of normalized input levels used 
during parameter estimation above, basal conditions (i.e. without any knockdown) were 
applied for 80 h, followed by knockdown of individual nodes using the Ymax parameter 
(Ymax,KD = 0.1*Ymax,basal) for 240 h. Steady-state activity levels of all nodes were 
measured with each knockdown, and changes in node activity (ΔActivityKD) were 
calculated as the difference between node activity after knockdown and basal node 
activity. Knockdown sensitivity of each node was calculated as the sum of absolute 
ΔActivityKD levels for the node across all knockdown simulations, and knockdown 
influence of each node was calculated as the sum of absolute ΔActivityKD levels for all 
other nodes in the network upon knockdown. 
Patient stratification analysis 
 Targeted simulations assessing stratified model responses to drug targets with 
patient-specific conditions were conducted using a series of dose-response simulations. 
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An aggregate list of top influencers was constructed from the top 10-ranked nodes in 
knockdown influence for each patient condition above (19 nodes total). For each node, a 
series of knockdown simulations was performed under each patient-specific condition. 
Following a simulation of basal conditions using each patient’s normalized input levels 
for 80 h, the Ymax parameter for each node was lowered to either 0.8, 0.6, 0.4, or 0.2 
times the Ymax under basal conditions for 240 h (corresponding with 20-80% node 
inhibition). Steady-state activity levels of all nodes were measured with each dose and 
compared to steady-state levels prior to dosing. 
Statistical analyses 
  Data are shown as mean levels across the ensemble of model parameter sets. 
Significant differences between pre-TAVR and post-TAVR experimental groups were 
determined using two-tailed Student’s t-tests MATLAB. Correlations between activity 
data were determined using Pearson correlation in MATLAB, and Student’s t-tests with 
Benjamini-Hochberg correction for multiple comparisons were used to assess statistical 
significance. An aggregated matrix content score (MCS) was also derived for each 
patient from individual output activity levels using rank-normalized values. Model 
outputs were rank-normalized for each patient, and mean activity levels for all 
procollagens and matricellular proteins (ActivityMatrix), mean activity levels for all matrix 
proteases (ActivityProtease), and mean activity levels for all protease inhibitors were used 
for aggregation: 𝑀𝐶𝑆 =  𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 − 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 + 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 . Output 
nodes were categorized as follows: ActivityMatrix: proCI, proCIII, fibronectin, periostin, 
osteopontin, LOXL1, P4H; ActivityProtease: proMMPs 1, 2, 3, 8, 9, 12, 14, CTSC, CTSL; 
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ActivityInhib: TIMP1, TIMP2, PAI1. Correlations involving MCS levels were determined 
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 Cardiac fibrosis poses a central challenge in preventing heart failure for patients 
who have suffered a cardiac injury, and currently prescribed therapeutics do not account 
for the need to prevent scar formation when it can be detrimental to cardiac function. 
Interactions between biochemical and biomechanical cues within the myocardium guide 
the activation of cardiac fibroblasts during post-injury fibrosis, and while single-pathway 
studies of fibroblast activation have been limited in assessing the broad effects of these 
interactions, computational network models can account for this biological complexity 
and identify influential mechanisms mediating cell behavior. Our investigation aimed to 
identify highly influential mechanisms-of-action mediating cardiac fibroblast activation 
and synthesis of matrix-related proteins through a combination of in vitro experiments 
and computational simulations exploring fibroblast chemo- and mechano-transduction. 
 In the first aim of this investigation, we developed a high-throughput in vitro 
screen for subjecting cardiac fibroblasts to combinations of canonical biochemical 
agonists and cyclic mechanical tension to assess the extent of mechano-chemo 
interactions in cardiac matrix synthesis. We showed that fibroblast-secreted proteins were 
differentially sensitive towards biochemical stimuli, as the agonists tested primarily 
altered the expression of MMPs 1, 8, 9, 12, osteopontin, and periostin over other collagen 
I-associated peptides among other species. Moreover, we found that tension altered 
cardiac fibroblast sensitivity towards biochemical cues by either sensitizing cells towards 
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agonists that suppress matrix protease secretion such as AngII, or de-sensitizing cells 
towards agonists that upregulate protease secretion such as IL-1 and TNFα. This 
screening approach allowed for the discovery of significant signaling interactions guiding 
matrix-related protein expression among many possible combinations, and these findings 
can be used to prioritize future, targeted studies investigating fibroblast behavior. 
 In the second aim of this investigation, we expanded a network model of 
fibroblast signaling to incorporate a robust mechanotransduction topology for predicting 
cell responses in variable mechanical contexts. This model was able to reproduce 
qualitative experimental findings through validation of both input-output relationships 
and responses to currently prescribed drugs for MI patients. Mechano-chemo interaction 
analysis identified crosstalk mechanisms by which tension amplifies, dampens, or 
reverses fibroblast responses to individual biochemical stimuli compared to a low-tension 
context. Global sensitivity analysis identified highly influential pathways mediating 
network-wide responses as well as collagen synthesis in several mechanical contexts, 
with autocrine TGFB signaling acting as a positive feedback loop to stimulate 
procollagen production. We also demonstrated the utility of this signaling model in drug 
discovery by screening drug combinations for the capacity to regulate matrix expression 
based on the mechanical context, finding 13 mechano-adaptive therapies that promote 
matrix accumulation in regions where it is needed and reduce matrix levels in regions 
where it is not needed. 
 In the third aim of this investigation, we developed a transcriptional regulatory 
network using RNA-sequencing data that improved the accuracy of modeling patient-
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specific biochemical conditions over the previous signaling network alone. When 
combined with our network of fibroblast signaling and optimized for patient proteomic 
and transcriptomic datasets via global parameter estimation, the model accurately 
predicted changes in fibroblast activation markers and cell-secreted proteins in agreement 
with in vitro and clinical outcomes. Using global sensitivity analyses, we identified 
influential mechanisms mediating changes in network-wide activity and fibrosis-related 
protein secretion following transcatheter aortic valve replacement, such as the IL6-
gp130-STAT and ET1-ROS-JNK pathways. We also demonstrated the capacity of this 
composite model to predict individual patient responses to drug treatment, with simulated 
knockdowns of individual nodes revealing stratified changes in fibrosis-related protein 
expression across the patient pool.  
 While ideal anti-fibrotic therapies should act in a targeted, patient-specific manner 
to only promote fibrosis when and where it is safe to do so, previous therapies have 
proven ineffective due in part to complex intracellular signaling by cardiac fibroblasts. 
Overall, this investigation moved our understanding of cardiac fibrosis forward by 
identifying mechanisms-of-action that occur in specific mechanical contexts and in 
individual patients, and model predictions can serve as new testable hypotheses for 
potential treatments of maladaptive cardiac fibrosis specific to local mechanics. 
6.2. Study Limitations 
 While this investigation generated additional insight into the complexities of 
fibroblast signaling and fibrotic behavior, several limitations were apparent that should be 
noted when interpreting the results of each study. One chief limitation involves the scope 
 180
of the investigation as it relates to the clinical manifestations of fibrosis; while we studied 
fibroblast secretion of pro- and anti-fibrotic proteins as a cause of pathological tissue 
remodeling, protein secretion is one of several factors affecting overall tissue mechanics 
and performance during heart failure progression. Other factors such as the orientation of 
insoluble collagen fibers and the generation of local traction forces by fibroblasts must 
also be considered when translating cellular-level changes to differences in tissue 
properties, and therefore our findings should be considered in conjunction with the larger 
fibroblast mechanosensing and mechanotransduction body of literature. 
 Within the experimental aim of our investigation, we acknowledge several 
limitations when comparing our in vitro platform to in vivo myocardial conditions: 
 High variance in our treatment conditions were likely due in part to contamination 
of other cell types during fibroblast isolation such as cardiomyocytes and 
macrophages. Because we did not specifically assess for the purity of primary cell 
cultures, the extent of this factor is unknown, and future studies should apply 
additional methods for cell purification.  
 The fibrin matrix chosen for our study differs in several aspects from native 
myocardium including material properties such as elastic modulus as well as 
motifs for cell-matrix adhesion. While this choice of material allowed us to 
measure collagen synthesis without excessive inhibition by a pure collagen 
matrix, combinations of fibrin and collagen may be substituted in future studies 
for a closer approximation of myocardial ECM.  
 181
 The stretch regimen applied during our study additionally differed from 
conditions experienced in vivo, as the axial strain applied (6.5%) is lower than 
reports of in vivo circumferential strains in several animal models. Additionally, 
the strain frequency of 1 Hz, while applicable to human resting heart rates (~60 
bpm), is substantially lower than resting heart rates for mice (~450 bpm). While 
these differences suggest that our platform did not fully model in vivo 
physiological and pathological conditions, the study revealed changes in 
fundamental fibroblast behavior with disease-relevant biochemical and 
biomechanical signals, and future studies should consider closer approximations 
to myocardial biomechanics. 
Within the computational aims of our investigation, we acknowledge several 
additional limitations when comparing our models to fibroblast signaling in vivo: 
 While our models of intracellular signaling and transcriptional regulation 
incorporate topological information and inferred dynamics from many different 
biological pathways, our semi-mechanistic approach does not include quantitative 
kinetic information such as reaction rates, absolute concentrations, and 
pharmacokinetic parameters. Additionally, our models assume similar Hill 
kinetics between all signaling species which may not hold true for several 
reactions such as those involving inside-out mechanotransduction. Further 
translation of these models into therapeutic development will require additional 
mechanistic detail and integration into pharmacokinetic models for the accurate 
prediction of safety and efficacy. 
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 Our inference of the transcriptional regulatory model and fitting of the composite 
signaling-transcription model in Chapter 5 rely on a limited dataset of 16 patient 
conditions which may not reflect the larger population of severe aortic valve 
stenosis patients. While this patient-matched dataset provided a powerful basis for 
investigating mechanisms-of-action in response to plasma protein signatures, 
further validation against larger trial populations is necessary to extrapolate 
predicted trends. Furthermore, these datasets generated from in vitro experiments 
do not fully reflect VIC phenotypes in the native aortic valve, and preclinical 
animal studies would be essential for future validation and therapeutic 
development. 
6.3. Recommendations for Future Studies 
 The model-centered approach used in this investigation presents a variety of 
opportunities to both improve our understanding of mechanisms underlying cardiac 
fibrosis and to predict fibrosis-related development for individual patients. While the 
work presented here furthers the groundwork for these efforts by developing the 
underlying signaling and transcriptional topologies in cardiac fibroblasts, future efforts to 
expand model topology, optimize model fit, and validate findings are essential to using 
this approach for translational applications to improve patient care. 
Model Topology Expansion 
 While the current investigation focused on cardiac fibrosis development in 
fibroblasts via well-studied transduction pathways such as β-integrin, TRP, and syndecan 
mechanosensing as well as TGFβ, AngII, and interleukin chemosensing, fibroblasts 
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respond to a wide variety of mechanical and biochemical stimuli in vivo, and 
incorporation of these various modes of signaling into future models may further answer 
questions related to fibroblast responses within specific disease contexts. For mechanical 
signaling, future delineation of various modes of cell deformation (i.e. stretch vs. stiffness 
vs. pressure) would provide a more accurate representation of the mechanical 
microenvironments as well as a link to specific disease states such as hypertension-
induced pressure overload. This delineation was not included in this investigation due to 
the lack of specific literature evidence linking these individual modes to mechanosensing 
receptors, and targeted experiments measuring the relative activation of receptors such as 
integrins and stretch-activated ion channels with individual mechanical stimuli in cardiac 
fibroblasts are necessary for both model implementation and for improving mechanistic 
understanding. For biochemical signaling, future integration of additional agonists known 
to alter fibroblast activation such as epidermal growth factor (EGF), interferon-γ (IFNγ)1, 
or additional interleukins such as IL-112 would provide a more robust topology for 
predicting fibroblast behavior given the diversity of the cardiac proteome. Because these 
and other species may only be differentially expressed after certain initial pathologies, 
tailoring the current signaling network to particular disease scenarios through the addition 
of differentially-expressed signaling proteins and removal of others could provide further 
insight into fibroblast-mediated remodeling within particular disease states. 
 While we successfully constructed an initial network describing transcriptional 
regulation in myofibroblasts, the accuracy of this topology is highly dependent on the 
relatively limited RNA-sequencing dataset used for inference, and future integration of 
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transcriptomic datasets of larger sample sizes are essential for improving the accuracy of 
this network. Ideally, large scale RNA-sequencing of patient-derived fibroblasts or 
fibroblasts treated in a patient-specific manner like the dataset employed here would 
provide further confidence in inferred TF-target interactions, but practical considerations 
make this ideal a long-term effort. Single cell transcriptomics has gained traction in 
recent years its ability to generate detailed insight of the transcriptional landscape for 
thousands of cells simultaneously, and many bioinformatic tools have been developed to 
infer gene regulatory networks using relatively fewer samples3. Additionally, several 
recent studies have used single cell “omics” methods to investigate cardiac stromal cell 
behavior post-MI4–6, and so using these single-cell datasets to infer fibroblast 
transcriptional regulation could complement the transcriptional network presented here 
by revealing additional influential mechanisms mediating fibrosis-related gene 
expression. While several drawbacks in single cell sequencing limit the usefulness of 
these datasets such as relatively low number of genes and counts detected, they may be a 
useful tool for discovering influential mechanisms in lieu of large-scale bulk RNA-
sequencing experiments.  
One additional direction that could improve predictive capabilities of both 
signaling and transcriptional models is the investigation of non-coding RNAs such as 
microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). A growing body of 
research has identified miRNAs as highly influential mediators of cardiac fibrosis and 
overall function for their role in cell signaling7–9, and the inhibition of the lncRNA Meg3 
has been shown to inhibit MMP-2 gene expression in cardiac fibroblasts and collagen 
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deposition after transverse aortic constriction in mice10. These signaling-related 
transcripts have also been incorporated into networks via the inference of miRNA-TF 
interactions11, demonstrating that applying network biology methods to signaling-related 
transcripts can generate insight into additional modes of signaling and transcriptional 
regulation. The incorporation of well-known miRNA and lncRNA species within the 
current signaling network via a curated literature search could serve as an initial step for 
incorporating this type of signaling, and future experiments measuring changes in 
miRNA or lncRNA via microarray or long-read sequencing could identify new 
transcripts for further incorporation. 
High-Throughput Phosphoproteomics for Parameter Optimization 
A critical area for bridging the gap between our current suite of models and 
potential translational applications is the improvement of robust parameter optimization. 
While our normalized signaling model presented in Chapter 4 was able to reproduce 
qualitative changes in fibroblast-secreted ECM proteins and proteases compared to 
independent experimental studies, accurate quantitative predictions of signaling 
intermediate activity and protein expression are necessary to reliably predict cell 
responses to potential drug treatments. While our optimization of reaction weight 
parameters based on a small sample of patient-derived proteomic and transcriptomic data 
in Chapter 5 proved useful for predicting relative patient responses to simulated drugs, a 
robust dataset measuring activity changes in intracellular signaling intermediates would 
provide a basis for extensively training model parameters. This dataset could be 
generated using controlled in vitro conditions such as isolated cardiac fibroblasts 
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stimulated with individual biochemical and/or biomechanical stimuli, as well as 
fibroblasts isolated from mice subjected to MI or AVS. High throughput 
phosphoproteomic assays such as reverse phase protein array (RPPA) or Luminex 
phosphoprotein arrays provide quantitative methods for measuring intracellular protein 
activation and inhibition across many signaling species and have been used for robust 
fitting of network models12,13. To optimally fit the dynamics of signaling pathways, 
experiments should be conducted in either a dose-response manner (in the case of in vitro 
experimental conditions) or at multiple time points for pairing with changes in 
biochemical concentrations (in the case of in vivo experimental conditions). 
Validation of Model Predictions 
 The validation of model predictions remains an essential step for translating 
model-based findings into therapeutic solutions for cardiac fibrosis. Our simulations 
throughout this investigation suggested that several key pathways highly influence 
fibroblast secretion of ECM-related proteins in various contexts, such as the NOX-ROS-
AP1 signaling axis under high levels of mechanical stimulation or the IL6-gp130-STAT 
axis in post-TAVR biochemical conditions. While these findings show some agreement 
in the literature, testing the hypotheses that these signaling pathways mediate ECM-
related protein expression should be conducted in vitro in a targeted manner. These 
predictions can be tested using pharmacological inhibition or RNA interference for 
intracellular signaling species, and the use of variable-stiffness substrates can be used as a 
positive mechanical stimulus alone, in combination with individual biochemical stimuli, 
or in combination with patient sera samples. Fibrosis-regulating drug candidates from our 
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comprehensive in silico drug screen in Chapter 4 can also be validated using a similar 
experimental design, and future experimental efforts will focus on testing the hypothesis 
that combinatory perturbation of the PI3K-Akt and IL6-gp130 pathways can lead to 
mechano-adaptive changes in fibrosis-related protein expression in cardiac fibroblasts. 
Additional Directions for Cardiac Network Models 
 While our model-based approach of cardiac fibroblast behavior was able to 
identify intracellular pathways regulating protein expression related to fibrosis, it is 
important to note that cardiac fibrosis is regulated by many cellular and extracellular 
systems working in tandem. While fibroblasts play a large role in synthesizing matrix 
proteins and proteases in response to environmental cues, other cell types such as 
cardiomyocytes, macrophages, and neutrophils play highly influential roles through 
intercellular communication and cell-ECM interactions. Other groups have constructed 
models of these other cell types with similar rates of success as our investigation, and 
integrating these systems together could aid our understanding of how the larger 
multicellular system mediates pathological collagen accumulation. While simply 
combining many large-scale networks together may be computationally challenging, 
developing specific, mechanistic models of highly influential pathways guiding the 
behavior of each cell type may reduce complexity while generating new insight into 
intercellular communication. Such mechanistic models would also be more amenable to 
translational applications such as drug development, thus further bridging the gap 
between model-based discovery and patient care. 
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 One final application of our current modeling approach is in the development of 
multiscale models in which molecular-level changes in signaling, cellular-level changes 
in matrix secretion and local mechanical stresses, and tissue-level changes in mechanical 
properties and function are modeled simultaneously. These models show promise in 
directly translating molecular-level changes into clinically-relevant changes in tissue 
function, and the application of our fibroblast model suite to cellular-level changes via 
agent-based models and to tissue-level changes via finite element models could allow for 
a complete solution to treating cardiac fibrosis both in terms of therapeutic development 
for the general population as well as in precision medicine via the use of individual 
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Aim 1 Supplemental Figures 
 
 
Figure A-1: Validation of strain for PDMS wells and fibroblast-seeded gels during cyclic uniaxial tension. 
(A) Average strains of individual PDMS wells subjected to uniaxial tensile deformation. Green strain 
tensors were derived from the deformation of well sidewalls in the axial (11) and transverse (22) directions 
(N=4 technical replicates). (B) Average strain of individual fibroblast-seeded fibrin gels subjected to 
uniaxial tension. Green strain tensors were derived using similar directional conventions as in A-1A (N=4 
technical replicates). 
 
Figure A-2: Viability of fibroblast populations across all experimental groups and biological replicates. 
Viability was determined using a live/dead fluorescent double staining kit after the duration of each 
treatment regimen and is shown as the proportion of calcein-positive cells to total cells for images taken of 
each gel (400.2±183.9 cells per image, N=7 biological replicates). 
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Figure A-3: Fibroblasts maintain alignment along the axis of stretch in fibrin gels. Fluorescent images for 
fibroblast-seeded fibrin gels across all experimental groups were collected after conducting cell viability 
analysis for each sample (Fig. A-2). The orientations of calcein-positive cells for one image per gel 
(400.2±183.9 cells per image, N=7 biological replicates) were calculated using CellProfiler software. 
Orientations are expressed as the angle in degrees from the axis of stretch, with 0° denoting cell alignment 




Figure A-4: Immunocytochemistry and imaging analysis for fibroblast-seeded fibrin gels. (A) Fibrin gels 
probed for αSMA and DAPI were analyzed for fluorescence intensity and cell count per image using 
CellProfiler software. Cell counts per image, as determined by DAPI-labeled nuclei, were extrapolated to 
measured areas of each gel in order to estimate total cell counts per gel. (B) Comparison of bulk gel 
compaction from before treatment to after treatment for high-dose agonist treatments and agonist-stretch 
combinations. (C) Comparison of fluorescence intensity for αSMA across high-dose agonist treatments and 
agonist-stretch combinations. Gel-averaged intensities were determined by averaging the integrated 
intensity of each cell across all cells in each image (N=8 biological replicates). (D) Comparison of 
extrapolated cell counts across high-dose agonist treatments and agonist-stretch combinations. 
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Figure A-5: Statistical significance of individual agonists compared to un-stretched or stretched controls 
shown in Fig. 3.3. P-values of Dunnett’s post-hoc tests are displayed for agonist treatments only versus un-
stretched controls (A), agonist-stretch combinations versus un-stretched controls (B), and agonist-stretch 
combinations versus stretched controls (C). 
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Appendix B 
Aim 2 Supplemental Figures 
 
 
Figure B-1: Schematic of fibroblast chemo-/mechano-transduction network modifications for current study. 
Added nodes relating to mechanotransduction mechanisms, mechano-chemo crosstalk mechanisms, and 






Figure B-2: Optimization of reaction parameters for maximizing accuracy of qualitative predictions. 
Parameter sweeps of half-maximal effective concentration (EC50) and Hill coefficients (n) were conducted 
by simulating changes in output node expression (A) and intermediate node activity (B) in response to 
single input stimuli (see Materials and Methods, Model Validation section for full description). Shading of 
parameter combinations represents the total proportion of correct qualitative predictions compared to each 
independent experimental validation set used in Figure 4.2. 
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Figure B-3: Comparison of mechano-chemo interaction trends across individual biochemical stimuli. (A) 
Probability density distributions of changes in area under normalized dose response curves (∆AUC) with 
incremental levels of tension. Distributions were estimated from data using a kernel density smoothing 
function with a bandwidth of 0.01, and dashed lines represent a ±5% threshold used to identify nodes that 
exhibited amplified or dampened responses towards biochemical stimuli with added tension. (B) 
Comparison of topological measures of centrality for biochemical inputs. Topological analysis of the full 
network was conducted using the NetworkAnalyzer plugin for Cytoscape. 
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Figure B-4: Results of Kolmogorov-Smirnov tests with Benjamini-Hochberg correction comparing ΔAUC 
distributions for biochemical inputs between levels of tension. 
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Figure B-5: Full network perturbation analaysis results. Changes in activity for all nodes in the network 
were measured following comprehensive knockdown of individual nodes (Ymax = 0.1) under given levels 
of tension. Values reflect changes in node activity between perturbed and un-perturbed conditions at each 
tension level. Refer to the model logic file available on GitHub for the order of nodes perturbed/measured. 
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Figure B-6: Comparisons of model-predicted and experimentally-measured changes in procollagen 
expression and signaling intermediate activity. (A) Simulated and experimental measurements of 
procollagen I/collagen synthesis in response to increasing doses of neprilysin inhibitor LBQ657 (LBQ). 
Simulated concentrations of NEPi represent positive modifiers added to Ymax parameters, and 
experimental concentrations represent concentrations of LBQ657 in μM. (B) Simulated and experimental 
measurements of procollagen I/collagen synthesis in response to increasing doses of angiotensin receptor 
blocker valsartan (VAL). Simulated concentrations represent negative modifiers subtracted from Ymax 
parameters, and experimental concentrations represent concentrations of valsartan in μM. (C) Simulated 
and experimental measurements of PKG activity in response to valsartan and/or neprilysin inhibitor 
sacubitril (SAC). Experimental values reflect phorphorylation of PKG analog VASP (vasodilator-
stimulated phosphoprotein). (D) Simulated and experimental measurements of Rho activity in response to 







Figure B-7: Screen of individual drug targets for mechano-adaptive matrix expression. Changes in matrix 
content as a function of output node expression were measured following comprehensive knockdown and 
overexpression of individual nodes in low or high tension contexts. Perturbations were scored for mechano-
adaptive behavior based on matrix content change values as described in Materials and Methods, Mechano-
Adaptive Drug Screen section. Overlapping low- and high-tension values indicate perturbations that 
equally altered matrix content regardless of the tensional context. 
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Appendix C 
Aim 3 Supplemental Figures 
 
 
Figure C-1: Schematic of inferred transcriptional network for current study. Signaling-activated TFs 
(yellow boxes), secondary TFs (white hexagons), and model outputs associated with fibrosis or autocrine 
feedback (green/orange boxes) are connected by directed activation and inhibition reactions (red and blue 
arrows, respectively). Edge widths and transparency represent relative “importance” scores of each TF-
target interaction as measured via the GRNBoost2 algorithm. 
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Figure C-2: Full network perturbation analaysis results. (A) Changes in activity for all nodes in the network 
were measured following comprehensive knockdown of individual nodes (Ymax = 0.1) under individual 
patient pre- and post-TAVR conditions. Values reflect average changes in node activity between perturbed 
and un-perturbed conditions with each patient condition. Refer to the model logic file available on GitHub 
for the order of nodes perturbed/measured. (B) Coefficients of variation (CV) across patient cohort for node 
influence and sensitivity values.  
 
